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Eukaryotic organisms implement conserved surveillance machinery to sense and respond 
to DNA damage.  Fundamental to the repair process is coordinated regulation of repair genes and 
initiation of cell cycle arrest protocols.  Failure to preserve these checkpoints results in 
accumulation of mutated DNA and aberrant cell phenotypes that are characteristic of human 
disease.  The yeast, Saccharomyces cerevisiae, utilizes the MEC1 checkpoint pathway to 
regulate the DNA damage response.  This study addressed two overarching themes of 
transcriptional and post-translational regulation within the MEC1 pathway.  We first applied our 
understanding of the MEC1 DNA damage transcriptional response to develop advanced 
luciferase whole cell biosensors that could detect a broad range of carcinogens using the 
promoter sequence of the MEC1 DNA repair gene, HUG1.  The enhanced whole cell yeast 
biosensor exhibited improved sensitivity and dynamic range when compared to fluorescent-
based biosensors while reducing reporter read-out processing time through a one-step, in vivo 
measurement regime.   
Previous global transcription studies performed in our lab identified a dose-dependent 
biphasic response of MEC1 repair genes to alkylating agents.  The origin of this unique profile, 
however, remained unknown.  Using a GFP promoter-reporter construct placed under MEC1 
pathway genes, we found that the biphasic response persists through the MEC1 pathway, and that 
neither reactive oxygen species accumulation nor pro-apoptotic genes contributed to the 
expression profile.  Cell cycle analysis revealed that cells immediately enter a senescent state 
after experiencing high alkylating concentrations which we proposed was the root cause of the 
MEC1 pathway gene repression. 
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The role of a functionally uncharacterized MEC1 DNA repair protein, HUG1, in the 
DNA damage response was also explored.  Using overexpression phenotype and subcellular 
localization assays, we demonstrated that HUG1 is a negative regulator of the MEC1 pathway 
and that its co-localization with the positive MEC1 effector, Rnr2p, was likely the source of its 
regulation. Protein affinity assays confirmed the Hug1p-Rnr2p interaction while mutagenesis 
analysis probed domains within Hug1p to determine regions necessary to its inhibitory action.  
Finally, we discovered that Hug1p also interacts with human ribonucleotide reductase homologs, 







Cells in the human body experience tens of thousands of DNA lesions per day, evolving 
out of both errors in DNA replication mechanisms (i.e., endogenous damage) and through 
environmental stresses (i.e., exogenous damage) such as UV light or chemical 
carcinogens.(Ciccia & Elledge, 2010; Harper & Elledge, 2007; Lindahl & Barnes, 2000; Zhou & 
Elledge, 2000)  To counteract this mutagenic damage and preserve genome fidelity, eukaryotic 
organisms employ sophisticated cellular machinery that regulate and halt cell growth to allow 
DNA repair to occur.  Paramount to this response is the arrest of cells at particular stages in the 
cell cycle (also known as checkpoints) to prevent mutated DNA from being passed on to 
daughter generations.  Failure to properly activate a checkpoint response results in accumulation 
of mutagenized DNA which inevitably causes aberrant gene expression and protein formation 
that leads to human disease.(Ciccia & Elledge, 2010; Di Domenico et al., 2014; Halazonetis et 
al., 2008; Harper & Elledge, 2007; Lord & Ashworth, 2012; Zhou & Elledge, 2000) 
The complexity of human disease progression is a confounding factor in counteracting 
and treating aberrations in checkpoint pathway genes.  Advances in next-generation sequencing 
(NGS) technologies have revolutionized high-throughput detection of genes involved in disease 
progression and have even been used to assess treatment efficacy.(Desmedt et al., 2012)  
However, as NGS is an emerging technology, cost restricts its application.  Likewise, a 
fundamental understanding of underlying mechanisms is required to establish disease onset, 
prevention, and treatments.(Xuan et al., 2013)  A basic science approach that analyzes distinct 
genetic and proteomic contributions to complex interacting system is thus imperative to 
elucidating mutation processing, disease initiation, and disease evolution. 
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One such basic science approach involves analysis of an arm of the checkpoint activation 
cascade: the DNA damage response (DDR).  Insights into DDR gene transcription and enzymatic 
mechanisms have set the foundation for current human disease therapeutics.(Davar et al., 2012; 
Woods & Turchi, 2013).  However, the mammalian DDR is incredibly intricate, with differential 
expression of cellular machinery that is cell type-, damage extent-, and cell cycle-
dependent.(Jackson & Bartek, 2009)    The complexity of this response is a burden on discovery, 
as conclusions are constrained to the experiment conditions and cellular system utilized.  Simple 
model organisms offer a valuable alternative to the complex mammalian system, as they 
generally implement simpler (but conserved) pathways while being more cost effective and 
easier to maintain. 
As one of the simplest eukaryotic models, Saccharomyces cerevisiae offer several 
advantages over other eukaryotic systems in modeling DDR and DDR-related disease.  The 
budding yeast are genetically tractable, have a well-understood and annotated genome, and are 
inexpensive and easy to grow in rich media.(Botstein et al., 1997; Botstein & Fink, 2011)  Most 
importantly, however, proteins in S. cerevisiae retain homology with other eukaryotic systems as 
most of the genome has a high degree of evolutionary conservation.  In fact, 31% of potential 
protein-encoding genes in the yeast genome also share a homolog in the mammalian genome, 
despite yeast having a compact genome size that is roughly 1/250th the size of the human 
genome.(Botstein et al., 1997)  This resounding similarity in functional genes sequence lead to 
discoveries that not apply to the yeast specific responses, but can also be applied to analogous 
roles in other eukaryotes, including humans.  The DDR response exemplifies this idea of 
evolutionary conservation, as many DDR proteins serve similar function across the eukaryotic 
domain (discussed at length in Section 1.1.4 and 1.1.5).   
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A particular advantage of the model yeast system is its damage checkpoint response has 
been extensively studied.  Similar to the human ATR pathway, the yeast MEC1 pathway mounts 
a protein response to single and double strand DNA breaks that involves regulates several 
downstream factors at the transcriptional and post-translational scale to aid in cell cycle arrest 
and DNA repair (discussed in Section 1.1.5).(Ciccia & Elledge, 2010; Harper & Elledge, 2007; 
Zhou & Elledge, 2000; Zou & Elledge, 2003)  Previous work on MEC1 gene transcription in 
response to DNA damage has revealed a substantial and dynamic response to various types of 
DNA damaging agents, making it an ideal candidate for DNA damage based whole cell 
biosensors (discussed in Sections 0 and 0).(Benton, M. G. et al., 2007)  Likewise, MEC1’s 
differential response to a broad spectrum of DNA damage has revealed new protein functionality 
within the MEC1 response that considerably impact the regulation of the DDR.(Benton, M. G. et 
al., 2006; Gasch et al., 2000; Jelinsky, S. A. et al., 2000)  
Despite this, many aspects of the MEC1 checkpoint response still remain uncharacterized 
at the transcriptional and post-translational level.  For instance, transcripts of MEC1 pathway 
genes undergoes an acute biphasic response to increasing DNA damage by the alkylating agent, 
MMS; however, the origin of this unique profile is currently undefined. Uncovering the novel 
response mechanisms within the yeast DNA damage network has implications in analogous 
eukaryotic pathways through an extensive level of evolutionary conservation in the DNA 
damage response pathways.  Likewise, a thorough understanding of underlying DNA damage 
mechanisms offers exciting new opportunities to develop improved whole-cell yeast biosensors 
with advanced sensitivity, dynamic range, and response time.  Finally, several functionally 
uncharacterized MEC1 pathway targets, such as HUG1, appear to exert a control over the MEC1 
DNA damage response, but their mechanism and roles within MEC1 remain unclassified.(Basrai 
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et al., 1999)  The absence of a human homolog to the yeast protein, HUG1, suggests it may be a 
new DDR inhibitor with effects on MEC1 regulatory activity and with applicability to novel drug 
design. 
This chapter will focus on providing background necessary to understand and establish 
the research objectives addressed in the proceeding chapters of this dissertation.  To frame the 
long-term goal of this project, cancer statistics and state-of-the-art will be briefly reviewed, 
followed by a brief overview of the applicability of the yeast eukaryotic model in advances to 
human disease.  The yeast DNA damage response will then be dissected at both a transcriptional 
and post-translational level to provide a basis for the two overarching themes of this project.  
DNA damage transcriptional activity will be explored to establish both its use in the 
development of biosensor technologies as well as being applied towards understanding a unique 
transcriptional response within the yeast DNA damage response.  Finally, MEC1 downstream 
post-translational targets will be discussed with emphasis on protein function unique to 
Saccharomyces cerevisiae to contextualize significant findings and to introduce foundational 
research that inspired the current work. 
1.1. Literature Review 
1.1.1. A primer on DNA 
DNA is an essential macromolecule that carries all of the genetic information necessary 
to develop and sustain life.  In most organisms, DNA is composed two anti-parallel helixes; each 
strand is, in the most basic sense, a simple polymer composed of alternating deoxyribonucleotide 
monomers.  Each deoxyribonucleotide consists of a nucleotide base and 5-carbon deoxyribose 
sugar with a phosphate group required for covalent linkage.  Four different types of nucleotides 
are found in DNA: adenine (A), thymine (T), cytosine (C), and guanine (G), and are further 
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subdivided into two groups, purines (A and G) and pyrimidines (C and T), characterized by the 
rings structure of the corresponding nucleotide.(Alberts et al., 2002)   
DNA contains a highly stable backbone that is the result of covalent phosphate linkages 
between the deoxyribose sugars.  The characteristic DNA double helix is the result of hydrogen 
bonding between complementary nucleotides on an adjacent, anti-parallel DNA strand.  These 
weak hydrogen forces between nucleotides are the foundation of DNA’s utility, as the bonds are 
easily broken and allow the DNA strands to be pulled apart without disrupting the integrity of the 
phosphate backbone.  This allows for many vital cellular processes (such as DNA replication and 
transcription) to occur without disturbing the fidelity of the DNA itself and is key to the 
conserved and stable transfer of the genetic code to subsequent generations.(Alberts et al., 2002) 
The DNA sequence encodes the blueprint for all cellular machinery required for life.  
Through a process known as transcription, specific DNA sequences known as genes can be 
transcoded into another molecule, known as messenger RNA (mRNA), which serves as a 
template for the creation of proteins through the process of translation.  This sequence forms the 
central dogma of molecular biology and is the origin of all cellular activities required for 
developing, maintaining, and sustaining an organism throughout its lifespan.(Alberts et al., 2002) 
The DNA sequence itself contributes to the regulation of gene expression.  Specific DNA 
sequences act as sites for protein interaction whereby gene expression can be repressed or 
activated depending upon the needs of the cells.  This transcriptional control allows organisms to 
maintain strict modular control over the types and quantities of genes being expressed during any 
given moment and allows for immediate and global adaptations to environmental 




1.1.2. A briefing on DNA damage and the generalized DNA damage response 
Inevitably, DNA will incur damage due to internal errors in replication or external 
genotoxic factors such as UV-radiation.  Unrepaired DNA damage non-specifically alters the 
genetic sequence encoded by DNA, a change which have drastic effects on vital processes within 
the cell.  Alterations to gene expression, in particular those involved in metabolism and cell 
cycle, pose significant risk to genome stability and can lead to aberrant cell function and 
growth.(Ciccia & Elledge, 2010; Harper & Elledge, 2007; Zhou & Elledge, 2000)  As such, 
organisms have developed a sophisticated network of cellular responses to counteract damage 
and preserve the genome fidelity.  These checkpoint responses (discussed in detail in Section 
1.1.5) prevent cell growth and repair DNA prior to duplication, however checkpoint disruption 
by DNA mutagenesis can negatively affect the cells ability to promote arrest and regulate gene 
expression.(Halazonetis et al., 2008; Harper & Elledge, 2007; Hendry et al., 2015; Jackson & 
Bartek, 2009; Lindahl & Barnes, 2000; Lord & Ashworth, 2012; Zhou & Elledge, 2000)  
Compounding effects of DNA mutagenesis by accumulated DNA damage, including checkpoint 
response deactivation, tumor-suppressor genes repression, and proto-oncogene activation, 
inevitably lead to the onset of cancer phenotypes.(Hanahan & Weinberg, 2000; Hanahan, D. & 
Weinberg, R. A., 2011)  As DNA damage response is a vital cellular system that mitigates DNA 
mutagenesis and prevents aberrant phenotypes from evolving, a thorough appreciation of its 
intricate role in genome maintenance is paramount to understanding the onset and progression of 
genetic diseases like cancer. 
1.1.3. Cancer and the DNA damage response 
Cancer accounts for one in four deaths in the United States and is the second leading 
cause of death, second only to heart disease. (Elkin & Bach, 2010; Mariotto et al., 2011; Siegel 
et al., 2013)  The domestic cost of care was estimated at $124.5 billion in 2010. Unfortunately a 
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growing, treatable population and escalating chemotherapeutic costs means the economic burden 
of cancer care will rise by at least 27% by 2020.(Elkin & Bach, 2010; Mariotto et al., 2011; 
Siegel et al., 2013)  Significant improvements in early detection and treatment quality have 
reduced cancer-related mortality rates over the past several decades, with a survival rates rising 
from 49% in 1975-1977 to 68% in 2004-2010.(Society, 2015)  However, the development of 
more effective and inexpensive therapeutics will further improve survivability and help attenuate 
the financial concerns associated with cancer treatment. 
A thorough understanding of cancer initiation and progression is imperative to advancing 
next-generation therapeutics and reducing overall treatment costs.  In healthy cells, the DNA 
damage response (DDR) is responsible for preserving genomic fidelity and prevention of 
mutated gene passage to successive generations.(Harper & Elledge, 2007)  Consequently, 
eukaryotic organisms have evolved highly conserved DNA damage checkpoint systems to signal 
DNA damage and coordinate subcellular mechanisms to ensure cell cycle arrest, DNA repair, 
and damage recovery.  However, mutations to critical DDR genes often lead to increased 
genomic instability, a major contributor to cancer.  To combat DDR dysfunction, diverse classes 
of cytotoxic and cytostatic therapeutics have been designed to discriminately target and eliminate 
tumors by initiating cell death via apoptosis, necrosis, mitotic catastrophe, autophagy, and/or 
senescence.(Hanahan, D. & Weinberg, Robert A., 2011; Ricci & Zong, 2006)  Despite the initial 
success of these treatments, therapy-induced acquired resistance that subverts the intended 
chemotherapeutic response leads to increased malignancy and reduced drug efficacy.  Indeed, 
both intrinsic and acquired resistances are believed to cause 90% of treatment failure in patients 
with metastatic cancer.(Hanahan, D. & Weinberg, Robert A., 2011; Ricci & Zong, 2006)  
Interestingly, DDR genes responsible for cell cycle arrest, DNA damage repair, and apoptosis are 
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often mutated in cancers with increased drug resistance.(Hanahan, D. & Weinberg, Robert A., 
2011; Hartwell et al., 1997; Lord & Ashworth, 2012; Ricci & Zong, 2006)  Thus, mutated DDR 
genes implicated in genomic instability or drug resistance provide promising targets for future 
chemotherapeutics. 
1.1.4. Yeast as a model for human disease  
Due to the high complexity of the human DDR response and interactions, determination 
of ideal targets in the DDR is not trivial. Fortunately, model eukaryotic organisms, such as the 
yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe, can provide insights into 
analogous functional roles of DDR proteins in cancer.(Simon et al., 2000)  Yeasts in particular 
offer distinct advantages as model organisms in that they have a small and well-annotated 
genome, are genetically tractable, have short doubling times with low nutrient requirements, and 
share homology with several DDR genes implicated in tumorigenesis (Table 1.1).(Foury, 1997; 
                                                 
* Table 1.1 is adapted from Hartwell, L.H., P. Szankasi, C.J. Roberts, A.W. Murray, and S.H. Friend, Integrating 
genetic approaches into the discovery of anticancer drugs. Science, 1997. 278(5340): p. 1064-8. It is reprinted by 
permission of The American Association for the Advancement of Science.   
Table 1.1.* Human genes altered in tumors and respective genes in the model eukaryote, Saccharomyces cerevisiae. 
Functionally but not structurally analogous genes are given in brackets. 
Function Human genes 
System analogs or structural 
homologs 
DNA damage checkpoint p53, ATR, ATM [RAD9], MEC1, TEL1 
DNA mismatch repair MSH2, MLH1 MSH2, MLH1 
Nucleotide excision repair XP-A, XP-B RAD14, RAD25 
Double-strand break repair BRCA2, BRCA1 [RAD51], [RAD54] 
Cell cycle control 




Hartwell et al., 1997)  In fact, there have been numerous cancer treatment advances based on 
yeast studies.  For example, by exploiting protein functional homology and the genetic 
malleability in yeast, researchers have devised high-throughput screening methods to identify 
anti-cancer treatments with high therapeutic advantage and putative targets for therapeutic 
treatments.   
Likewise, 692 yeast genes were identified which may contribute to mutant chromosome 
instability (CIN) phenotypes in human disease.(Buschini et al., 2003; Simon et al., 2000)  
Isogenic yeast strains modeling defects in DNA repair, cell cycle checkpoints, and cell cycle 
regulation were used as models of cancer cells and screened for drug efficacy.(Buschini et al., 
2003; Simon et al., 2000)  In our lab, we have sought to further characterize yeast CIN gene 
targets with high chemotherapeutic potential and further elucidate DNA damage mechanisms 
and cellular responses induced by the yeast DNA damage stress.   
1.1.5. On understanding the DNA damage response  
Cells in the human body incur tens of thousands of DNA damaging lesions per a 
day.(Lindahl & Barnes, 2000)  When exposed to exogenous and endogenous DNA damage, 
eukaryotes employ a sophisticated, evolutionarily-conserved surveillance network to identify 
DNA lesions and replication stresses.  Organisms invoke a canonical protocol upon detection of 
DNA damage that coordinates cellular activities to ensure aberrant DNA repair prior to the cell 
dividing (Figure 1.1).(Zhou & Elledge, 2000)  Repairing DNA prior to mitosis and meiosis 
ensures that a stable and high-fidelity genome is replicated to the next cellular generation.  
Generally speaking, cells detect DNA damage through the use of damage sensing proteins; these 
“sensors” bind DNA and activate a series of transducers with highly specific activity and 
function.  Transducers are capable of turning on genes or modifying proteins to enable desired 
effects.  The downstream targets activated by transducers are known as “effectors” and act as a 
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diverse class of proteins that mediate or induce cell protocols, such as initiating cell cycle arrest 
or increasing availability of DNA monomers to aid in DNA repair.  The process is highly 
coordinated with a series of cellular checkpoints to ensure DNA damage is managed 
appropriately prior to proceeding through cell.   
Mammalian and yeast cells implement a functionally analogous mechanism to respond to 
DNA damage, however specific proteins utilized in the response vary (Table 1.2).(Hustedt et al., 
2013; MacQueen & Hochwagen, 2011)  The DNA damage checkpoint is broadly regulated by 
two response systems: the ATM-mediated double-strand DNA break (DSB) response and the  
                                                 
† Figure 1.1 is adapted from Zhou, B.-B.S. and S.J. Elledge, The DNA damage response: putting checkpoints in 
perspective. Nature, 2000. 408(6811): p. 433-439.  It is reprinted by permission of Nature Publishing Group. 
 
Figure 1.1.† General outline of the DNA damage response signal-transduction pathway. 
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ATR-mediated single-stranded DNA (ssDNA) detection network.(Abraham, 2001)  In 
Saccharomyces cerevisiae, Tel1 (ATM)‡ is largely involved in telomere maintenance and DSB  
recognition while Mec1 (ATR) has a role in regulating both ssDNA and DSB checkpoint 
response (Baldo et al., 2008; Di Domenico et al., 2014; Naiki et al., 2004).   
                                                 
‡ Yeast proteins are given with their respective human homologs in parentheses. 
 
§Table 1.2 is adapted from Hustedt, N., S. Gasser, and K. Shimada, Replication Checkpoint: Tuning and 
Coordination of Replication Forks in S Phase. Genes, 2013. 4(3): p. 388. The article and its contents are open access 
and distributed under the terms and conditions of the Creative Commons Attribution 3.0 license. 
Table 1.2.§ Conserved checkpoint proteins and their function. (Hustedt et al., 2013) 
S. cerevisiae H. sapiens Function 





9-1-1 complex, DNA damage checkpoint clamp, 
Mec1 activation 
Dpb11 TOPBP1 Mec1 ATR activation 





MRX/MRN complex, DSB resection, Tel1/ATM 
recruitment 
Mec1-Ddc2 ATR-ATRIP checkpoint signaling kinase 
Tel1 ATM checkpoint signaling kinase 
Mrc1 Claspin fork-associated, checkpoint mediator 
Rad9 53BP1, BRCA1 checkpoint mediator 
Sgs1 BLM, WRN fork-associated, Rad53 activation 
Rad53 CHK2 effector kinase 
Chk1 CHK1 effector kinase 
Gene name abbreviations: Rad24 (radiation sensitive 24), RFC (replication factor c), Ddc1 
(DNA damage checkpoint 1), Mec3 (Mitosis entry checkpoint 3), Hus1 (hydroxyurea 
sensitive 1), Dpb11 (DNA polymerase B 11), TOPBP1 (DNA topoisomerase 2 binding 
protein 1), Dna2 (DNA synthesis defective 2), Mre11(meiotic recombination 11), Xrs2 (X-
ray sensitive 2), Nbs1 (Nijmegen breakage syndrome 1), ATR (ATM and Rad3-related), 
ATRIP (ATR interacting protein), Tel1 (telomere maintenance 1), ATM (Ataxia 
telangiectasia mutated), Mrc1 (mediator of the replication checkpoint 1), 53BP1 (tumor 
suppressor p53 binding protein 1), BRCA1 (breast cancer 1, early-onset), Sgs1 (slow growth 
suppressor 1), BLM (Bloom syndrome protein), WRN (Werner syndrome ATP-dependent 
helicase), CHK2 (checkpoint kinase 2), CHK1 (checkpoint kinase 1). 
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Activation of the MEC1 (ATR) signal transduction cascade induces translational and 
post-translational activity that initiates cell cycle arrest protocols and DNA repair mechanisms.  
The DNA damage checkpoint is proposed to be triggered once threshold levels of DNA lesions 
are detected and replication forks slow or stall.(Minca & Kowalski, 2011)  In Saccharomyces 
cerevisiae, the resulting stalled replication forks expose single-stranded DNA (ssDNA) which act 
to prime DNA damage sensing complexes (Figure 1.2) (Cimprich & Cortez, 2008; Hustedt et al., 
2013)  Replication protein A (RPA) coat and stabilize bare ssDNA which recruit constitutively 
associated Ddc2p-Mec1p (ATRIP-ATR) to DNA damage sites (Hustedt et al., 2013; Rouse & 
Jackson, 2002; Zou & Elledge, 2003).   
Mec1p (ATR) is subsequently activated by the heterotrimeric proliferating cell antigen 
(PCNA)-like 9-1-1 complex, Rad17-Ddc1-Mec3(RAD9-RAD1-HUS1) (Majka, J. & Burgers, 
2003; Majka, Jerzy et al., 2006) which coordinates G1 arrest, but is also involved in S- or G2/M 
arrest mediated by Dna2p (DNA2) (Kumar & Burgers, 2013) or Dpb11 (TOPBP1) (Ogiwara et 
al., 2006) activity, respectively. (Figure 1.2) (Hustedt et al., 2013).  Successful activation of the 
MEC1 (ATR) signal transduction pathway initiates phosphorylation events that activate 
downstream effector kinases, Rad53p (CHK2), Chk1p (CHK1), and Dun1p.  These effector 
kinases trigger further downstream targets that regulate origin firing, gene transcription, and 
dNTP pools and act together to arrest the cell and repair DNA before cellular reentry into the 
normal cell cycle programming. (Harper & Elledge, 2007; Hustedt et al., 2013; Zhou & Elledge, 
2000; Zou & Elledge, 2003) 
1.1.6. MEC1 pathway transcriptional response 
This dissertation explores two overarching themes with respect to the MEC1 pathway: 
MEC1 regulation at the translational level (i.e., MEC1 gene expression profiling and uses 
thereof) and at the post-translational level (i.e., effects of MEC1 target proteins within the DNA  
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damage response.  Chapters 2 and 3 highlight key discoveries in MEC1 gene expression as it 
applies towards whole cell biosensor development and in defining the origins of a unique MEC1 
DNA damage gene response at increasing DNA damage dosages.  This section serves a primer to 
these chapters, describing literature necessary in understanding the role of MEC1 gene 
expression in biosensor technologies as well as discussing yeast global transcriptional response 
to DNA damage and how the results contribute to establishing Chapter 3 objectives.  Section 
                                                 
** Figure 1.2 is adapted from Hustedt, N., S. Gasser, and K. Shimada, Replication Checkpoint: Tuning and 
Coordination of Replication Forks in S Phase. Genes, 2013. 4(3): p. 388. The article and its contents are open access 
and distributed under the terms and conditions of the Creative Commons Attribution 3.0 license.   
 
Figure 1.2.** MEC1 checkpoint activation by DNA damage and replication stress. (Hustedt et al., 2013) 
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1.1.7 discusses post-translational aspects of the MEC1 pathway, including literature related to 
MEC1 DNA damage targets and their role in regulating the MEC1 response.    
The MEC1 checkpoint initiates a vast, differential network of target genes with 
dependence on cell cycle stage and the quantity and type of DNA damage.  Through total RNA 
extractions and microarray analysis, global transcriptional analysis has been undertaken to define 
Saccharomyces cerevisiae gene expression profiles in response to an assortment of cellular stress 
agents, genotoxic chemicals, and ionizing and UV radiation.(Benton, M. G. et al., 2006; Fry et 
al., 2005; Gasch et al., 2000; Jelinsky, S. A. et al., 2000).  Most surprisingly, DNA damage 
induced a differential transcript response in nearly 2500 of the total 6200 open-reading frames in 
Saccharomyces cerevisiae.(Jelinsky, S. A. et al., 2000)  A single, low dosage of the DNA 
alkylating agent, methyl methanesulfonate (MMS), induced differential expression of nearly 
~325 gene transcripts (5% of the genome),(Jelinsky, Scott A. & Samson, 1999) and this response 
was later shown to be specific to the MMS titer.(Jelinsky, S. A. et al., 2000)  Likewise, a similar 
alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) was shown to provoke an 
entirely different array of genes in response to damage.(Jelinsky, S. A. et al., 2000)  A survey of 
DNA damaging agents including 4-nitroquinoline 1-oxide (4-NQO), γ-irradiation, mitomycin C 
(MMC), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), tert-butyl hydroperoxide (t-BuOOH), 
were investigated for their response and shown provoke vast gene transcript effects independent 
of overall toxicity.(Jelinsky, S. A. et al., 2000)   
A similar microarray study performed by our lab has also revealed that MEC1 DNA 
repair pathway genes exhibit a dose dependent response to MMS response.(Benton, M. G. et al., 
2006)  Transcripts of DUN1 (a MEC1 effector kinase), RNR2 and RNR4 (MEC1 positive 
effectors and subunits of the ribonucleotide reductase enzyme which synthesizes DNA 
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monomers – dNTPs - for DNA repair and synthesis), and HUG1 (MEC1 target protein with 
unknown function; reviewed in section) were show an increase at low- to mid-dosages of MMS 
(0.001-0.01% v/v final concentration) and sharply decrease at higher MMS dosages (0.1% v/v 
final concentration).(Benton, M. G. et al., 2006)  Correlatively, genes induced at the 0.1% DNA 
damage dosage level correspond with genes expressed upon entry in stationary phase.(Jelinsky, 
S. A. et al., 2000)  These intriguing results taken together suggest DNA damage checkpoint 
pathway genes fail to induce or are repression through a shared general stress response that is 
experienced during stationary phase or at high threshold levels of MMS, however no data exists 
that unify these two stages of cellular response.(Jelinsky, S. A. et al., 2000)  Chapter 3 of this 
dissertation explores potential mechanisms that may be influencing this unique biphasic gene 
response, including DNA damage induced dose-dependent response contributions from DNA 
damage extent, reactive oxygen species accumulation, pro-apoptotic genes, and cell cycle phase.   
The MEC1 DNA damage response is extremely dynamic in sensing DNA damage type 
and extent.  Likewise, downstream MEC1 target genes, such as HUG1, are some of the highest 
differentially expressed genes in the yeast genome.(Basrai et al., 1999)  These characteristics, 
alongside its genetic tractability and ease in maintenance, make yeast an ideal candidate for use 
as whole cell biosensors.  The term “biosensor” applies to a broad class of analytical devices that 
use living organisms or biomolecules (such as enzymes or antibodies) to detect environmental 
perturbations or increased titers of a target analyte.(Turner, 2015)  In the case of whole cell 
biosensors, yeast cultures are utilized as the sensing conduit through which signals activate a 
detectable reporter.  Reporters are placed under a gene’s promoter for the express purpose of 
activating and reporting gene expression once stimulated by certain environmental conditions.  
Promoter–reporter systems have been designed to detect a broad array of environmental 
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perturbations, including the presence of heavy metals (Mascorro-Gallardo et al., 1996; Virta et 
al., 1995), organic pollutants (Selifonova & Eaton, 1996), sugar sources (Chambers et al., 2004; 
Marrakchi et al., 2008) and DNA-damaging agents (Benton, Michael G. et al., 2007; Boronat & 
Pina, 2006).   
Reporter choice plays an important role in a biosensing system and typically includes use 
of one of three types of biological molecules: biological fluorophores, such as green fluorescent 
protein (GFP) which can be read by a fluorometer, chromophores such as β-galactosidase (which 
produces a blue color after reacting with the lactose analog, X-gal) and are read by a 
spectrophotometer, or enzymatic complexes that perform chemical reactions to provide a read-
out (such as luciferase’s reaction with D-luciferin to emit a photon of light) and are detected by 
luminometers or scintillators. (Daunert et al., 2000).  Several design considerations must be 
made when selecting a reporter. Chromophore and enzymatic reporters generally require cell 
lysates to obtain accurate measurements; the extraction process is typically harsh and results in 
reporter deactivation. Fluorophore reporters, on the other hand, require expensive equipment 
(such as an epifluorescent microscope or flow cytometer) for detection and are typically not 
amenable to field-use.  (Garrido et al., 1994; McNabb et al., 2005)   
An ideal biosensor maintains quantitative accuracy while achieving high dynamic range 
when reporting analyte detection.  Previous work in our lab have demonstrated the utility of a 
GFP reporter under promoter control of the MEC1 pathway gene, HUG1 to identify a survey of 
DNA damaging agents, including alkylating agents MMS, ethyl methanesulfonate (EMS), and 
1,2-dimethylhydrazine (SDMH), replication stress agent hydroxyurea (HU), cellular stress agents 
phleomycin, camptothecin, and 4-NQO, and DNA damaging agent γ-radiation.(Benton, M. G. et 
al., 2007)  Sensitivity of the HUG1 DNA damage promoter-reporter system to the alkylating 
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agent MMS was also increased after deletion of genes required for repairing alkylated DNA, 
MRE11 and MAG1.(Benton, Michael G. et al., 2008)  These experiments exposed the power of 
whole cell yeast biosensors and their distinct advantages in genetic tractability.  Through rational 
design of yeast biosensors, highly sensitive and specific reporter systems can be engineered to 
sense a dynamic range of target analytes, including carcinogenic targets as detected by reporters 
constructed in DNA damage response promoter elements.  
One of the advantages of the luciferase system is its sensitivity in detection, however, as 
the luciferase enzyme requires extraction prior to taking measurements, its adoption in field-use 
has been limited.  Recent advances in the luciferase system have improved sensitivity and 
reproducibility of signaling in vivo, have eliminated the rate-limiting extraction step, and have 
allowed for a quick and accurate one-step measurement of bioluminescence.(Leskinen et al., 
2003; Tauriainen et al., 1999; Vieites et al., 1994).  In our study (Chapter 2), we explored the 
utility of the advanced luciferase as a reporter for carcinogens by expressing it under promotion 
of the DNA damage response gene, HUG1.  We first developed a new plasmid construct that 
allows for one-step, PCR mediated promoter-reporter engineering with the advanced luciferase 
reporter.  We then characterized detection parameters (such as response time and sensitivity) of 
the new HUG1 promoter-luciferase reporter system and compared these findings to the 
established HUG1 promoter, GFP reporter system. 
1.1.7. MEC1 DNA damage response targets 
Post-translational modification of proteins act as another mechanism of control over gene 
expression and protein functionality in the DNA damage response.  DNA repair proteins and 
their regulation are of particular interest to this project, and as such are extensively overviewed 
to provide context for the project objectives.  These sections introduce features of the DNA 
repair genes in order to establish the motives behind the project objectives.  It will also serve to 
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contextualize experimental approach, design, and interpretations explored in Chapters 4 and 5.  
These chapters are particularly focuses on identifying the functional and mechanistic role of a 
previously uncharacterized DNA damage response protein, HUG1.   
Our investigations into the yeast MEC1 DNA damage response revealed that the MEC1 
downstream effectors, ribonucleotide reductase subunits (RNR1, RNR2, and RNR4) are CIN 
genes and demonstrate prominent sequence and functional homology to the human RNR 
complex.(Hendry et al., 2015; Stirling et al., 2011)  Interestingly, dysfunctional levels of a yeast 
RNR2 analog, human p53R2, have been observed in several cancer types, including 
melanoma,(Matsushita et al., 2012) esophageal squamous cell carcinoma,(Yokomakura et al., 
2007) and non-small cell lung cancer.(Uramoto et al., 2006)  Likewise, mRNA silencing 
experiments designed to target and inhibit human RNR2 analogues were successful in reducing 
tumor progression and decreasing tumor resistance to DNA damage inducing 
chemotherapeutics.(Halazonetis et al., 2008; Kunos et al., 2009; Matsushita et al., 2012; Shao et 
al., 2006)   As such, RNR genes offer specific and viable targets for chemotherapeutic design.  
Ribonucleotide reductase (RNR) is an evolutionarily conserved enzyme that is utilized by 
all domains of life - from bacteria to higher eukaryotes.  RNR is responsible for the rate-limiting 
enzymatic reduction of ribonucleotides to the DNA monomers, deoxyribonucleotides. RNR is 
typically active only during the DNA synthesis phase (S-phase) as dNTPs are required for DNA 
replication.    However, an increase in RNR expression is generally seen upon DNA damage, as 
more dNTPs are required for DNA strand repair.  As such, RNR is a fundamental component of 
the DNA damage response.(Elledge & Davis, 1989; Hendry et al., 2015; Huang & Elledge, 
1997; Kolberg et al., 2004; Nguyen et al., 1999; Torrents, 2014)   
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Though RNR function is strictly evolutionarily conserved, three distinct classes of RNRs 
have been discovered that differ by metal cofactors and thiyl radical generation chemistry which, 
in all three classes, coordinate to produce essential thiyl radicals at the active sites of the enzyme.  
Class I reductases (found in almost all eukaryotes, some prokaryotes, and some viruses) form 
active complexes containing two distinct multimeric subunits, R1 (also known as α) and R2 (also 
known as β), which require oxygen to generate stable tyrosyl radicals at the β2 diiron-oxygen 
cluster (Figure 1.3).(Cotruvo & Stubbe, 2011; Kolberg et al., 2004)   
The active form of the Saccharomyces cerevisiae RNR utilizes a distinct type of R2 
subunit (known RNR4 or β’) which forms a heterodimer with the β subunit.  The β’ subunit lacks 
iron the capacity to binding and therefore is incapable of forming the tyrosyl radical.(Huang & 
Elledge, 1997; Wang et al., 1997)  RNR4 deletions result in severe growth inhibition lethality 
and found to be defective in β subunit iron loading, revealing its vital role in the yeast RNR 
diiron cluster assembly.(Chabes et al., 2000; Nguyen et al., 1999; Zhang et al., 2011) Yeast also 
express a DNA damage-inducible form of the large subunit, Rnr3p, which demonstrates strong 
synergism in catalytic activity when combined with the α large subunit, Rnr1p.(Domkin et al., 
2002)  Rnr3p functional role in the DNA damage response still remains unclear, however it has 
been proposed that it may be necessary when dNTP production is low due to lower Rnr1p 
expression.(Domkin et al., 2002) 
Class II reductases, on the other hand, contain a single R1 subunit that form active 
monomers (α) or dimers (α2).  The thiyl radical is produced by cleavage of adenosylcobalamin, 
forming a deoxyadenosyl radical which fulfills an analogous function to R2 of other RNR 
classes.(Kolberg et al., 2004; Torrents, 2014)  Class III reductases are typically found in 
anaerobic organisms and are thereby repressed in the presence of oxygen.  Instead, it uses an iron 
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sulfur cluster alongside S-adenosylmethionine to generate free radicals required for reduction 
chemistry.(Nordlund & Reichard, 2006)   
Key to maintaining a stable genome is the proper regulation of dNTP pools throughout 
DNA synthesis and repair.  In fact, excessive dNTP production has been linked to increased 
mutation rates, while low dNTP levels stall DNA synthesis and, as a result, cell division.(Chabes 
et al., 2003; Chabes & Stillman, 2007; Poli et al., 2012).  Due to this, RNR is tightly regulated 
by a complex allosteric feedback mechanism regulated by substrate availability and product 
concentration.(Hofer et al., 2012).   
Allosteric regulations occur in the R1 subunit at the both the specificity site and the 
activity site (S- and A-site, respectively; Figure 1.3.A).   Allosteric regulation starts in the S-site, 
which can bind ATP and all dNTPs with the exception of dCTP.  When dNTPs bind into the S-
                                                 
††Figure 1.3 is adapted from Hofer, A., Crona, M., Logan, D. T., & Sjöberg, B.-M. (2012). DNA building blocks: 
keeping control of manufacture. Critical Reviews in Biochemistry and Molecular Biology, 47(1), 50-63. The article 
and its contents are open access and distributed under the terms and conditions of the Creative Commons Attribution 
3.0 license. 
 
Figure 1.3.†† Allosteric control of Class Ia ribonucleotide reductases.  (A) Cartoon diagram of a Class Ia ribonucleotide 
reductase.  Two α subunits form the l arge subunit homodimer (α- α) and two β (or a β-β’ for yeast) subunits form the 
small subunit dimer.  Allosteric regulation of ribonucleotide occurs at both the RNR specificity site and the activity 
site.  NTP reduction to dNTPs occurs at the catalytic site. (A) Ribonucleotide reductase feedback inhibition via 
ribonucleotides and deoxyribonucleotides.  (Hofer et al., 2012) 
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site, a conformational change induces alterations to the catalytic site that affects substrate 
reduction.  Binding of ATP and dATP to the S-site changes substrate specificity to CDP and 
UDP, which is subsequently reduced to dCDP and dUDP respectively (.B).  Interaction with 
dTTP at the S-site, on the other hand, stimulates GDP to dGDP reduction, while dGTP stimulates 
ADP to dADP reduction (Figure 1.3.B).  The A-site is an enzyme on/off switch that monitors 
relative amounts of dATP-to-ATP.  At high dATP concentrations, RNR activity is switched off 
by the A-site dATP feedback mechanism (Figure 1.3.B).   
Interestingly, Saccharomyces cerevisiae exhibit a relaxed dATP feedback mechanism that 
allows for increased survival to DNA damage due to elevated dNTP levels.(Chabes et al., 2003)  
As this study focuses on the yeast, Saccharomyces cerevisiae, and its RNR complex, the dNTP 
reduction chemistry will be framed according to its particular enzyme class, Class Ia RNR  
The ribonucleotide reduction process involves the conversion of a 2’-hydroxyl group on 
the ribonucleotide monomer to a hydrogen by radical reduction chemistry (Figure 1.4).  First, a 
thiyl radical is generated by long range radical transfer from the tyrosyl radical in the 
ribonucleotide reductase small subunit, R2.  The thiyl radical then reacts with ribonucleotides to 
extract the 3’-hydrogen from the ribose ring, resulting in a free radical intermediate (Figure 1.4.1 
to Figure 1.4.2).  The reactive intermediate makes the 2’-hydroxyl group more reactive, which 
becomes protonated and leaves as a water molecule leaving behind a 2’-ketyl radical (Figure 
1.4.3).   
Two active site cysteines are then oxidized and form a disulfide anion radical after 
transferring a hydrogen to the radical ribose intermediate (Figure 1.4.4).  Radical electron 
transfer then occurs through a hydrogen bond network whereby the radical relocates to the 
intermediate ribose 2’-position (Figure 1.4.5).  The radical then abstracts a hydrogen from the 
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nearby cysteine, and the final product – deoxyribonucleotide (dNTP) – leaves the active site 
(Figure 1.4.6).  Long range radical transfer through the electron transport chain in R2 carries the 
radical back to the R2 subunit to form the stable tyrosyl radical.  Regeneration of the reduced 
active site cysteines evolves from the redox reaction between the cysteine pairs, thioredoxin, and 
thioredoxin reductase to reduce free NADPH. (Kolberg et al., 2004) 
Despite being functionally analogous to the human RNR complex, the yeast RNR 
complex undergoes considerably different transcriptional and post-translational regulations.  
However, these protein deregulation mechanisms provide interesting opportunities for 
                                                 
‡‡Figure 1.4 is adapted from Kolberg, M., K.R. Strand, P. Graff, and K. Kristoffer Andersson, Structure, function, 
and mechanism of ribonucleotide reductases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 
2004. 1699(1–2): p. 1-34.  It is reprinted by permission of Elsevier. 
 
Figure 1.4.‡‡ Proposed class Ia ribonucleotide reductase catalytic mechanism to reduce ribonucleotides to 
deoxyribonucleotides.  Numbering is for E. coli specific amino acids involved in catalysis.(Kolberg et al., 2004) 
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discovering novel RNR binding and interaction motives that may be exploited in designing 
future chemotherapeutics therapeutics.    
Transcription of RNR subunits, RNR2, RNR3, and RNR4 is repressed during normal cell 
growth by the DNA binding protein, Crt1p (Figure 1.5), which recognizes specific X-box 
sequences in the RNR2, RNR3, and RNR4 gene promoter sequences.(Huang et al., 1998)  Crt1p 
recruits the Ssn6p-Tup1p which act to repress RNR gene expression.  Once the cell experiences 
DNA damage, Crt1p is hyperphosphoryated and detaches from the RNR promoter region, 
enabling transcription of RNR genes.(Huang et al., 1998)  Also in response to DNA damage, an 
HMG-box binding protein, Ixr1p, is recruited to the RNR1 promoter and activates its 
transcription.(Tsaponina et al., 2011)  
Yeast also utilize a unique post-translational method to sequence and inhibit RNR 
subunits.  Yeast RNR subunit negative regulators, DIF1 and SML1, reduce RNR complex 
activity during normal cell growth through nuclear redistribution of the Rnr2p-Rnr4p subunit and 
inhibition of the Rnr1p homodimer, respectively.(Lee & Elledge, 2006; Lee et al., 2008; Wu & 
Huang, 2008; Zhao, Xiaolan et al., 1998)  Upon DNA damage or replication arrest, however, 
Sml1p and Dif1p are phosphorylated and degraded.(Andreson et al., 2010; Lee et al., 2008)  
This, along with the transcriptional induction of RNR genes and localization of the RNR 
complex to the cytoplasm, serves to increase dNTP pools.(Andreson et al., 2010; Lee et al., 
2008; Zhao, X. & Rothstein, 2002) 
Post-translational regulation by Dif1p and Sml1p are unique to the yeast response 
mechanism.  As a negative regulator of the yeast DDR, Sml1p inhibition of Rnr1p appeared 
promising as a chemotherapeutic candidate.  Immediately following the discovery of SML1’s 
functional role, experiments were undertaken to test the capabilities of SML1 inhibiting the 
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murine RNR1 homolog, R1.  Binding affinity assays demonstrated weak Sml1p association to 
murine R1 that was greatly affected by the dNTP feedback mechanisms and competition with 
murine R2 binding.(Andreson et al., 2010; Chabes et al., 1999)  Due to these weak interaction 
characteristics, no further Sml1p studies have examined its potential chemotherapeutic fitness. 
Despite extensive analysis of MEC1 targets in DNA repair, several MEC1 pathway 
targets remain functionally uncharacterized.  Interestingly, though it is the most differentially 
expressed gene in the MEC1 DNA damage response to hydroxyurea, UV- and γ-radiation, and 
                                                 
§§Figure 1.5 is adapted from Sanvisens, N., de Llanos, R., & Puig, S. (2013). Function and regulation of yeast 
ribonucleotide reductase: cell cycle, genotoxic stress, and iron bioavailability. Biomed J, 36(2), 51-58. 
 
Figure 1.5.§§ Transcriptional and post-translational regulation of the yeast ribonucleotide reductase complex during S-
phase (blue arrows) and genotoxic stress (red arrows). (Sanvisens et al., 2013) 
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MMS, (Basrai et al., 1999) Hug1p still remains functionally and mechanistically undefined.  
hug1Δ mutants have been shown to recover the synthetic lethality of mec1Δ and rad53Δ deletion 
strains.(Basrai et al., 1999)  This is similar to other negative regulators of the MEC1 pathway, 
including DIF1 and SML1.(Andreson et al., 2010; Chabes et al., 1999; Lee et al., 2008; Wu & 
Huang, 2008; Zhao, X. & Rothstein, 2002)  Likewise, DIF1 and HUG1 share considerable 
sequence homology as result of gene duplication.(Lee et al., 2008)   
When the homologous “Hug” domain was mutated in DIF1, Dif1p lost the ability to 
localize the Rnr2p-Rnr4p subunit to the nucleus.(Lee et al., 2008)  This strongly suggests a 
potentially inhibitory interaction between Hug1p and Rnr2p-Rnr4p as Dif1p shows weak 
inhibition of RNR activity in vitro.(Lee et al., 2008; Wu & Huang, 2008)  Elucidating Hug1p’s 
role in the MEC1 pathway and defining its putative interaction with proteins in the DNA damage 
response will work towards defining novel MEC1 inhibitory mechanisms with applications in 
RNR inhibition in higher eukaryotic systems.  
1.2. Objective 
The eukaryotic DNA damage surveillance machinery is incredibly complex and highly 
specific towards the extent and type of DNA damage it responds to.  The vast protein network 
initiated upon genotoxic stresses is a hallmark of the cell’s dynamic action against a broad 
spectrum of environmental perturbations and carcinogens.  The material presented in this 
dissertation follows two overarching themes of the MEC1 DNA damage response in the budding 
yeast, Saccharomyces cerevisiae.  The first involves understanding and utilizing unique features 
of MEC1 gene transcription.  MEC1 transcriptional signatures provide ideal gene candidates that 
serve to advance sensitivity and broaden sensing capabilities of whole cell yeast biosensors to 
carcinogens.  In conjunction with this theme, this study also examines a unique biphasic 
transcriptional response of MEC1 DNA repair genes and establishes the genesis of this 
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characteristic profile.  Chapters 2 and 3, respectively, specifically address the theme of 
transcriptional.  Hallmark achievements of the individual chapters include: 
 Chapter 2 - Current fluorescent biosensors reporting DNA damage response genes have 
been shown to be sensitive to genotoxic agents, but lack efficient and inexpensive 
methods of detection.  By combining yeast MEC1 pathway genes promoters with a yeast 
optimized luciferase enzyme reporter system, an enhanced yeast whole cell biosensor was 
designed that detected carcinogenic compounds with improved sensitivity and dynamic 
range while shortening detection time when compared to comparable fluorescent-based 
reporters.  A new vector set was also developed to allow facile, PCR mediated promoter-
reporter construction with the optimized luciferase enzyme.   
 Chapter 3 - MEC1 DNA repair genes exhibit a dose-dependent biphasic response to 
alkylating agents, however the origin of this response is unknown.  A GFP promoter-
reporter system was used to identify the transcriptional response of major contributors to 
the MEC1 response to a survey of 9 cellular stress and DNA damaging agents.  External 
pathways to MEC1 were also examined for potential epigenetic regulation of MEC1 gene 
transcription.  Finally, cell cycle analysis was run to identify if cellular stage and arrest 
contributed to the MEC1 biphasic response. 
The second theme encompasses investigations into post-translational regulation of MEC1 
pathway genes.  As the MEC1 pathway is so complex, several target protein functional and 
mechanism roles have yet to be determined.  One such protein, HUG1, has characteristics of a 
MEC1 negative regulator and may be of clinical applicability, however little remains is known 
about its role in DNA repair response.  This study first establishes HUG1’s function in the 
MEC1 pathway and further identifies the mechanism and protein features utilized by HUG1 in 
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its recovery role.  Chapters 4 and 5, respectively, specifically address the theme of post-
translational regulation of the MEC1 repair process.  Hallmark achievements of the individual 
chapters include: 
 Chapter 4 - HUG1 has an uncharacterized role within the MEC1 pathway, despite 
exhibiting characteristics of MEC1 negative regulators.  Overexpression phenotyping 
assays were carried out to identify Hug1p effects on cells experiencing DNA damage and 
replication arrest.  Temporal expression and subcellular localization studies were also 
carried out to identify putative roles for HUG1 in the MEC1 response.    
 Chapter 5 - After characterizing HUG1 as a negative regulator of the MEC1 pathway, 
Hug1’s mechanistic role of inhibition was further examined.  Protein interaction assays 
and dNTP analysis were carried out to identify HUG1’s interaction partners and 
inhibitory mechanism.  Mutagenesis was then carried out across HUG1 to isolate regions 
necessary to Hug1p’s inhibitory activity. 
The final chapter summarizes major findings in this work and discusses future work 
based on these discoveries. 
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When cells are exposed to environmental perturbation, transcription is modulated in a 
specific manner, ultimately leading to the production of proteins that can increase the likelihood 
of survival. Assessing the transcriptional level of one or more of these responding proteins 
provides valuable information regarding the cellular surroundings. In fact, many researchers 
have exploited this sensitivity to a transient environment to develop a tool to explicitly determine 
cellular reactions to a wide range of stimuli. These ‘sensors’ typically consist of an easily 
detectable reporter gene regulated by an environmentally sensitive protein's promoter. Reporters 
such as β-galactosidase, GFP and luciferase have proved useful in these promoter–reporter 
systems, due to their considerable dynamic range and ease of use with multiple promoters 
(Daunert et al., 2000). Previously these promoter–reporter systems have been used to detect the 
presence of heavy metals (Mascorro-Gallardo et al., 1996; Virta et al., 1995), organic pollutants 
(Selifonova & Eaton, 1996), sugar sources (Chambers et al., 2004; Marrakchi et al., 2008) and 
DNA-damaging agents (Benton et al., 2007; Boronat & Pina, 2006). 
Despite the ubiquity of use, each sensor suffers from deficits that must be considered 
prior to implementation. β-Galactosidase- and luciferase-based systems require enzyme 
extraction for measurements, a process in which enzyme loss/deactivation and experimental time 
are major concerns (Garrido et al., 1994; McNabb et al., 2005). Fluorophore-derived reporter 
systems do not require enzyme extraction; however, applications in high-throughput systems are 
                                                 
††† This chapter previously appeared as Ainsworth W.B., Rome C.M., Hjortsø M.A., Benton M.G., Construction of 
a cytosolic firefly luciferase reporter cassette for use in PCR-mediated gene deletion and fusion in Saccharomyces 
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limited due to the necessity of whole-cell separation and expensive equipment required for 
measurement (e.g. flow cytometry). 
Improvements to each of these systems has increased the viability of these assays in high-
throughput systems (Huang & Shusta, 2005; Osipov et al., 2011). Advances to luciferase 
systems – most notably, a transition from in vitro to in vivo assays (Leskinen et al., 2003) – has 
been a watershed event in promoter–reporter systems. Detection remains inexpensive (a major 
advantage of the original detection method), while retaining large, accurate and quantifiable 
dynamic ranges without the variability reported between in vitro samplings (Tauriainen et al., 
1999; Vieites et al., 1994). Most importantly, measurement of in vivo bioluminescence can be 
taken quickly, accurately and in one-step (Michelini et al., 2005), without the additional lysis 
step commonly required of other luciferase assays (Liu et al., 2008; McNabb et al., 2005). 
Additionally, recently discovered secretable luciferases show promise as next-generation 
reporters that remain compatible with current detection techniques (Ochi et al., 2011; Tochigi et 
al., 2010). 
Applications of the new luciferase reporters hinge heavily on the method of introduction 
to host systems. Current luciferase systems utilize one of two common methods of 
transformation: yeast integrative plasmids (YIps) (Leskinen et al., 2003) and yeast centromere 
plasmids (YCps) (Ochi et al., 2011; Tochigi et al., 2010), both of which present advantages and 
disadvantages. YIps directly integrate reporters into the genome at the promoter locus, which 
preserves transcriptional regulation and accurately reflects native expression levels. Thus, YIps 
are typically employed when quantitative native promoter expression is desired. YIps, however, 
are specific to the promoter for which they were created, and are thereby largely inflexible when 
extending reporter functionality to other promoters. YCps are self-replicating, external plasmids 
  
37 
which express reporters under promoter control within the plasmid. As such, YCps do not knock 
out functional genes and expression reflects an unaltered phenotype of the host. Thus, YCps are 
best employed when seeking qualitative promoter response information regarding promoter 
responses. Despite the replication stability offered by the presence of the CEN/ARS fragments, 
these plasmids may exist in multiple copies inside the host, thereby exaggerating true promoter 
expression levels. In the context of biosensors, complete knowledge of active promoter regions 
must also be ascertained to effectively express a reporter using this system. Finally, plasmid loss 
remains a concern, as hosts must be maintained under constant selective pressure (Romanos et 
al., 1992; Rose & Broach, 1991; Stearns et al., 1990). 
For promoter–reporter applications requiring stable, accurate reporter quantification with 
promoter flexibility, a new transformation system is required. PCR-mediated gene 
deletion/fusion techniques have been developed for fluorophore-based reporter systems and 
show promise for extension to luciferase reporters (Benton et al., 2007; Longtine et al., 1998; 
Wach et al., 1997; Wach et al., 1994). Similarly to YIps, this method integrates directly into the 
genome, but does so via a simple, one-step PCR-mediated gene cassette containing the reporter 
of interest. In-frame insertions are directed by 5′ and 3′ homologous regions directly up- and 
downstream of the gene, expressing the reporter under direct promoter control. Primers 
containing these 5′ and 3′ homologous regions can be tailored according to the promoter of 
interest, allowing for promoter flexibility without prior knowledge of the promoter's sequence 
(Longtine et al., 1998). 
In this study, a novel plasmid, which introduces a cytosolic expressing firefly luciferase, 
LUC*(−SKL), capable of one-step, in vivo measurements (Leskinen et al., 2003) into a 
promoter–reporter system via PCR-based gene deletion (Longtine et al., 1998), was engineered. 
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The plasmid was utilized to introduce LUC*(−SKL) under HUG1 promoter control and to 
confirm cytosolic localization by fluorescence microscopy. The dose–response of this novel 
construct was compared with that of a similar HUG1Δ::yEGFP1 promoter–reporter system and 
showed a similar response pattern. To demonstrate the flexibility of the plasmid construct under 
multiple promoters and as a C-terminal fusion construct, an RNR3 knockout and a TEF1 fusion 
construct were also developed and confirmed to show functional luciferase activity. Thus, the 
newly constructed plasmid demonstrates utility for simple and accurate one-step reporting under 
a diverse set of promoters where gene expression and protein data are desired. 
2.2. Materials and methods 
2.2.1. Plasmid and strain construction 
A modified luciferase gene absent restriction enzyme sites (LUC*) was amplified from 
plasmid pBluc* (Bonin et al., 1994) using primers pBluc*–SKL SmaI Cass_F and pBluc*–SKL 
AscI Cass_R (Table 2.1). The reverse primer contains a C-terminal truncation of the peroxisome-
localization tag, SKL, which leads to cytosolic expression of Luc*(−SKL)p (Gould et al., 1988; 
Leskinen et al., 2003). A region containing the restriction enzyme sites SmaI and PacI in direct 
tandem and an additional cytosine base to ensure proper reading frame were added directly 
upstream of the LUC* sequence start codon. This region preserves a conservative primer-binding 
sequence, such that previously described PCR primers (Longtine et al., 1998) can be extended 
for use in this plasmid. A PacI region was not exclusively used, as LUC* contains a PacI 
restriction site beginning at base 1321 of pBluc*. A restriction site encoding AscI was added to 
the reverse primer sequence, directly downstream of the stop codon of LUC*. PCR products 
were combined, phenol–chloroform extracted once, then digested with SmaI and AscI restriction 
enzymes for 10 min on a 37°C heat block. Plasmid pFA6-GFP(S65T)-His3MX6 (Longtine et al., 
1998) was also digested with SmaI and AscI and the 4.0 kb fragment was excised from a gel, 
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using a Thermo Scientific Fermentas GeneJET Extraction Kit (cat. no. K0691, Thermo 
Scientific, Glen Burnie, MD, USA). 
The digested PCR product and plasmid fragment were ligated using T4 ligase in a 3:1 
molar ratio, respectively, at 4°C overnight. 5 µl ligant were added to DH5α cells (cat. no.18265-
017, Invitrogen, Grand Island, NY, USA) and transformed according to the manufacturer's 
protocol. Transformants were plated on ampicillin (AMP)-selection plates and allowed to grow 
until colony formation (approximately 16 h). Colonies picked from selection plates were grown 
in Luria broth (LB)–AMP broth for ~16 h, after which the cells were harvested and plasmid 
DNA prepared by the alkaline lysis method (Ehrt & Schnappinger, 2003). Successful ligation 
was confirmed by PCR and Big Terminator Dye sequencing. The resulting plasmid was named 
pFA6-LUC*(−SKL)-His3MX6 (AddGene, Plasmid ID 40233). 
To create a PCR-based gene fusion/deletion-compatible yEGFP1 plasmid, plasmid 
pKT128 (EUROSCARF) was digested with restriction enzymes PacI and AscI to remove the 
linker sequence (Sheff & Thorn, 2004). The yEGFP1 fragment was extracted from a gel and 
subsequently ligated into the 4.0 kb fragment of a PacI–AscI-digested pFA6-GFP(S65T)-
His3MX6, as mentioned above, recovering compatibility with the PCR-based gene 
fusion/deletion primers. Transformation and verification were performed as described above. 
The new plasmid was named pFA6a-yEGFP1-His3MX6 (AddGene, Plasmid ID 40231). All 
DNA manipulations were performed using standard techniques unless otherwise stated 
(Sambrook & Russell, 2001).  
To verify Luc*(−SKL)p activity, a promoter–reporter system was developed using PCR-
mediated gene deletion (Longtine et al., 1998). Forward primer Hug1 KO Cass _F and reverse 
primer Hug1 KO Cass_R (Table 2.1) were designed to create a cassette containing the 
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LUC*(−SKL) and HIS3MX6 fusion flanked by 45 bp of homologous regions up- and 
downstream of the HUG1 ORF. The resulting PCR product was transformed into the yeast strain 
BY4743 (MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/met15Δ0 ura3Δ0/ura3Δ0) (Open 
Biosystems, Lafayette, CO, USA) using the lithium acetate/single-stranded carrier 
DNA/polyethylene glycol (PEG) method (Gietz & Schiestl, 2007), resulting in the new strain, 
ABY700 (MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/met15Δ0 ura3Δ0/ura3Δ0 
hug1Δ::LUC*(−SKL)/HUG1). Transformants were plated on synthetic complete media minus 
histidine (SC–HIS) selective plates and grown until colony formation. Colonies were picked into 
liquid SC–HIS media and grown overnight, after which cells were collected and DNA extracted 
via the bust n’ grab method (Harju et al., 2004). Successful integration into the host genome was 
confirmed by PCR, using primers Hug1 KO Ver_F and pBluc* Ver_R (Table 2.1). 
Strain ABY1101 (MATa/MATα his3Δ1/ his3Δ1 leu2Δ0/ leu2Δ0 met15Δ0/ met15Δ0 
ura3Δ0/ ura3Δ0 hug1Δ::yEGFP1/HUG1) was constructed and confirmed identically to 
ABY700, with the exception that the PCR template was pFA6a-yEGFP1-HIS3MX6, resulting in 
the knockout of HUG1 with yEGFP1. 
In order to demonstrate the flexibility of the luciferase reporter system to other promoters 
and utility in C-terminal fusion constructs, RNR3 was selected for further examination of gene 
deletion and TEF1 was chosen for gene fusion. RNR3 gene deletion and TEF1 C-terminal fusion 
both utilized pFA6a-LUC*(−SKL)-HIS3MX6 as construct templates. Primers used for RNR3 
gene deletion were RNR3 KO Cass _F and RNR3 KO Cass_R; primers used forTEF1 C-terminal 
fusion were TEF1 Fusion Cass_F and TEF1 Fusion Cass_R (Table 2.1). The cassettes were 
transformed as previously described, resulting in the creation of strains ABY707  
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Table 2.1. Sequence of primers used to construct and confirm all plasmids 
Primer Nucleotide Sequence (5' -- 3') Application 
pBluc*-skl SmaI Cass_F  
GCG GCG CCC GGG TTA ATT AAC 
ATG GAA GAC GCC AAA AAC ATA 
PCR-Mediated Gene 
Deletion/Fusion 
Plasmid Construction pBluc*-skl AscI Cass_R  
GTC TGG CGC GCC TTA AAG CTT 
CTT TCC GCC CTT 
pFA6 MCS US _F CGC CAG CTG AAG CTT CGT A 
GAL1 CEN/ARS 
Plasmid Construction pFA6 MCS DS SalI _R 
CGC GTC GAC ATT CGC TTA TTT 
AGA AGT GG 
Hug1 KO Cass _F   
TAT ATA TAA CTA CAA ACC ACA 
TCA GCA ATA AAA AAA AAC TAT 
ATG CGG ATC CCC GGG TTA ATT AA 
PCR-Mediated Gene 
Deletion 
Hug1 KO Cass_R  
GTT CTT TCC TAT CAT TGG CCT 
ACA AAA AAA AAG AGA AGC ATG 
CTC GAA TTC GAG CTC GTT TAA AC 
RNR3 KO Cass _F   
AGC AAG AAT AGC AGC AGC AAT 
AAA TCA AAT ACT CCC ACA CAA 
ATG CGG ATC CCC GGG TTA ATT AA 
RNR3 KO Cass_R  
CGC TCC AAG TTA GAT AAG GAA 
AGG GAA AAA TGC CAC CAG AAA 
GAA GAA TTC GAG CTC GTT TAA AC 
TEF1 Fusion Cass_F 
C GCT AAG GTT ACC AAG GCT 
GCT CAA AAG GCT GCT AAG AAA 
CGG ATC CCC GGG TTA ATT AA PCR-Mediated Gene 
Fusion 
TEF1 Fusion Cass_R 
A TAT AAA AGA TAT GCA ACT 
AGA AAA GTC TTA TCA ATC TCC 
GAA TTC GAG CTC GTT TAA AC 
pBluc* Ver_F AGA GAT ACG CCC TGG TTC CT 
PCR Verification 
pBluc* Ver_R AAT CTG ACG CAG GCA GTT CT 
Hug1 KO Ver_F TCG GAC TTA CTC AAA GGG TTG 
Rnr3 KO Ver_F TTC GTC ACT TGG CTC AAC AG 
TEF1 Fusion Ver_F CGT CTG TGG TGA CGC TAA GA 
pRS-GAL1 luc* Ver_F CAT CGA CTG AAA TCC CTG GT 
pRS-GAL1 yEGFP1 
Ver_F 
CAA GAC TGG ACC ATC ACC AA 
pRS-GAL1 Ver_R CCC TCC GAA GGA AGA CTC TC 
Restriction sites are underlined. Conserved primer binding regions are in italics. 
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(MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/met15Δ0 ura3Δ0/ura3Δ0 
rnr3Δ::LUC*(−SKL)/HUG1) and MGBY710 (MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 
met15Δ0/met15Δ0 ura3Δ0/ura3Δ0 TEF1–LUC*(−SKL)-HIS3/TEF1). Successful integration into 
the host genome was confirmed by PCR using primer pBluc* Ver_R and either primer Rnr3 KO 
Ver_F for RNR3 deletion or primer TEF1 Fusion Ver_F for TEF1 C-terminal fusion. 
For protein half-life studies, strict regulation of reporter expression was required. 
pRS413-GAL1 (Mumberg et al., 1995), a YCp containing the GAL1 promoter with a CEN/ARS 
fragment, allows for induction of the GAL1 promoter in the presence of galactose and a non-
inducing, non-repressive carbon source, such as raffinose. However, when switched to glucose, 
the transcription from the GAL1 promoter is strongly repressed. Utilizing this feature, reporters 
were placed under GAL1 control and monitored for protein degradation. To create PGAL1-
LUC*(−SKL), the LUC*(−SKL) fragment of pFA6a-LUC*(−SKL)-His3MX6 was copied by 
PCR using primers pFA6 MCS US _F and pFA6 MCS DS SalI _R (Table 2.1). These primers 
were designed such that the 5′-end of the fragment contained a portion of the MCS of the pFA6 
plasmid, while the 3′ end introduced a SalI restriction enzyme site. The resulting PCR fragment 
was extracted once with phenol:chloroform and subsequently digested with SmaI and SalI 
restriction enzymes. The digested product was then ligated into a SmaI–SalI digested pRS413, as 
outlined above. 5 µl ligant were then transformed into DH5α cells in accordance with the 
manufacturer's protocol and transformants selected as described above. Successful ligation of the 
LUC*(−SKL) reporter under the GAL1 promoter was confirmed using primers pRS-GAL1 luc* 
Ver_F and pRS-GAL1 Ver_R (Table 2.1). The new plasmid was named pRS413-PGAL1-LUC* 
(AddGene, Plasmid ID 40234). The PGAL1-yEGFP1 plasmid was constructed in a similar manner 
with a few exceptions. Template pFA6a-yEGFP1-HIS3MX6 was used in place of pFA6a-
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LUC*(−SKL)-HIS3MX6 to create the yEGFP1 cassette. Successful ligation of yEGFP1 under 
the GAL1 promoter was confirmed by primers pRS-GAL1 yEGFP1 Ver_F and pRS-GAL1 
Ver_R. The new plasmid was named pRS413- PGAL1-yEGFP1 (AddGene, Plasmid ID 40235). 
Both pRS413- PGAL1-LUC* and pRS413- PGAL1-yEGFP1 were transformed into the 
BY4741 parent strain, resulting in the creation of strains MGBY001 and MGBY003, 
respectively. Transformants were selected as described above, and confirmed using the primers 
pRS-GAL1 Ver_R and either pRS-GAL1 yEGFP1 Ver_F or pRS-GAL1 luc* Ver_F, 
respectively. 
2.2.2. Cell culture 
Methyl methanesulphonate (MMS) (cat. no. 129925, Sigma-Aldrich, St. Louis, MO, 
USA) and was added to the cultures as stated below. For both LUC*(-SKL) and yEGFP1 
expression assays, 10 ml preculture was grown in YPD overnight in a shaking incubator at 30°C 
and 150 rpm. For RNR3 knockout luciferase assays, log-phase cultures were diluted to 
OD600 = ~0.1 and subjected to either YPD for controls (no expression) or MMS for promoter 
induction. For HUG1 knockout luciferase assays, log-phase cultures were diluted in YPD to 
OD600 = ~0.1. MMS and/or YPD was added to the cultures, such that the final MMS 
concentrations were 0.00%, 0.005%, 0.01% and 0.05%. The cultures were grown for 2, 4, 6 and 
8 h, then prepared for expression analysis. TEF1–LUC* fusion strains were grown overnight in 
YPD, diluted to OD = ~0.1 and allowed to grow to mid-log-phase (OD = ~0.6). The cultures 
were then diluted to OD = ~0.2 in YPD prior to taking measurements. 
2.2.3. Fluorescence microscopy 
To determine the localization of the Luc*(−SKL)p and yEGFP1p, control and induced 
populations were grown for 8 h as described in Materials and methods. At the indicated time, the 
entirety of the population was harvested by centrifugation. For Luc*(−SKL)p, an 
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immunofluorescent assay on fixed cells was then performed as described (Pringle et al., 1991), 
with no modification. Goat anti-luciferase primary antibody (cat. no. AB3256, Millipore, 
Temecula, CA, USA) was used at a dilution of 1:2000. Rhodamine-conjugated rabbit anti-goat 
secondary antibody (cat. no. AP106R, Millipore, Temecula, CA, USA) was reconstituted to 1 
mg/ml in double-distilled water (ddH2O) and an equal volume of 100% glycerol and stored in a 
−20°C freezer until used. A dilution of 1:100 was used for the secondary antibody. Hoechst 
33348 (cat. no. I34406, Molecular Probes, Eugene, OR, USA) was added to a final concentration 
of 1 μ m as a nuclear stain. For yEGFP1p localization, intact cells were resuspended in 
phosphate-buffered saline (PBS). Hoechst 33342 was added to a final concentration of 1 μ m as a 
nuclear stain. The cells were then wet-mounted on a microscope slide and imaged. 
Images were acquired using a Zeiss Axio Observer Z1 inverted microscope fitted with an 
AxioCam MRm camera, and Pln APO 63×/NA 1.4 oil immersion objective with Optiovar 1.6×. 
Nuclear staining was imaged using Zeiss Filter set 49 (EX365, EM445/50); yEGFP1p was 
imaged using Zeiss Filter set 38 HE (EX470/40, EM525/50); and antibody-conjugated 
Luc*(−SKL)p was imaged using Zeiss Filter set 20 (EX546/12, EM575-640). Exposure times 
were set to 1000, 200 and 200 ms, respectively. 
Images were analysed and deconvolved using ImageJ. The point-spread function (PSF) 
was calculated using the ImageJ plugin, Diffraction PSF 3D. The resulting PSF image was used 
as the PSF (kernel) image in the ImageJ plug-in, Iterative Deconvolve 3D (Dougherty, 2005), 
where the default/suggested settings were used. 
2.2.4. FACS Analysis of hug1Δ::yEGFP1 expression 
For each replicate, approximately 30 000 cells were counted using an Accuri C6 Flow 
Cytometer (BD Accuri Cytometers, Ann Arbor, MI, USA). GFP induction analysis was 
performed using Accuri C6 Sampler Analysis software and GraphPad Prism 5 software. Intact 
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cells were defined as whole cells (measured by forward light scattered) with intact membranes 
(measured by propidium iodide exclusion). yEGFP1p expression was determined by gating 
around these parameters. 
2.2.5. Luciferase assay 
D-Luciferin, sodium salt (cat. no. L37080, RPI Corp., Mount Prospect, IL, USA) was 
resuspended at a concentration of 20 mM in 50 mM citrate buffer, pH 5.0 (Gomori, 1955) and 
stored at −20°C until used. For intact cell readings, 100 µl each sample was removed from the 
growing culture in medium and added to a 12 × 75 mm polystyrene tube, then D-luciferin (100 
µl, 2 m m) in 50 m m citrate buffer, pH 5.0, was added to the sample, briefly vortexed and read 
in an Optocomp I luminometer (MGM Instruments, Hamden, CT, USA). Results from the 
luminometer's data streaming function indicated maximum luciferase activity 25–35 s after 
addition of luciferin substrate (Figure 2.3.A). Thus, a 25 s delay and 10 s integration time was 
used to record the luminometer's arbitrary light unit (RLU) data. Over three independent trials, 
dosage was read in triplicate and only replicates with a coefficient of variance < 5% were kept. 
Previous studies indicate that cell permeabilization may enhance luciferase activity in 
dual-luciferase assay systems (Liu et al., 2008; McNabb et al., 2005). To test the effect of 
permeabilization on the luciferase promoter–reporter construct, an assay similar to one 
previously established (McNabb et al., 2005), utilizing a passive lysis buffer (PLB; cat. no. 
E1941, Promega, Madison, WI, USA) and the luciferase assay system (cat. no. E1500, Promega) 
was developed to compare results received from permeabilization to those of intact cells. PLB 
and luciferase assay buffer + reagent (LABR) from the luciferase assay system were prepared 
according to manufacturer's instructions. For the assay, 10 µl cells was removed from a growing 
culture and added directly to 100 µl 1× PLB. After 10 s of lysis, 10 µl this mixture was 
  
46 
transferred to 100 µl LABR, followed by a 10 s delay and a 10 s integration time. These steps 
were repeated for three independent trials for all integrated promoter–reporter constructs. 
2.2.6. Protein half-life assay 
D-Galactose (cat. no. G0750, Sigma-Aldrich, St. Louis, MO, USA), d-raffinose (cat. no. 
R0514, Sigma-Aldrich) and dextrose anhydrous (cat. no. BP350, Fisher BioReagents) were 
suspended in ddH2O to a final concentration of 20% and filter-sterilized before use. To maintain 
the plasmid throughout growth, cultures containing pRS413-GAL1 were grown in selective 
media. Strains were also grown under constant galactose induction to ensure steady-state 
expression of the reporter, whereupon constant levels of reporter are achieved due to the 
equilibrium of reporter degradation and production. Thus, when GAL1 promoter transcription is 
ultimately terminated upon transfer to dextrose, no additional reporter is made and loss of protein 
signal can be attributed to protein degradation. This method has been successfully utilized in 
other studies to determine the half-life of both firefly luciferase (McNabb et al., 2005) and cyan-
fluorescent proteins (Hackett et al., 2006). 
Starter cultures of strains MGBY001 and MGBY003 were seeded into 5 ml SC–HIS plus 
2% D-galactose and 1% D-raffinose and grown overnight. The next morning, cultures were 
diluted to an OD600 = ~0.2 in 5 ml SC–HIS plus 2% D-galactose and 1% D-raffinose and grown 
for an additional 4 h. At this point, the entirety of the culture was centrifuged, washed twice in 
equal volumes of PBS, and diluted in SC–HIS plus 2% dextrose to a final OD600 = 0.2. Samples 
were taken immediately after switching to dextrose. For luminescence assays, triplicate samples 
were read every 30 min. Prior to reading, the sample volume was adjusted using SC–HIS plus 
2% dextrose, such that the final OD600 = ~0.2. Once adjusted, luciferase activity was read as 
described above. For fluorescence assays, triplicate samples were harvested every hour. On the 
hour, exactly 1 ml culture was centrifuged, washed twice in PBS, resuspended in 1 ml PBS and 
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immediately taken to be analysed by flow cytometry. Gating parameters for yEGFP1 were 
identical to those previously described. 
2.2.7. Statistical analysis 
For promoter induction assays, yEGFP1p fluorescence as a function of dose and time was 
determined via flow cytometry, by taking the geometric mean fluorescence intensity in channel 
FL1 for at least three independent trials. Fold induction was defined as the ratio of the geometric 
mean in the green channel (FL1) of induced populations over control (no induction) populations 
for each trial. A Tukey's multiple comparison test with repeated measures was used to determine 
the p value for GFP fold induction values across all trials and doses for each individual time. The 
GFP induction was then averaged for all trials with the same dose and time of exposure, and the 
standard deviation (SD) was calculated. Criteria for positive results (i.e. no auto- or media 
fluorescence) were established as GFP fold induction > 2 and p ≤ 0.05. 
Luciferase activity was calculated using the raw RLU value from the luminometer for at 
least three independent trials. Fold induction was defined as the ratio of RLU of induced 
populations with addition of D-luciferin substrate over RLU of control (no induction) 
populations, with addition of D-luciferin substrate for each trial. Statistical analysis utilized for 
yEGFP1p data was also performed on the luciferase activity data. Criteria for a positive result 
were established as luciferase fold induction > 2 and p ≤ 0.05. 
For yEGFP1 protein half-life determinations, absolute fluorescence was obtained via 
flow cytometry and determined as the summation of the FL1 values for all events for at least 
three independent trials. Since identical cell counts were used in analysis, this value represents 
the total fluorescence value for a constant population of cells. A decrease in absolute 
fluorescence intensity can thus be correlated to the loss of protein due to degradation. The 
percentage of initial fluorescence was then determined to be the ratio of the absolute 
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fluorescence through time to the absolute fluorescence of the initial time point. Protein 
degradation was found to be first order by fit to a non-linear, exponential decay equation. 
Similar to yEGFP1p, luciferase protein half-life determinations were performed on a 
culture of a constant cell count by adjusting the sample to OD = 0.2 prior to reading. Luciferase 
activity was calculated using the raw RLU value from the luminometer for at least three 
independent trials. The percentage of initial luminescence was calculated as the ratio of the raw 
RLU value through time vs the initial raw RLU value. Luc*(−SKL) protein degradation was also 
found to be first order by fit to a non-linear, exponential decay equation. 
2.3. Results and discussion 
2.3.1. Successful integration and functional expression of cytosolic-expressing luciferase into the 
PCR-mediated gene deletion/fusion plasmid 
Previous works have suggested that deletion of the C-terminal peroxisome localization 
signal, SKL, leads to cytosolic localization of luciferase (Gould et al., 1988; Leskinen et al., 
2003). In this study, this cytosolic-expressing luciferase was introduced into a PCR-mediated 
gene deletion/fusion plasmid construct (Longtine et al., 1998). The one-step PCR gene 
deletion/fusion process used to construct knock-out or fusion strains provides a simple method of 
integrating single copies of reporters into the genome under promoter control, without prior 
knowledge of the promoter sequence. This method also allows direct comparisons of sensitivity 
and expression levels to fluorophore-based sensors created in the same manner. Sequencing data 
(Figure 2.1) demonstrates successful integration of LUC*(−SKL) into the gene deletion plasmid. 
Biosensor reporter systems are typically designed to respond to environmental stresses, such as 
heavy metals (Corbisier et al., 1999) and DNA damage (Afanassiev et al., 2000; Benton et al., 
2007).  Characterizations of temporal and dosage responses of Hug1-based GFP reporters have 
been established in great detail for multiple DNA damaging agents (Benton et al., 2007). Of the 
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DNA-damaging agents studied, methyl methanesulphonate (MMS) induces a highly 
characteristic dose–response from PHUG1-GFP reporter constructs, where expression levels show 
a biphasic response centred around the 0.01% MMS dosage (Benton et al., 2007).  
Due to this distinctive response, the HUG1 promoter was chosen for the LUC*(−SKL) 
reporter construct. Utilizing the engineered plasmid as a template, further confirmation of 
compatibility with PCR-mediated gene deletion was undertaken by knocking out HUG1 and 
replacing it with the LUC*(−SKL) reporter, thereby placing the reporter under genomic control 
of the HUG1 promoter. To demonstrate promoter flexibility of the plasmid constructs, the 
LUC*(−SKL) reporter was also placed under RNR3 promoter control by gene deletion. Also, 
yEGFP1 was placed under HUG1 promoter control as a positive control for strain-specific 
sensitivity and expression levels.   
Similar to HUG1, RNR3 shows a peak of expression when exposed to 0.01% MMS 
for ≥ 6 h (Ochi et al., 2011). These conditions were utilized to demonstrate functional expression 
of Luc*(−SKL)p from the RNR3 promoter.  Finally, LUC*(−SKL) was integrated at the C-
terminal of TEF1 to validate reporter utility in fusion constructs. Due to the constitutive 
expression of the TEF1 promoter, fusions to the C-terminal of TEF1 express high levels of 
reporter in functional constructs. Functional luciferase activity was reported in all three 
constructs (Table 2.2). Briefly, hug1Δ::LUC* and rnr3Δ::LUC* gene deletions show a 38-fold 
and 29-fold increase over the control samples, respectively.  TEF1–LUC* also shows clear 
expression of functional luciferase, with RLU values nearly twice as large as induced 
hug1Δ::LUC* deletion strains.  Other studies have indicated that permeabilization of samples 
prior to reading increases the sensitivity of the luciferase assay (Liu et al., 2008; McNabb et al., 
2005; Vieites et al., 1994). Permeabilization of yeast cultures using proprietary detergents has 
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been extensively investigated and found to have an immediate improvement on luciferase 
activity, but a long-term detrimental effect if permeabilization extends outside of the ideal read-
interval (McNabb et al., 2005).  
This observation was consistent with experiments performed on the construct developed 
(data not shown). To further investigate permeabilization effects on luciferase activity, 
experiments were performed within the ideal read-time indicated by McNabb et al. (McNabb et 
al., 2005). Results given in Table 2.2 show a large increase (9–40-fold) in the RLU values of 
permeabilized cells when normalized to method-related dilutions. Thus, the sensitivity of 
permeabilized cultures is significantly higher than intact cell readings when viewing raw RLU 
data. However, when RLU values were normalized to control samples for fold induction 
analysis, the difference between the two methods was less pronounced. As such, 
permeabilization appears to increase the lower detection limit and may prove more useful than  
 
Figure 2.1. Sequencing data and general characteristics of plasmid pFA6a-LUC*(−SKL)-His3MX6: CFBS, conserved 
forward binding site; CRBS, conserved reverse binding site. 
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the intact cell method for detecting weak promoters. However, if relative data of moderately-
expressing promoters is required, the intact cell method provides accurate data in an equally 
efficient and inexpensive manner. Further, trends obtained through the use of one-step, intact cell 
readings coincide well with data previously reported for other genotoxicity assays using the dual 
luciferase system (Liu et al., 2008). Most importantly, previous implementation of the 
permeabilization technique was performed in the context of the dual-luciferase assay, where 
access to both the firefly luciferase inhibitor and Renilla luciferase add additional concerns. 
Clearly, in these types of measurement, permeabilization is required for accurate readings. 
However, our study focuses on the creation of constructs capable of integrating a single 
Table 2.2. Relative light units (RLU), fold induction (FI), and sensitivity data of Luc*(−SKL)p expressed as a 








    
No induction 2.2 + 0.2 52.9 + 7.2 23 + 2 
MMS-induced 88.1 + 5.6 802 + 20 9 + 2 
FIc 




    
No induction 0.9 + 0.1 11.3 + 4.0 16 + 3 
MMS-induced 25.6 + 1.5 402 + 50 13 + 1 
FIc 29 + 5 38 + 10 
 
 
TEF1-LUC*(-SKL) Constitutive 90.6 + 3.3 
3620 + 
230 
40 + 2 
  a RLU values are expressed as the raw RLU value from the luminometer multiplied by the method-
related dilution factor. 
b Sensitivity is calculated as the ratio of RLU of permeabilized samples versus RLU of intact sample. 
c Fold induction is calculated as the ratio of MMS-induced samples vs samples with no induction. 
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luciferase gene into the genome and therefore does not have the additional restrictions of the 
dual-luciferase assay. 
2.3.2. Confirmation and localization of Luc*(–SKL)p and yEGFP1 by fluorescence microscopy 
Cytosolic localization increases the luciferase activity in intact yeast cells, presumably 
due to increased availability of luciferase to its substrate (Leskinen et al., 2003). Thus, any 
modified luciferase must be evaluated for proper localization to ensure that optimal activity will 
be obtained. To confirm localization of Luc*(−SKL)p to the cytoplasm, an immunofluorescent 
assay was performed on control populations and populations induced with 0.01% MMS for 8 h. 
Antibody-conjugated Luc*(−SKL)p appears to be evenly distributed in the cell cytoplasm, with 
little organelle-specific localization (Figure 2.2), consistent with previous reports (Leskinen et 
al., 2003).Some nuclear localization was noted; however, this appears to be a bleed-through 
artifact from out-of-focus light (Figure 2.2, arrow). Expression levels were also notably higher 
than control populations (Figure 2.2).  Similarly, confirmation and localization of a successful 
hug1Δ::yEGFP1 construct was determined in MMS-induced and uninduced strains under the 
same conditions. yEGFP1p is evenly distributed throughout the cell; unlike Luc*(−SKL)p, 
yEGFP1p demonstrates clear nuclear localization (Figure 2.2, arrow). This distribution is 
consistent with GFP expression patterns seen in other eukaryotes (Ogawa et al., 1995). 
2.3.3. Dose–response of hug1Δ::LUC*(−SKL) and hug1Δ::yEGFP1 to MMS 
To determine the effectiveness of the construct as a DNA-damage reporter, luciferase 
expression in response to MMS was monitored using the hug1Δ::LUC*(−SKL) promoter–
reporter system and compared to HUG1::yEGFP1. As previously reported, HUG1 promoter–
reporter systems demonstrate a biphasic response to MMS exposure, with a maximum centred at 
0.01% MMS (Benton et al., 2007). Dosage levels of 0.005%, 0.01% and 0.05% MMS were 
chosen, as these levels are sufficient in resolving the biphasic response. A biphasic response of  
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the hug1Δ::LUC*(−SKL) construct can be seen within 2 h of induction, and continues through 
the 8 h time points (Figure 2.3.B). Similarly, a biphasic response of the hug1Δ∷yEGFP1 
construct can be resolved within 2 h of induction, continuing for the duration of the 8 h 
experiment. Both constructs displayed maximum induction at 0.01% MMS. Clearly, the 
LUC*(−SKL) reporter accurately depicts qualitative information comparable to the yEGFP1 
positive control constructs. More importantly, the luciferase assay is significantly quicker to 
perform, requiring no processing prior to data obtainment. Real-time acquisition of luciferase 
activity took in the order of minutes per sample, while yEGFP1 constructs required hours for 
processing and flow-cytometry data acquisition. The simplicity and ease of the luciferase assay is 
therefore more accommodating for high-throughput assays.  Significant differences of temporal 
response were noted between the hug1Δ::yEGFP1 positive control and the hug1Δ::LUC*(−SKL) 
strain. A two-way ANOVA with Bonferroni multiple comparisons was performed to analyse any 
 
Figure 2.2. Confirmation of Luc*(−SKL)p and yEGFP1p localization by fluorescence 
microscopy. Co-localization is indicated by a colour merger of the two channels (magenta for 
TRITC + Hoechst; aqua for yEGFP + Hoechst); white arrow, nuclear colocalization; white bar 
has dimensions of 10 µm. 
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significant changes across time. If no significant differences were noted, the population was 
considered to have reached an expression level steady state.  
After the 2 h time point, the hug1Δ::LUC*(−SKL) construct reveals no statistical 
difference for p < 0.05 of the 0.005% dose fold induction. The hug1Δ::yEGFP1 construct, on the 
other hand, shows no statistical difference for p < 0.05 after the 4 h time point. Therefore, for the 
0.005% dosage, Luc*(−SKL)p reaches a steady-state much earlier than yEGFP1p. For the 0.01% 
dose, hug1Δ::LUC*(−SKL) shows significance to p < 0.001 throughout the 8 h experiment. 
hug1Δ::yEGFP1, on the other hand, shows no significant difference for p < 0.05 after the 6 h 
time point. Unlike at the lower dosage, yEGFP1p appears to reach a steady-state expression 
before luc*–SKL. For the 0.05% dose, hug1Δ::LUC*(−SKL) also shows no significant 
 
Figure 2.3. (A) Data stream of Luc*(−SKL)p at 8 h under 0.01% MMS induction. Integration time period is indicated 
by solid red lines. Fold induction vs MMS dosage plots for (B) Luc*(−SKL)p and (D) yEGFP1p. Fold induction vs 
time for (C) Luc*(−SKL)p and (E) yEGFP1p. 
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difference for p < 0.05 of fold inductions after the 6 h time point.  hug1Δ:yEGFP1 demonstrates 
significance for p < 0.0001 throughout the experiment. The highest dosage, therefore, mirrors the 
lowest dosage with respect to steady-state expression levels, with Luc*(−SKL)p reaching steady 
state before yEGFP1p. 
Differences between the reporters may be attributed to the half-life of the respective 
reporter. Firefly luciferase has been shown to have a half-life of approximate 96 min in vivo 
(McNabb et al., 2005), while GFP variants have a half-life which lasts anywhere from 3.3 h 
(Chambers et al., 2004) to 7 h in vivo (Mateus & Avery, 2000; Natarajan et al., 1998). For half-
life determinations of Luc*(−SKL)p and yEGFP1p in the strains utilized in this study, an assay 
similar to one used to determine the half-life of cyan fluorescent proteins (CFP) (Hackett et al., 
2006) was implemented. In short, LUC*(−SKL) and yEGFP1 were placed under GAL1 promoter 
control and assayed using galactose–glucose promoter regulation. Prior to GAL1 half-life 
experiments, the minimal induction time for LUC*(−SKL) after induction with galactose was 
determined to be approximately 40 min (Figure 2.4.A). However, after 120 min, luminescence 
continued to increase without reaching a stability limit. Thus, in order to achieve steady-state 
expression, cultures were grown overnight in galactose induction and diluted into galactose-
containing medium the next morning. Time points immediately following the carbon shift were 
taken and used to calculate the half-lives of the reporters.  
A lag of approximately 1 h was seen in both luciferase and fluorescence assays 
performed (data not shown). Data received from both assays were plotted (Figure 2.4.B, C) and 
fitted to first-order exponential decay kinetics. Results from these analyses indicate a half-life for 
Luc*(−SKL)p of 98 min, which correlates well with the 96 min previously reported (McNabb et 
al., 2005). yEGFP1p has a half-life of 184 min, which correlates closely with other reports of 
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3.3h using GFP and alternative carbon source induction (Chambers et al., 2004), but is 
significantly less than the 7 h half-life reported using yEGFP3 and cycloheximide (Mateus & 
Avery, 2000). Despite this, luciferase appears to degrade nearly twice as quickly as yEGFP1p in 
vivo, according to these data. yEGFP variants, therefore, may show a high level of accumulation 
prior to reaching an expression steady state. As luciferase has a much shorter half-life, it is 
conceivable that these reporter constructs would reach the expression steady state more quickly 
than the yEGFP1 counterpart. This trend can be seen in a comparison of the significance values 
of 0.005% and 0.05% dose in the two reporters. Luc*(−SKL)p appears to reach an expression 
steady-state at the 2 h time point for 0.005% dosage and the 6 h time point for 0.05% dosage.  
yEGFP1p, on the other hand, reaches an expression steady state at the 4 h time point for 
the 0.005% dosage and does not reach a steady state for the 0.05% dosage. yEGFP1p's high 
stability in vivo leads to a pronounced accumulation effect under constant induction. 
Luc*(−SKL)p, on the other hand, readily degrades between assay time points. Due to this, each 
reporter assumes a specific application in the context of biosensors. If real-time data of a 
promoter system are required, Luc*(−SKL)p would be ideal, due to its relatively short half-life in 
vivo. Alternatively, yEGFP1 constructs amplify promoter signals through the accumulation 
 
Figure 2.4. (A) Induction time of PGAL1-LUC*(−SKL) taken immediately after induction with galactose. (B) Protein 
half-life plot for Luc*(−SKL)p with fit to exponential decay equation; half-life approximated as 98 min. (C) Protein 
half-life plot for yEGFP1p with fit to exponential decay equation; half-life approximated as 184 min. All points 
represent the average of three independent trials, with error bars representing 1 SD. 
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effect. This could be useful if the promoter itself is weak or the promoter experiences weak 
induction. 
We have successfully constructed a plasmid that allows for both simple, one-step PCR-
mediated gene deletion and fusion and luciferase expression under a genomic promoter of 
choice, and a one-step measurement of luciferase from intact yeast cells. Results are shown to be 
highly reproducible and correlate well with comparable reporter constructs. We have applied this 
construct directly to DNA damage biosensing; however, its use extends to any application where 
promoter response levels are desired. 
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Cellular survival in response to DNA lesions and replication arrest requires the 
coordination of checkpoint-mediated mechanisms to ensure DNA damage repair, cell cycle 
arrest, and recovery for genome stability. Checkpoint pathways regulate the expression of protein 
kinases, which mediate a transcriptional response and cell cycle arrest through downstream 
effectors. In Saccharomyces cerevisiae, the evolutionarily conserved MEC1 (ortholog to the 
human ataxia telangiectasia mutated- and Rad3-related – ATR – protein) checkpoint pathway 
regulates origin firing, fork progression, and DNA repair and recovery (reviewed in (Nyberg et 
al., 2002)).   
Mec1p and its effector kinases, Rad53p and Dun1p, activate both positive and negative 
effectors that regulate deoxyribonucleotide (dNTP) pools, cell cycle arrest, and recovery (Nyberg 
et al., 2002). The activity of the positive effector RNRs (Ribonucleotide reductases), which are 
responsible for the rate-limiting conversion step of ribonucleotides (rNDPs) to dNTPs, is tightly 
regulated. The homodimer Rnr1p and the heterodimers Rnr2p and Rnr4p, which compose the 
Rnr complex, are transcriptionally repressed by Crt1p (Basrai et al., 1999; Huang et al., 1998) 
while Rnr1p contains binding sites for dATP allosteric inhibition (Nguyen et al., 1999). In the 
absence of DNA damage, negative regulators such as Sml1p and Dif1p regulate Rnr complex 
activity through inhibition of the Rnr subunit, Rnr1p, and by subcellular compartmentalization of 
the Rnr2p–Rnr4p subunits to the nucleus (Lee et al., 2008; Wu & Huang, 2008). However, in 
                                                 
††† This chapter previously appeared as Ainsworth, W.B., B.T. Hughes, W.C. Au, S. Sakelaris, O. Kerscher, M.G. 
Benton, and M.A. Basrai, Cytoplasmic localization of Hug1p, a negative regulator of the MEC1 pathway, coincides 
with the compartmentalization of Rnr2p–Rnr4p. Biochem Biophys Res Commun, 2013. 439(4): p. 443-448.  It is 
reprinted by permission of Elsevier. 
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response to DNA damage or replication arrest, Sml1p and Dif1p are phosphorylated and 
degraded (Andreson et al., 2010; Lee et al., 2008). This, along with the transcriptional induction 
of RNRs and localization of the Rnr complex to the cytoplasm, serves to increase dNTP pools 
(Andreson et al., 2010; Lee et al., 2008; Zhao, X. & Rothstein, 2002). Checkpoint mediated 
response to DNA damage and replication arrest has been studied extensively, however we do not 
fully understand how cells recover from checkpoint arrest and downregulate Rnr activity to 
maintain genome stability. 
In this paper, we examined the role of Hug1p (Hydroxyurea, Ultraviolet, Gamma) as a 
negative regulator of the MEC1 pathway. HUG1 is one of the most differentially expressed 
genes identified in a screen for gene expression in response to HU treatment (Velculescu et al., 
1997). Unlike SML1 and DIF1, the transcription of HUG1 is induced in cells treated with HU or 
exposed to ultraviolet or gamma radiation in a MEC1-dependent manner (Basrai et al., 1999). A 
deletion of HUG1 has been shown to rescue lethality due to a MEC1 null allele and suppress the 
HU sensitivity of dun1Δ mutants (Basrai et al., 1999). Studies with HUG1 have primarily 
focused on its transcriptional response to replication arrest and DNA damage (Ainsworth et al., 
2012; Basrai et al., 1999; Benton et al., 2007; Sharma et al., 2007; Wei et al., 2013). Using a 
polyclonal serum to Hug1p, we have shown that HUG1 encodes for a protein. Our results for 
HUG1 overexpression phenotypes, a delayed induction pattern of Hug1p in response to HU 
treatment, and the MEC1-dependent compartmentalization of Hug1p in response to replication 
arrest define a novel role for Hug1p as a negative regulator of the MEC1-checkpoint response 





3.2. Materials and methods 
3.2.1. Strains, plasmids, cell cycle arrest with HU and growth sensitivity to HU, MMS and BLM 
Strains and plasmids are described in Table 3.1. Transformations, cloning, and cell 
culture were performed using standard methods as previously described (Adams et al., 1997; 
Basrai et al., 1999; Mumberg et al., 1994; Zhao, Xiaolan et al., 1998). Additional strain and 
expression vector construction procedures are outlined in the Supplementary materials and 
methods. Primer sequences are available upon request. Cell cycle arrest with 0.1 M HU (Fluka 
Chemika) was as described (Basrai et al., 1999). Cells (>90%) exhibited a large budded 
phenotype with S-phase DNA content, as determined by flow cytometry using an Accuri C6 
flow cytometer (BD Accuri Cytometers) (Carter et al., 2005). Serial dilutions of cells grown in 
medium selective for the plasmid were assayed for growth with dextrose (2%) or raffinose (2%) 
plus galactose (2%) with 0.1 M HU, 0.01% MMS (Sigma–Aldrich), or 5 mU/mL BLM (Bristol-
Myers Squibb) as described (Carter et al., 2005). 
3.2.2. Western blots and subcellular fractionation 
Western blots for Hug1p, Hug1p-GFP, Rnr3p-HA, Sir2p, Pgk1p, Tub2p and subcellular 
fractionation were performed as described (Carter et al., 2005; Liang & Stillman, 1997) using 
anti-HA (12CA5 Roche), -GFP (A11122 Invitrogen), -Sir2p (yN-19) (sc-6666 Santa Cruz), -
Pgk1p (459250 Invitrogen), -Hug1p and -Tub2p (antisera generated in Basrai Laboratory). 
3.2.3. Localization of Hug1p-GFP 
Hug1p-GFP expressing strains were grown to exponential phase in YPD and treated with 
0.1 M HU for 3.5 h. For localization of GAL1-HUG1-GFP, cells were grown to exponential 
phase in synthetic medium with raffinose (2%) followed by growth in galactose (2%) medium 
for 2 h, shifted to dextrose (2%) medium with or without 0.1 M HU for 3.5 h. Harvested cells 
were prepared for microscopy as described (Pringle et al., 1991) except that paraformaldehyde 
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was the only fixative and Hoechst 33342 (Thermo Scientific) was used for nuclear staining. 
Images were acquired using a Zeiss Axio Observer Z1 microscope. 
Image deconvolution and analysis were performed in ImageJ using plug-ins Diffraction 
PSF 3D to calculate the point-spread-function and Iterative Deconvolve 3D (Dougherty, 2005) 
for deconvolution. Localization analysis was performed as described (Malinovska et al., 2012). 
Cytoplasmic localization was determined empirically to be a nuclear-to-cytoplasmic 
                                                 
‡‡‡ Table 3.1 appears in the original publication as Supplementary Table 1.  
Table 3.1.‡‡‡ Genotypes of strains and plasmids. 
Strains Genotype Reference 
U952-3C W1588-4A sml1Δ::HIS3 (Zhao, Xiaolan et al., 1998) 
U953-61D W1588-4A mec1Δ::TRP1 sml1Δ::HIS3 (Zhao, Xiaolan et al., 1998) 
U960-5C W1588-4A rad53Δ::HIS3 sml1-1 (Zhao, Xiaolan et al., 1998) 
U971 
MATα ade2-1 can1-100 leu2,3-112 his3-11,15 
trp1 ura3-1 RAD5 dun1Δ:URA3 
(Zhao, Xiaolan et al., 1998) 
W1588-4A 
MATa ade2-1 can1-100 leu2,3-112 his3-11,15 
trp1 ura3-1 RAD5 
(Zhao, Xiaolan et al., 1998) 
Y217 
MATa ade2-1 his3 leu2-3,112 lys2 trp1 ura3-
Δ100 rnr3::RNR3-URA3-TRP1 crt4-2/tup1 
(Huang et al., 1998) 
Y577 
MATa ade2-1 can1-100 his3-11 leu2-3,112 
lys2 trp1-1 ura3-1 crt1Δ 
(Huang et al., 1998) 
YMB847 YPH499 hug1Δ2::HIS3 This study 
YMB1618 YPH499 hug1::HUG1-GFP-HIS3 This study 
YMB1657 YPH499 rnr3::RNR3-HA-HIS3 This study 
YPH449 
MATa ade2-101 leu2-Δ1 lys2-801 his3-Δ200 
trp1-Δ63 ura3-52 
(Sikorski & Hieter, 1989) 
   
Plasmids Genotype Reference 
pMB368 pRS426-PGAL1-HUG1* (URA3, 2μ) This study 
pMB379 pRS426-PGAL1-HUG1 (URA3, 2μ) This study 
pMB394 pRS424-PGAL1-HUG1 (TRP1, 2μ) This study 
pMB444 pRS316-PHUG1-HUG1 (URA3, CEN) This study 
pMB588 pRS415-HUG1-GFP (LEU2, CEN) This study 
pMB734 pRS414-PGAL1-HUG1-GFP (TRP1, CEN) This study 
pMB830 pRS415-PGAL1-HUG1-GFP (LEU2, CEN) This study 
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intensiometric ratio below 0.9, even distribution between 0.9 and 1.1, and nuclear localization 
above 1.1. For each strain, at least 100 large budding cells with a nucleus at the bud neck were 
counted.  Statistical analysis on the subcellular localization data was performed in SAS 9.3 using 
three-way factorial analysis of variance (ANOVA) with Tukey’s multiple comparison range test. 
Additional statistical analysis is provided in the supplementary materials and methods. 
3.3. Results  
3.3.1. Overexpression of HUG1 increases the sensitivity of wild-type strains to HU, MMS and 
BLM 
We have previously shown that a deletion of HUG1 suppresses the viability of mec1Δ 
strains and HU sensitivity of dun1Δ strains (Basrai et al., 1999). Similar results have been 
reported in the HUG1 paralogs, DIF1 and SML1, both of which are negative regulators of the 
Rnr complex and the checkpoint response (Andreson et al., 2010; Lee et al., 2008; Zhao, Xiaolan 
et al., 1998). To determine if Hug1p acts as a negative regulator of the MEC1 pathway, wild-type 
strains overexpressing HUG1 were assayed for growth on media containing HU and DNA 
damaging agents. GAL1-HUG1 was found to increase the sensitivity of wild-type strains to HU 
on medium containing galactose (GAL) and 0.15 M HU (Figure 3.1.A, Row 2). GAL1-HUG1 or 
vector (Figure 3.1.A, Rows 2 and 1, respectively) did not show growth defects on dextrose 
(DEX) plates with and without HU and GAL plates without HU. The phenotype was specifically 
due to expression of Hug1p, as a frame-shift mutation in the HUG1 open reading frame (GAL1-
HUG1*) abolished the dosage lethality phenotype (data not shown). 
Since the viability of mec1Δ strains is suppressed by sml1-1 or sml1Δ (Andreson et al., 
2010; Lee et al., 2008; Zhao, Xiaolan et al., 1998), the dosage lethality of GAL1-HUG1 in wild-
type strains was examined for dependence on SML1.  Similar to the wild-type strain, the sml1Δ 
strain with GAL1-HUG1 exhibited growth inhibition on HU containing medium (Figure 3.1.A, 
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Row 6). Results verifying that SML1 is not required for the dosage lethality of strains containing 
GAL1-HUG1 are supported by recent work describing the ubiquitylation and subsequent 
degradation of Sml1p in response to DNA damage (Andreson et al., 2010).  
As expected, the mec1Δsml1Δ strain was sensitive to growth on HU containing plates 
with or without GAL1-HUG1 (Figure 3.1.A, Rows 3 and 4).  mec1Δsml1Δ strains expressing 
GAL1-HUG1 also showed a slow growth phenotype even in the absence of HU (Figure 3.1.A, 
Row 4, center panel). These results are similar to the negative regulator, DIF1, which displays 
dosage lethality in mec1Δsml1Δ strains (Lee et al., 2008). 
In addition to HU sensitivity, GAL1-HUG1 strains exhibited significant growth inhibition 
on MMS and BLM containing media (Figure 3.1.B, Row 3) when compared with empty-vector 
strains (Figure 3.1.B, Row 2). As expected, the mec1Δsml1Δ strain displayed growth inhibition 
 
Figure 3.1. Overexpression of HUG1 sensitizes growth to HU, BLM and MMS. (A) Serial dilutions of wild-type strain 
(WT, W1588-4A), mec1Δsml1Δ (U953-61A) and sml1Δ (U952-3B) with vector (pRS316) or GAL1-
HUG1(pMB379) were grown on plates with dextrose (DEX), galactose (GAL) or galactose with 0.15 M HU (GAL + 
HU) and incubated at 30° for 2–3 days. (B) Serial dilutions of mec1Δsml1Δ (U953-61A) or hug1Δ (YMB847) with 
vector (pRS414-GAL1) or GAL1-HUG1 (pMB394) were grown on plates with galactose (GAL), galactose with 5 
mU/mL BLM (GAL + BLM), or 0.01% MMS (GAL + MMS) and incubated at 30° for 2–3 days. 
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on plates containing MMS and BLM (Figure 3.1.B, Row 1). Taken together, the synthetic dosage 
lethality of GAL1-HUG1 strains along with previous data support a role for Hug1p as a negative 
regulator of the MEC1-mediated checkpoint response to DNA damage and replication arrest. 
3.3.2. Expression of Hug1p shows delayed induction to 0.1 M HU compared to Rnr3p, a positive 
effector of the MEC1 pathway 
Using transcriptome profiling, we previously reported that HUG1 represents one of the 
most highly differentially expressed genes in the yeast genome (Basrai et al., 1999; Velculescu et 
al., 1997). Initial genome sequencing efforts annotated all ORFs of at least 100 contiguous 
codons, hence HUG1was not annotated as it encodes for a protein of 68 amino acids. To validate 
that HUG1encodes for a protein, a rabbit polyclonal serum specific to Hug1p was generated. 
Results from Western blot analysis corroborated results of Northern blot analysis (Basrai et al., 
1999), as Hug1p expression was observed in a wild-type strain treated with HU (Figure 3.2.A, 
Lane 2). The control includes a hug1Δ strain that shows Hug1p expression when transformed 
with a plasmid expressing HUG1 from its own promoter (pHUG1; Figure 3.2.A, Lane 6). In 
agreement with previous results, tup1 and crt1Δ strains constitutively expressed Hug1p (Figure 
3.2.A, Lanes 7–10). Crt1p, Tup1p and Ssn6p are transcriptional repressors that bind to X-box 
sequences in the promoter of HUG1 and RNRs in the absence of DNA damage and replication 
arrest (Basrai et al., 1999). The polyclonal serum also showed that, in agreement with previous  
Northern blot analysis, no HU induced expression of Hug1p was detected in mec1Δsml1Δ strains 
(Figure 3.2.B, Lane 6) and SML1 was not required for the expression of Hug1p (Figure 3.2.B, 
Lane 4). 
To gain further insight into the role of Hug1p, HU induced expression of Hug1p was 
compared with Rnr3p, a positive regulator of the MEC1 pathway. Hug1p expression was 




Figure 3.2. Genes in the MEC1 pathway are required for HU induced 
expression of Hug1p and delayed induction of Hug1p compared to Rnr3p. (A) 
Western blot analysis of wild-type (WT, YPH499), hug1Δ (YMB847), hug1Δ 
(YMB847) with pHUG1 (pMB444), tup1Δ (Y217), crt1Δ (Y577) grown with 
or without 0.1 M HU for 3.5 h and probed with anti-Hug1p or -Pgk1p (loading 
control). (B) Western blot analysis of wild-type (WT, W1588-4A), sml1Δ 
(U952-3C), mec1Δsml1Δ (U953-61D) grown with or without 0.1 M HU for 
3.5 h (C) Western blot analysis of RNR3-HA strains (YMB1657) after 
treatment with 0.1 M HU for various times and probed with anti-Hug1p, -HA 
(Rnr3p-HA) and -Tub2p (loading control). 
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which no further induction was apparent (Figure 3.2.C). Consistent with previous reports (Huang 
et al., 1998), Rnr3p-HA was detected 30 min post-HU addition, increased until 90–120 min post-
HU addition, and subsequently declined (Figure 3.2.C). The delayed induction of Hug1p with  
high levels present at 3.5–5 h post-HU addition resembles the profile of Crt1p (Huang et al., 
1998), a negative regulator of RNRs and HUG1 gene expression. 
3.3.3. Hug1p-GFP localizes to the cytoplasm in HU treated cells 
The subcellular localization of Hug1p-GFP was analyzed by fusing GFP to the C-
terminus of Hug1p expressed from its native promoter at the chromosomal locus in the genome. 
Western blot analysis showed expression of Hug1p-GFP in cells treated with HU (Figure 3.3.A). 
Fluorescence microscopy of Hug1p-GFP cells without HU treatment showed only background 
fluorescence (Figure 3.3.B, left column).  
However, upon treatment with HU, Hug1p-GFP was enriched in the cytoplasm and was 
notably excluded from the nucleus in 96.3 ± 3.1% of the cells (Figure 3.3.B, right column). DNA 
content measurement by FACS and nuclear morphology of the cells confirmed S-phase arrest of 
the HU treated cells (data not shown).  To rule out artifacts in localization due to GFP tagging of 
Hug1p, the data were corroborated by subcellular fractionation of cells expressing non-epitope 
tagged Hug1p expressed from its native promoter.  
Total, nuclear (Nuc) and cytoplasmic (Cyto) fractions of cells with or without HU were 
analyzed by Western blot using anti-Sir2p (nuclear marker), -Pgk1p (cytoplasmic marker) or -
Hug1p. Sir2p was enriched in the nuclear fraction (Figure 3.3.C, Lane 5) and Pgk1p in the 
cytoplasmic fraction (Figure 3.3.C, Lane 6) in HU treated cells. Hug1p was only observed in the 
cytoplasmic fraction of the HU treated cells and was excluded from the nucleus (Figure 3.3.C, 
Lane 6). The enrichment of Hug1p in the cytoplasmic fraction supports the data showing Hug1p 
localization to the cytoplasm in HU treated cells. 
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3.3.4. Cytoplasmic localization of Hug1p in response to HU treatment is not merely due to 
overexpression of the protein 
Since HUG1 expression is induced in response to DNA damage and replication arrest in a 
checkpoint dependent manner (Basrai et al., 1999), we examined if the cytoplasmic localization 
of Hug1p under these conditions may reflect its high level of expression using cells expressing 
GAL1-HUG1-GFP. Western blot analysis showed that GAL1-HUG1-GFP was expressed in 
 
Figure 3.3. Hug1p-GFP is localized to the cytoplasm in response to HU treatment. (A) Western blot analysis showing 
HU induced expression of HUG1-GFP expressed from its native promoter at the endogenous locus in wild-type (WT, 
YPH499), hug1Δ (YMB847), and HUG1-GFP (YMB1618) strains grown with or without 0.1 M HU for 3.5 h and 
probed with anti-GFP or Tub2p (loading control). (B) Cells expressing Hug1p-GFP grown in the absence (left column) 
or presence of 0.1 M HU for 3.5 h (right column) show exclusion from the nucleus. Arrow indicates bud neck; white 
line outlines the nucleus; white scale bar length is 5 μm. (C) Total, nuclear (Nuc) and cytoplasmic (Cyto) fractions of 
wild-type strains (YPH499) grown in the absence or presence of 0.1 M HU for 3.5 h analyzed by Western blot using 
a polyclonal serum to Hug1p, Sir2p (Nuc), or Pgk1p (Cyto). 
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wild-type, mec1Δsml1Δ, and sml1Δ strains grown in galactose medium (Figure 3.5.A). Cells 
grown in the presence of galactose for 2 h, followed by growth in glucose medium with or 
without HU were examined for nuclear morphology and localization of GAL1-HUG1-GFP. 
Nuclear-to-cytoplasmic intensiometric ratios were quantified as described (Malinovska et al., 
2012) to determine Hug1p-GFP subcellular compartmentalization for all strains (Figure 3.4§§§). 
In the absence of HU, Hug1p-GFP was primarily localized to the nucleus (88.2 ± 2.0%) whereas 
a majority of the HU treated cells (86.6 ± 3.3%) exhibited cytoplasmic localization (Figure 
3.5.B, WT). The similar localization pattern of GAL1-HUG1-GFP to that of HUG1-GFP 
expressed under the native HUG1 promoter revealed that the cytoplasmic localization of Hug1p-
GFP is independent of protein expression levels. 
3.3.5. Cytoplasmic localization of Hug1p-GFP is MEC1-dependent and coincides with the 
compartmentalization of Rnr2p–Rnr4p to the cytoplasm 
Since genes in the MEC1 pathway are required for the DNA damage and replication 
arrest induced expression of Hug1p (Basrai et al., 1999), we examined whether the cytoplasmic 
localization of Hug1p is dependent on the MEC1 effector kinases, MEC1, RAD53, and DUN1. In 
the absence of HU, Hug1p-GFP mainly localized to the nucleus in mec1Δ sml1Δ strains (92.1 ± 
8.5%), similar to that observed in wild-type strain (88.2 ± 2.0%).  
However, contrary to the cytoplasmic localization of Hug1-GFP in wild-type cells (86.6 
± 3.3%), very few of the mec1Δsml1Δ cells showed localization to the cytoplasm (8.5 ± 1.1%) in 
response to HU treatment. The majority of Hug1p-GFP in the mec1Δsml1Δ cells was nuclear 
(64.0 ± 7.3%) or was evenly distributed throughout the cell (27.5 ± 7.0%). The localization 
pattern observed in mec1Δsml1Δ strains was independent of SML1 as sml1Δ strains exhibited a 
localization pattern more closely resembling wild-type strains. In the sml1Δ strain, Hug1p-GFP 
                                                 
§§§ Figure 3.3 appears in the original publication as Supplementary Figure 1. 
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localized to the nucleus (97.1 + 1.0%) in the absence of HU and to the cytoplasm (85.5 ± 2.3%) 
in the presence HU (Figure 3.5.B). 
We next examined the localization of GAL1-HUG1-GFP in rad53Δ and dun1Δ strains. In 
the absence of HU, both rad53Δ (74.8 ± 11.2%) and dun1Δ (83.9 ± 0.5%) strains showed nuclear 
localization of Hug1p-GFP similar to that observed in the wild-type strain (Figure 3.5.B). 
However, unlike the wild-type cells, in the presence of HU, only a small fraction of rad53Δ cells 
localized to the cytoplasm (15.7 ± 4.9%) with a majority of the cells exhibiting an even 
distribution (46.3 ± 4.5%) or nuclear localization (37.9 ± 9.3%) of Hug1p-GFP signal.  
In the presence of HU, the dun1Δ strains exhibited a cytoplasmic localization profile of 
Hug1p-GFP that was intermediate to the pattern in mec1Δsml1Δ and wild-type strains. 
Cytoplasmic localization was observed in approximately half the population (52.5 ± 5.0%) of 
dun1Δ cells whereas the remaining cells had either an even distribution (45.3 ± 4.1%) or nuclear 
localization (1.9 ± 0.9%) of Hug1p-GFP. Taken together, these data indicate that Hug1p-GFP 
 
Figure 3.4.§§§ Representative microscopy images used for quantitation of the Hug1p-GFP localization pattern (as 
described in Materials and Methods and (Malinovska et al., 2012)) of WT (YMB888), sml1∆ (U952-3B), mec1∆sml1∆ 
(U953-61A), dun1∆ (U971) and rad53∆ (U960-5C) expressing GAL1-HUG1-GFP (pMB830) grown in galactose 
medium without or with 0.1M HU for 3.5 hours. White line outlines the nucleus; white scale bar length is 5µm. 
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localizes to the cytoplasm in response to HU treatment and this localization is dependent on 
MEC1, RAD53, and DUN1 and is independent of SML1. 
3.4. Discussion 
Checkpoint mediated recovery from DNA damage and replication arrest is in part 
mediated by stringent regulation of Rnr activity. Negative effectors of the MEC1 pathway, 
namely SML1 and DIF1, interact with Rnr complex subunits and regulate its activity and 
 
Figure 3.5. Cytoplasmic localization of Hug1p-GFP depends on MEC1 pathway genes and is coincident with 
compartmentalization of Rnr2p–Rnr4p. (A) Western blot analysis of wild-type (WT, W1588-4A), sml1Δ (U952-3B), 
and mec1Δsml1Δ (U953-61A) strains expressing GAL1-HUG1-GFP (pMB830) grown with or without galactose 
(GAL) in the absence or in the presence of 0.1 M HU for 3.5 h probed with anti-GFP or -Tub1p (loading control). (B) 
Hug1p-GFP subcellular localization pattern as quantified by fluorescence microscopy (as described in Materials and 
methods and (Malinovska et al., 2012)) of wild-type (WT, YMB888), sml1Δ (U952-3B), mec1Δ sml1Δ (U953-61A), 
dun1Δ (U971) and rad53Δ (U960-5C) expressing GAL1-HUG1-GFP (pMB830) grown in galactose medium with or 
without 0.1 M HU for 3.5 h. The graph shows means of three replicates with at least 100 cells counted per experiment. 
Asterisks (*) indicate significant difference when compared to respective wild-type cells (Tukey’s HSD; p < 0.05). 
(C) Delayed induction and cytoplasmic localization of Hug1p in response to HU treatment may serve to downregulate 
Rnr complex activity. Rnr complex with solid outline indicates catalytically active form, while the one with dashed 
outline designates catalytically inactive form. Dif1p mediates the localization of Rnr2p–Rnr4p to the nucleus where 
Wtm1p anchors it, while Sml1p inhibits the activity of Rnr1p in the cytoplasm. Dif1p and Sml1p are phosphorylated 
and degraded in response to HU treatment and Rnr2p–Rnr4p localizes to the cytoplasm for catalytic activity. The 
delayed induction of Hug1p and its cytoplasmic localization and co-compartmentalization with the Rnr complex may 
serve to downregulate Rnr activity and facilitate recovery from checkpoint response. 
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subcellular compartmentalization. The downregulation of Dif1p and Sml1p in response to DNA 
damage or replication arrest increases dNTP pools (Andreson et al., 2010; Lee et al., 2008; Wu 
& Huang, 2008). However, after recovery from checkpoint arrest, Rnr activity must be 
attenuated by negative regulators for normal cell cycle progression (Andreson et al., 2010; 
Chabes & Stillman, 2007; Kim & Siede, 2011; Lee et al., 2008; Poli et al., 2012; Wu & Huang, 
2008; Zhao, Xiaolan et al., 1998; Zhao, X. & Rothstein, 2002). We propose that Hug1p is a 
negative regulator of the MEC1 pathway, which unlike DIF1 and SML1, is induced in response 
to DNA damage and replication arrest. This is based on our results which show that: (a) strains 
expressing GAL1-HUG1 are sensitized to growth in the presence of HU and DNA damaging 
agents, (b) the temporal pattern of Hug1p expression in the presence of HU exhibits a lag when 
compared with Rnr3p, a positive regulator of the MEC1 pathway, and resembles that of Crt1p, a 
negative regulator of the MEC1 pathway, and (c) suppression of lethality of mec1Δ and HU 
sensitivity of dun1Δ strains by deletion of HUG1. 
We propose that Hug1p may serve to negatively regulate the MEC1 pathway by co-
compartmentalization with Rnr2p–Rnr4p to the cytoplasm in response to HU treatment. The 
cytosolic localization is not simply due to overexpression of Hug1p as corroborated by 
localization analysis of GAL1-HUG1-GFP. Consistent with a requirement of MEC1 pathway 
genes for the induction of HUG1, cytoplasmic localization of Hug1p was dependent on MEC1, 
RAD53, and DUN1. Interestingly, Hug1p and Rnr2p–Rnr4p subcellular compartmentalization 
data share similar dependencies on the MEC1 pathway genes (Yao et al., 2003). The localization 
to the same cellular compartment may allow Hug1p to interact with Rnr2p–Rnr4p through an 
undetermined, potentially inhibitory mechanism (Figure 3.5.C) and downregulate Rnr activity.  
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As seen in the model, in cycling cells, Dif1p mediates the localization of Rnr2p–Rnr4p to 
the nucleus where Wtm1p anchors it, while Sml1p inhibits the activity of Rnr1p in the 
cytoplasm. After 1.5–2 h of HU induction, Dif1p and Sml1p are phosphorylated and degraded; 
Rnr2p–Rnr4p is exported from the nucleus to the cytoplasm where it forms the active Rnr 
complex with the Rnr1p homodimer. After 3.5 h of HU treatment, the high level of Hug1p 
expression and its localization to the cytoplasm and co-compartmentalization with the Rnr 
complex serve to downregulate Rnr activity and, potentially, dNTP pools. The delayed 
expression of Hug1p to replication arrest and co-compartmentalization with Rnr2p–Rnr4p may 
act to negatively regulate Rnr activity in the absence of negative MEC1 effectors, DIF1 and 
SML1, and permit cellular recovery in post-stress conditions. Taken together, our data define a 
novel role for HUG1 in the DNA damage and replication arrest pathway. 
3.5. Supplementary materials and methods 
3.5.1. Construction of expression vectors and strains 
Plasmid pMB368 constructed from pMB379 contains a frame-shift mutation in the 
HUG1 ORF at codon 16 (aspartic acid to valine) with a premature stop at position 26. pMB588 
contains the HUG1 open reading frame with a C-terminal GFP fusion in pRS415 (Mumberg et 
al., 1994; Niedenthal et al., 1996). Plasmid pMB734 contains a SnaBI fragment of HUG1-GFP 
from pMB588 cloned into pRS414.  The GAL-HUG1-GFP fragment from pMB734 was cloned 
into pRS415 (Mumberg et al., 1994) to create pMB830. YMB1657 and YMB1618 were 
constructed using a PCR-mediated gene fusion method (Longtine et al., 1998). 
3.5.2. Statistical Analysis 
Statistical analysis of the subcellular localization profile data was performed using three-
way factorial analysis of variance (ANOVA) with Tukey’s multiple comparison range test in 
SAS 9.3.  A three-way factorial ANOVA yielded a main effect for localization, F (2,90)=417.72, 
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p<0.0001, however strain and HU treatment effects were non-significant.  Interaction effects 
between strain and localization and HU treatment and localization were also significant, F 
(8,90)=87.99, p<0.0001 and F (2,90)=80.17, p<0.0001, respectively.  Interaction effect between 
all main effects was also significant, F (8,90)=80.17, p<0.0001. 
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This chapter is currently under peer review for publication.  In response to critical levels 
of DNA damage and cellular stress, the MEC1 DNA damage checkpoint pathway coordinates 
cell cycle arrest and induces effector targets which work to preserve genomic stability.  
Microarray and promoter-reporter analysis of MEC1 effector transcription profiles has revealed a 
sophisticated and differential expression network response to increasing DNA damaging agents, 
however the actors and mechanism of this response remain unknown.  In this study, we 
investigated the transcriptional response of five MEC1 pathway genes (MEC1, RAD53, DUN1, 
RNR3, and HUG1) to a panel of DNA damaging and cellular stress agents using a GFP 
promoter-reporter system.  We discovered a unique biphasic response of MEC1 and its effectors 
to alkylating agents that persisted through the MEC1 cascade.  We determined that the biphasic 
signal was not the result of reactive oxygen species accumulation.  Interestingly the early phase 
alkylating agent response shows dependence on pro-apoptotic yeast proteins, AIF1 and MCA1, 
however the late phase did not show similar dependencies.  Finally, cell cycle analysis reveals a 
differential phase arrest that was dependent on alkylating agent titers and correlates with the 
biphasic response.  These results demonstrate new insights regarding cellular fate and the MEC1 
response when differentially exposed to alkylating DNA damaging agents.  
4.2. Introduction 
 Faithful duplication of genomic information is of paramount importance to cellular 
survival and stable cell growth, however exogenous and endogenous DNA damage constantly 
challenge genome stability.  To counteract these threats and preserve genomic integrity, 
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eukaryotic organisms have evolved a conserved and sophisticated surveillance system (known as 
checkpoints) to identify DNA lesions and mount a response.(Ciccia & Elledge, 2010; Harper & 
Elledge, 2007)  Detection of DNA damage by sensor proteins leads to the stimulation of a 
conserved cascade of adaptors, transducers and effectors that, upon activation, trigger an array of 
cellular activities which act to preserve genome fidelity through replication fork stabilization, 
cell cycle arrest, DNA repair, and (depending on the severity of damage) apoptosis.(Branzei & 
Foiani, 2006; Ciccia & Elledge, 2010; Harper & Elledge, 2007; Zhou & Elledge, 2000)  
The DNA damage checkpoint in eukaryotes is broadly regulated by two response 
systems: the ATM-mediated double-strand DNA break (DSB) repair cascade and the ATR-
mediated single-stranded DNA (ssDNA) repair network.(Abraham, 2001)  In Saccharomyces 
cerevisiae, Tel1p (ATM) is largely involved in telomere maintenance and DSB recognition while 
Mec1p (ATR) has a role in regulating both ssDNA and DSB checkpoint response (Baldo et al., 
2008; Di Domenico et al., 2014; Naiki et al., 2004).    Activation of the MEC1 signal 
transduction cascade induces translational and post-translational activity that initiates cell cycle 
arrest protocols and DNA repair mechanisms.(Huang et al., 1998; Lee et al., 2008; Sanchez et 
al., 1996; Zhao & Rothstein, 2002) The DNA damage checkpoint is proposed to be triggered 
once threshold levels of DNA lesions and stalled replication forks are detected. (Minca & 
Kowalski, 2011; Shimada et al., 2002)  The resulting stalled replication forks expose single-
stranded DNA (ssDNA) which act to prime DNA damage sensing complexes.(Cimprich & 
Cortez, 2008)    For S. cerevisiae, replication protein A (RPA) coats and stabilizes bare ssDNA 
which recruits the heterotrimeric proliferating cell antigen (PCNA)-like 9-1-1 complex (Rad17p, 
Ddc1p, and Mec3p) and the constitutively associated Ddc2p- Mec1p to DNA damage sites 
(Rouse & Jackson, 2002; Zou & Elledge, 2003).  Mec1p is subsequently activated by the Rad9p 
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mediator and the 9-1-1 complex (Rad17p, Ddc1p, and Mec3p) (Majka, J. & Burgers, P. M., 
2003; Majka et al., 2006) that coordinates checkpoint activation through Dna2p- (Kumar & 
Burgers, 2013) or Dpb11p-associated (Ogiwara et al., 2006) activity.   
Stimulation of Mec1p via the DNA damage sensing mechanism initiates the MEC1 
checkpoint pathway, which exerts control over the DNA damage response through 
transcriptional and post-translational modifications to gene and protein targets. (Huang et al., 
1998; Lee et al., 2008; Sanchez et al., 1996; Zhao & Rothstein, 2002)  A systematic study of 
protein abundance and localization in response to DNA damaging agents methyl 
methanesulfonate (MMS) and replication stress agent hydroxyurea (HU) has uncovered the 
significance of protein subcellular compartmentalization with respect to DNA damage and 
replication stress type.(Tkach et al., 2012)  Similarly, global transcription studies on the 
Saccharomyces cerevisiae response to alkylating, ionizing, and other physical and chemical 
cellular stresses have revealed a vast network of genetic responses exhibiting dose- and agent 
dependencies.(Benton et al., 2007; Benton et al., 2006; Fry et al., 2005; Gasch, A. P. et al., 
2000; Jelinsky & Samson, 1999)  In fact, over 2500 of the approximately 6200 Saccharomyces 
cerevisiae genes showed significant changes in transcript levels in response to carcinogen-
induced cell damage.(Jelinsky et al., 2000)  Gene clustering information from the differential 
transcriptomic expression results has led to discoveries of previously uncharacterized pathways 
and proteins with imperative function in the DNA damage response.(Fry et al., 2005; Gasch, A. 
P. et al., 2000; Jelinsky et al., 2000; Jelinsky & Samson, 1999)   
Recent studies utilizing mRNA transcript profiling and a GFP promoter-reporter assay 
have identified a unique biphasic expression profile of MEC1 pathway genes to increasing 
alkylating agent concentrations (Benton et al., 2007; Benton et al., 2006).  One study suggests 
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this profile may arise from differential cellular responses to changing MMS dosages, methylation 
and degradation of proteins required for MEC1 gene expression, or methylation and inactivation 
of the ribonucleotide reductase enzyme leading to deoxyribonucleotide reduction and MEC1 
pathway exit, however little evidence yet exists to confirm these theories.(Benton et al., 2006)  
Thus, the origin of the biphasic MEC1 gene response remains unknown.  In this study, we sought 
to uncover the elements responsible for the biphasic MEC1 pathway gene expression.  Using 
several GFP promoter-reporter constructs of MEC1 pathway genes, we examined the differential 
and temporal expression of HUG1, RNR3, DUN1, RAD53, and MEC1 to various DNA damage 
and cellular stress agents to determine if the origin of the biphasic response arose from genes 
within the MEC1 pathway.  Pro-apoptotic genes and reactive oxygen species accumulation were 
also examined as potential external contributors to the unique response.  Finally, cell cycle arrest 
assays were performed to assess variability in cell phase arrest under increasing MMS 
concentrations.   
4.3. Materials and methods 
4.3.1. Plasmid and strain construction 
The strains used in this study are outlined in Supplementary Table 4.2.  Promoter-reporter 
constructs for MEC1, RAD53, DUN1, HUG1, and RNR3 were created using PCR-mediated gene 
deletion (Longtine et al., 1998) and the diploid parent strain BY4743 (GE Dharmacon; 
YSC1050) to prevent the synthetic lethality of MEC1 or RAD53 gene deletion (Desany et al., 
1998).  Plasmid pFA6a-GFP(S65T)-HIS3MX6 (a kind gift of John Pringle) was used as template 
for construction of all promoter-reporter constructs using primers listed in Supplementary Table 
4.3.  Primers with flanking 45bp of homology immediately up- and downstream of the respective 
gene ORF were used to amplify a PCR cassette that includes a fusion of GFP(S65T) and 
HIS3MX6.  PCR products were purified and directly transformed into BY4743 using a lithium-
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acetate transformation method (Gietz & Schiestl, 2007a, 2007b). Transformants were selected on 
synthetic defined media lacking histidine and verified by colony PCR using primers binding into 
the promoter region of the indicated gene and into the GFP(S65T) ORF (Supplementary Table 
4.3).   
4.3.2. DNA damage exposure and cell stress experiments 
DNA damage exposure and cell stress experiments were performed as previously 
described (Benton et al., 2007).  Agent concentrations were limited to exposures that maintained 
a minimum 90% cell viability after eight hours as determined by propidium iodide (PI) live/dead 
cell staining.  All DNA damaging experiments for each promoter-reporter system consisted of at 
least three independent trials.  Strains were treated with each DNA damaging agent at the 
indicated concentrations and sampled in two hour intervals for a total exposure time of eight 
hours.  At the each time point, samples were washed in phosphate buffered saline (PBS) and 
resuspended at final cell densities empirically determined to reduce flow cytometry read errors 
resulting from detector occlusion.  Samples were stored in the dark no more than one day at 4°C 
until analyzed by flow cytometry. 
4.3.3. Free radical detection and N-acetyl-L-cysteine (NAC) experiments 
Dihydrorhodamine 123 (DHR123) was used to detect free radical formation in 
accordance with previous studies (Madeo et al., 1999; Wysocki & Kron, 2004) with some 
modifications.  Prior to DHR123 addition, the DNA damage induction was performed as 
described.  DHR123 at a final concentration of 5µg/mL was then added to aliquots of the 
induced strains two hours before harvesting.  The strains were sampled every two hours for a 
total induction time of 8 hours.  Samples were washed and resuspended in PBS and stored at 4°C 
prior to flow cytometric analysis. 
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N-acetyl-L-cysteine (NAC) pretreatment of cultures was performed as previously 
described (Kim et al., 2013) with some modifications.  Log phase cultures were diluted to 
OD600=0.05 in pre-warmed YPD supplemented with 50mM NAC and grown with shaking at 
30°C for two hours.  DNA damage exposure and flow cytometry was then carried out as 
described in the previous section. 
4.3.4. DNA analysis and cell cycle arrest 
To analyze cell cycle progression in response to MMS, log-phase wild type (BY4741) 
cultures were exposed to the MMS dosages described in the previous section. Samples were 
harvested at the indicated times, washed once in distilled water, and then fixed with ethanol.  
DNA staining with SYBR Green I (Invitrogen) was then carried out in accordance with 
previously described methods without modification (Fortuna et al., 2001). 
4.3.5. Flow cytometry analysis 
Flow cytometry data for the promoter-reporter system were collected by Accuri C6 Flow 
Cytometer using the C6 Sampler software whereby at least 10,000 gated events per sample were 
counted.  To prevent inclusion of undesirable small particle contaminants, samples were gated in 
the forward scatter channel (FSC) to remove small event sizes less than 50,000 relative units.  
Cell viability was determined using propidium iodide (PI) live/dead cell staining.  Viable cells 
were defined as whole cells with PI impermeable, intact membranes.  Inviable cells exhibiting PI 
permeable membranes were differentiated by large red fluorescence shifts in the FL3 channel 
(488nm laser with 670nm longpass filter) and were gate excluded from the total cell count.  GFP 
signal of the promoter-reporter response was measured from channel FL1 (488nm laser with 
530/30nm filter) with all prior gating settings applied.  Data was analyzed using the Accuri C6 




4.3.6. Data analysis and statistics 
The mean GFP fluorescent intensity was used to assess promoter-reporter responses to 
drug induction.   The fold induction (FI) for the promoter-GFP reporters was calculated as the 
mean fluorescent intensity of drug-induced strains vs the mean fluorescent intensity of an 
uninduced control.  Fold inductions were averaged across independent trials with matching DNA 
induction agent, time, and dosage.  A Student t-test was performed on all induced strains relative 
to the untreated control strains to calculate a p-value for GFP fold induction.  To eliminate false 
positives due to auto-fluorescence, positive GFP signal was established to be fold inductions 
greater than 2 and a p-value less than or equal to 0.05 when compared to controls.  One-way 
analysis of variance (ANOVA) was used to determine the significant differences of temporal 
deviations of corresponding drug-induced strains.  Dunnett’s test was used as the post-hoc test to 
identify strains with significant differences from the control. 
4.4. Results 
4.4.1. Differential dosage response of MEC1 pathway genes to DNA damage and cell stress 
agents using GFP promoter-reporter construct 
Previous studies have demonstrated a global, differential transcriptional response that is 
highly specific to the genotoxic or cellular stress agent.(Benton et al., 2006; Fry et al., 2005; 
Gasch, A. P. et al., 2000)  A unique biphasic response of the MEC1 repair pathway genes, 
DUN1, RNR2, RNR4, and HUG1, was identified in a study surveying the transcription outputs 
after exposing cultures to MMS dosages spanning three-orders of magnitude.(Benton et al., 
2006)  However, it remains unknown whether the source of this response is due to regulation 
within the MEC1 pathway or is the result of external repression controls.  
To investigate MEC1 internal transcription signaling, we implemented a GFP(S65T) 
promoter-reporter gene deletion construct (see Materials and Methods) to fuse GFP under the  
  
86 
promoter control of MEC1, DUN1, RAD53, RNR3, and HUG1 in the BY4743 diploid parent 
strain.  These genes were chosen to span the MEC1 cascade in order to identify the source of the 
distinctive biphasic transcriptional signal should it occur within the MEC1 pathway.  GFP 
Table 4.1. DNA damage, replication arrest, and cellular stress agents implemented in MEC1 GFP promoter-reporter 
assays. 
AGENT MECHANISM REFERENCE 
Methyl methanesulfonate 
(MMS) 
SN2-type methylation of 7-
deoxyguanosine and 3-deoxyadenosine 
blocks DNA synthesis 




Mixed SN1/SN2 ethylation of 
nucleophilic base; ethlyation of 
guanine in DNA to form O6-
ethylguanine leads to thymine 
mispairing by DNA polymerase 





Carbocation mediated methylation of 
purine bases; increases mismatched 
base pairing during replication 
(Likhachev et al., 1978) 
Hydroxyurea (HU) 
Inhibitor of the ribonucleotide 
reductase by tyrosyl free radical 
scavenging; reduces 
deoxyribonucleotide availability to 
DNA polymerase 
(Koc et al., 2004; 
Yarbro, 1992) 
Phleomycin 
Inhibitor of DNA synthesis through 
DNA binding double strand break 
formation in the presence of metal ions 
and oxygen 
(Earhart, 1979; Suzuki 
et al., 1970) 
4-nitroquinoline 1-oxide 
(4-NQO) 
4-NQO metabolite reacts with DNA to 
form adducts to N6- on deoxyadenine 
and C8- or N2- on deoxyguanine, 
which induces single stranded DNA 
breaks 
(Bailleul et al., 1989) 
Camptothecin 
Binds and inhibits topoisomerase I 
cleavage and re-ligation activity; leads 
to replication fork breakage and arrest 
(Liu et al., 2000) 
Formaldehyde 





Reactive oxygen species that induces 
DNA single- and double-strand breaks 
and apurinic/apyrimidinic lesions 
(COOKE et al., 2003; 
Salmon et al., 2004) 
Hydrochloric acid (HCl) 
General cellular stress agent that 
increases environment acidity  
(Carmelo et al., 1998) 
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promoter-reporter strains were then exposed to an array of DNA damage and stress agents 
(outlined in Table 4.1) and harvested every 2hrs for a total exposure time of 8hrs.  The mean 
GFP intensity of at least 30,000 cells at each time point was then measured by flow cytometry.   
GFP response curves for the five MEC1 pathway genes are given in Figure 4.1 and 
Supplementary Figure 4.5, Figure 4.6, Figure 4.7, Figure 4.8, and Figure 4.9.  MMS provoked 
the highest reporter induction in all knockout strains with maximal peak intensities occurring 
after 8 hour exposure for all strains at the 0.05% v/v concentration (Figure 4.1.A).  Expression 
patterns resulting from MMS exposure are consistent with previously reported global 
transcriptional profiles (Benton et al., 2006; Fry et al., 2005; Gasch, A. P. et al., 2000; Jelinsky 
& Samson, 1999) and are reflective of signal amplification through the MEC1 phosphorylation 
cascade, as effectors HUG1 and RNR3 demonstrated the highest signaling across doses and time, 
while transducers DUN1, RAD53 and MEC1 had decreasing response intensities, respectively, 
when compared to comparable dose and times.   
Interestingly, all genes exhibited the distinct biphasic response originally observed in the 
mRNA transcript profiling of HUG1, RNR3, and DUN1 at differential doses of MMS (Benton et 
al., 2007; Benton et al., 2006), indicating that the drastic reduction in expression across all 
MEC1 genes at the highest two MMS dosages is likely the result of a repression event occurring 
upstream or outside of the MEC1 pathway. 
The hug1Δ::GFP fold induction for all MMS dosages was notably attenuated relative to 
previous reports;   likewise, the peak intensity of the MMS dosage curve shifted from 0.01% to 
0.05%.(Benton et al., 2007)  This discrepancy can be attributed to construction of the promoter-
reporter system in diploid instead of haploid strains, as similar GFP reporters created in the 
isogenic haploid strain yield anticipated reporter intensity and peak dosage (see Figure 4.3.A).   
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Similar profiles were obtained when strains were exposed to the alkylating agent, EMS 
(Figure 4.1.B), whereby the biphasic profile persisted in all genes tested.  hug1Δ::GFP signals 
were again attenuated relative to comparable EMS induction in haploid strains strain (Benton et 
al., 2007), however the peak dose intensity occurred at the same time point and dosage (8hrs and 
 
Figure 4.1. Representative induction pattern comparison of MEC1 pathway reporter constructs to genotoxic 
and/or cellular stress agents: (A) MMS (8hr exposure), (B) EMS (8hr exposure), (C) SDMH (6hr exposure), 
(D) hydroxyurea (4hr exposure), (E) phleomycin (8hr exposure), (F) 4-NQO  (6hr exposure), (G) 
camptothecin (4hr exposure), (H) hydrogen peroxide (8hr exposure), and (I) formaldehyde (4 hr exposure).  
Exponentially cells growing cells in rich medium were treated with each agent and harvested at times 2, 4, 
6, and 8 hrs. GFP promoter-reporter signal was monitored by flow cytometry.  Fold induction is given as 
the ratio of agent induced GFP signal to that of an untreated control. Results are the average of at least three 
independent experiments and error bars represent standard deviation. 
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0.05%, respectively).  Expression levels for the 0.1% v/v EMS dosage were considerably higher 
for the hug1Δ::GFP than in the haploid strain (Benton et al., 2007), which again can be 
attributed to the diploid strain constructs utilized in this study (data not shown).    
SDMH, hydroxyurea, phleomycin, and 4-NQO (Figure 4.1.C-F) all exhibited 
monotonically increasing dose response to the respective agents.  Notably, the alkylating agent 
SDMH did not show the biphasic induction patterns of MMS and EMS despite previous studies 
reporting otherwise (Figure 4.1.C) (Benton et al., 2007).   
Small increases in SDMH dosages above 1% w/v resulted in substantial (>85%) cellular 
death as indicated propidium iodide staining (data not shown), despite comparable dosages 
eliciting a non-lethal (>90% cell survival by propidium iodide staining) response in similar GFP 
reporter strains.(Benton et al., 2007)  For SDMH, a significant fold induction in reporter signal 
was only identified at the highest dosage (1%; Figure 4.1.C), however the fold induction 
(1.7+0.4) was below our established positive GFP expression threshold.   
SDMH is also the only agent that did not follow the predicted phosphorylation cascade 
expression levels, whereby only dun1Δ::GFP met the criteria for significant fold induction 
(2.1+0.2).  At the 1% dosage and 6hr exposure time, there was a significant effect due to gene 
promoter on the fold induction of the GFP reporter as determined by a one-way ANOVA 
[F(4,10)=5.20, p<0.02], however a Tukey HSD post-test (α=0.05) revealed a significant 
difference only between the dun1Δ::GFP and mec1Δ::GFP reporter, but no statistical difference 
between other gene reporters.  Thus, with the exception of the dun1Δ::GFP and mec1Δ::GFP 
comparison, genes exposed to SDMH have indistinguishable reporter expression at the 1% w/v 
dosage level at 6hr exposure.   
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Hydroxyurea, phleomycin, and 4-NQO (Figure 4.1.D-F) induced gene expression were 
consistent with phosphorylation cascade signal amplification, as HUG1 and RNR3 showing 
highest fold induction to increasing dosages, followed respectively by DUN1, RAD53, and 
MEC1.  Despite a monotonic increase in GFP signal across the strains, peak and significant GFP 
detection thresholds differed between various strains and dosages. Significant fold increases 
were noted in response to hydroxyurea dosages at 10mM and above for hug1Δ::GFP and 
rnr3::GFP, 50mM and above for dun1Δ::GFP and rad53Δ::GFP, and 100mM for mec1Δ::GFP 
from the 4hr exposure onward (Figure 4.1.D).  For phleomycin, dosages below 0.05µg/mL did 
not show significant fold increase in GFP signal.  Only RNR3 and HUG1 exhibited significant 
GFP expression at the 0.05µg/mL phleomycin dosage.   
However, significant signal was noted for all strains at the 5µg/mL concentration (Figure 
4.1.E).  4-NQO did not have significant increases in GFP signaling for dosages at or below 
0.1µg/mL; however a significant monotonic increase in all strains was seen in higher dosages 
(Figure 4.1.F).  Camptothecin, hydrogen peroxide, and formaldehyde (Figure 4.1.G-I) did not 
elicit a significant fluorescent response in any strain with the thresholding values described in the 
Materials and methods.    
4.4.2. Reactive oxygen species (ROS) accumulation in wild-type cells exposed to differential 
MMS  
The GFP promoter-reporter results for mec1Δ::GFP show a measurable reduction in 
MEC1 transcription at the highest dosages of MMS, indicating that the biphasic signal induced 
by alkylating agents MMS and EMS does not originate within the MEC1 repair pathway.  To 
determine other putative contributing factors, we investigated cellular pathways shown to be 
capable of epigenetic regulation in response to catastrophic levels of DNA damage.  In 
Saccharomyces cerevisiae, increases in DNA damage by MMS and UV-C have been shown to 
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increase accumulation of reactive oxygen species (ROS) (Rowe et al., 2008);  ROS can also act 
as signaling molecules that trigger a variety of cellular stress responses, including apoptosis and 
necrosis.(Carmona-Gutierrez et al., 2010; D'Autreaux & Toledano, 2007; Eisenberg et al., 2010; 
Fleury et al., 2002)   To investigate the ROS accumulation at the higher MMS concentrations, 
we exposed wild-type (BY4741) strains to varying dosages of MMS for 2, 4, 6, and 8 hours and 
monitored ROS accumulation using dihydrorhodamine 123, a general reactive oxygen species 
stain (Figure 4.2). 
For every exposure time (2, 4, 6, and 8 hours), all but the highest MMS dosage tested 
(0.2% v/v) had a slight but distinguishable increase in DHR123 staining when compared to 
control strains (Figure 4.2.A, D).  However, the highest MMS dosage tested (0.2% v/v) 
demonstrated considerable ROS accumulation beginning at 4hrs exposure and increased until the 
final 8hr exposure time (Figure 4.2.A-C).  Interestingly, the highest MMS dosage at the 6hr 
exposure had bimodal staining characteristics whereby approximately 50% of the measure events 
expressed little ROS accumulation.   
Despite these intriguing results, the deficiency in ROS accumulation at lower dosages of 
MMS indicate that ROS accumulation levels are not the driving factor behind the MEC1  
pathway gene reduction.  Likewise, pre-incubation of hug1Δ::GFP cultures with the free radical 
scavenger, N-acetylcysteine (NAC), prior to MMS induction did not result in a significant 
change in peak intensity or maximum induction dosage (Supplementary Figure 3), thereby 
suggesting ROS signaling had little effect on the overall MEC1 repair pathway response.     
4.4.3. Differential MMS dosage response of the hug1Δ::GFP promoter-reporter in AIF1 and 
MCA1 deletion strains  
The ROS increase at the highest MMS concentration warranted further investigation due 




Figure 4.2. Reactive oxygen species (ROS) accumulation in wild-type (BY4741) strains at varying MMS 
concentrations. (A) ROS accumulation histograms as measured by flow cytometry using dihydrorhodamine 123 
staining of MMS dosages ranging from 0 (control) to 0.2% v/v at 2 hr (top left panel), 4 hr (top right panel), 6 hr 
(bottom left panel), and 8 hr (bottom right panel) exposure times.  (B) ROS accumulation histograms demonstrating 
fluorescent peak shift of the highest (0.2% v/v) MMS dosage for exposure times 2, 4, 6 and 8 hrs.  (C) Average fold 
induction of ROS accumulation in wild-type strains continuously exposed to 0.005 to 0.2% v/v MMS at 2, 4, 6, and 
8hrs.  Results are the average of at least three independent trials with error bars representing the standard deviation. 
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yeast apoptosis signaling (Madeo et al., 1999).  Oxygen radical formation induced by low levels 
of hydrogen peroxide and cellular stress caused by acetic acid are known to initiate apoptosis in 
yeast.(Ludovico et al., 2001; Madeo et al., 1999)   
Strains containing deletions of the mitochondrial cell death effector, AIF1 (apoptosis 
inducing factor-1) and the yeast metacaspase, MCA1 (formally YCA1), were more resistant to 
hydrogen peroxide, indicating a regulatory role in the free-radical, apoptotic response.(Wissing 
et al., 2004)  Likewise, activation of MCA1 has also been show to coincide with the MEC1-
RAD53 DNA damage response. (Weinberger et al., 2005)  
Due to the increased ROS accumulation measured at high MMS dosages, we investigated 
the role of the apoptotic proteins, MCA1 and AIF1, in the MMS DNA damage response.  The 
hug1Δ::GFP reporter construct was introduced into aif1Δ and mca1Δ haploid deletion strains 
and expression induced at varying MMS dosages.  The GFP intensity was then measured via 
flow cytometry.   
Unexpectedly, the aif1Δ and mca1Δ both affected GFP reporter peak dosage and 
intensity relative to the hug1Δ::GFP strain.  Peak dosage for hug1Δ::GFP appears at 0.01% 
MMS while the peaks in aif1Δ hug1Δ::GFP and mca1Δ hug1Δ::GFP both shift to a higher 
0.05% MMS concentration.  Likewise, GFP signaling is considerably attenuated at all exposure 
times in the aif1Δ hug1Δ::GFP and mca1Δ hug1Δ::GFP strains relative to hug1Δ::GFP alone.  
Despite the peak dosage shift, all strains exhibit reporter repression at all time points and the two 
highest MMS doses (0.1 and 0.2% MMS), and respective fold inductions were statistically 
equivalent.  These results are the first to implicate yeast apoptotic markers AIF1 and MCA1 in 
MEC1 signal amplification, however it is clear that they have no contribution towards initiating 
MEC1 gene repression at higher MMS doses. 
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4.4.4. Cell cycle arrest profiles in response to increasing MMS dosages 
Previous reports have shown that transcripts of yeast cultures exposed to 0.1% MMS 
mirrored transcripts of cultures arrested in stationary phase, (Jelinsky et al., 2000)  while 0.015% 
MMS has been shown to slow cell progression and arrest cells in the S-phase.(Gasch, Audrey P. 
et al., 2001; Paulovich & Hartwell, 1995)  Taken together, these data suggest a cell-phase 
dependency for the DNA damage response and the respective gene expression.  We sought to 
characterize the cell cycle transitions of wild-type (BY4741) strains exposed to MMS dosage 
ranges utilized in the reporter assays in order to identify potential overlap between cell cycle 
progression and MEC1 reporter expression.  Wild-type strains were induced with MMS for short 
and long time intervals, whereupon they were fixed in ethanol and the DNA stained with SYBR 
Green I.  DNA content was then measured by flow cytometry and cell cycle phase determined 
using the FlowJo cell cycle application and gating software. 
Cultures induced with no to little (0-0.005% v/v) MMS proceeded normally through the 
cell cycle with clear phase transitions and no delay or S-phase arrest noted (Figure 4.4.A-D).   
 
Figure 4.3. hug1Δ::GFP reporter expression in (A) hug1Δ::GFP only, (B) aif1Δ, and (C) mca1Δ strains at exposure 
times 2, 4, 6, and 8hrs.  Log phase cultures were treated with 0.0005 to 0.2% v/v MMS, harvested at the times indicated, 
and GFP reporter intensity assessed by flow cytometry.  Fold induction is calculated as the ratio of induced GFP signal 





Figure 4.4. Cell cycle analysis of wild-type (BY4741) strains treated with differential MMS concentrations through a 
range of exposure time points.  (A-H) Wild-type strains were exposed to MMS concentrations 0, 0.0005, 0.001, 0.005, 
0.01, 0.05, 0.1, and 0.5% v/v, respectively, for 25, 50, 60, 80, 100, 120, 240, 360, and 480 minutes to monitor cell 
cycle phase by SYBR Green I staining and flow cytometry.  (I) A representative DNA content histogram is given with 
indicative gating for cell cycle phase determinations. 
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Mid-range MMS dosages (0.01% and 0.05% v/v) showed S-phase arrest as early as 100 minutes 
exposure time and persisted throughout the remaining 8hr exposure.   
Of the total cells counted for the 0.01% and 0.05% dosages, 34% and 84% were arrested 
at the end of the experiment, respectively, which is consistent with previously reported data 
(Paulovich & Hartwell, 1995).  Most interestingly, the two highest dosages of MMS (0.1 and 
0.2% v/v) resulted in an immediate freeze in cellular phase (Figure 4.4.G, H).  Notably, cultures 
experiencing this high dose did not undergo a measurable cell cycle phase transition, starting 
from the earliest time point (20 minutes).  This immediate cell cycle arrest stage persisted for the 
remaining run time of the experiment.     
4.5. Discussion 
The eukaryotic response to exogenous and endogenous DNA damage requires 
sophisticated machinery that ensures genomic stability through coordinated cell cycle arrest and 
DNA repair.  Understanding the intricacies of this machinery is paramount to assessing the cell’s 
molecular response to environmental changes.  Global transcription analysis of the yeast 
response to alkylating agents, ionizing radiation, and other cellular stresses have revealed a 
complex and differential network of gene expression.(Fry et al., 2005; Gasch, A. P. et al., 2000; 
Jelinsky et al., 2000; Jelinsky & Samson, 1999)  These studies have also uncovered novel 
transcriptional profiles within the DNA damage response - including the unique biphasic 
response of MEC1 repair pathway genes DUN1, HUG1, RNR2 and RNR4 to alkylating agents 
(Benton et al., 2007; Benton et al., 2006) – whose regulatory origins remain unknown.  
Characterizing the source of this unusual cellular response to alkylating agents was the 
fundamental purpose of this study. 
We first set out to identify if the MEC1 biphasic response originated within the MEC1 
phosphorylation cascade.  In the Saccharomyces cerevisiae DNA damage response, DNA 
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damage sensors detect DNA lesions and activate Mec1p kinase.(Abraham, 2001; Cimprich & 
Cortez, 2008; Craven et al., 2002; Di Domenico et al., 2014; Majka, J. & Burgers, P. M., 2003; 
Majka et al., 2006; Minca & Kowalski, 2011; Ogiwara et al., 2006; Rouse & Jackson, 2002)  
Mec1p-mediated hyperphosphorylation of effector kinase, Rad53p, then provokes a 
phosphorylation cascade involving transducer Dun1p activation that relieves DNA repair protein 
transcriptional repression and post-translational inhibition.(Basrai et al., 1999; Chen et al., 2007; 
Lee et al., 2008; Zhao & Rothstein, 2002)  As previous reports have demonstrated a dose 
dependent transcriptional repression of DUN1, HUG1, RNR2, and RNR4 when challenged with 
extreme doses of MMS, we extended the genes studied to those further upstream in the MEC1 
phosphorylation cascade, MEC1 and RAD53.  Using a GFP promoter-reporter detection system, 
we assayed the transcript specific response to a survey of DNA damaging agents (Table 4.1) at 
varying dosages and times (Figure 4.1 and Supplementary Figure 3).  Our results confirmed that 
the alkylating agent-mediated biphasic expression profile persisted through effectors HUG1 and 
RNR3 to the upstream transducers DUN1, RAD53, and MEC1, and that this signaling was 
specific to the alkylating agents MMS and EMS (Figure 4.1).  Therefore, we have concluded that 
MEC1 gene repression at extreme alkylating agent dosages must occur outside of the MEC1 
phosphorylation cascade.  Coinciding with this finding, MMS-induced global protein 
degradation was shown to be independent of the MEC1 DNA repair pathway and intermediate 
repair pathways.(Burgis & Samson, 2007)  However, deletions of RPN4, a MMS-responsive 
transcriptional activator (Jelinsky et al., 2000), did not show significant effects on total protein 
degradation.(Burgis & Samson, 2007)  We also created GFP promoter-reporter constructs to 
monitor the transcriptional profiles of genes involved in double stranded DNA break repair 
(MRE11 and RIF1) (Chamankhah & Xiao, 1999; Martina et al., 2014), PCNA-like DNA clamp 
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loading (DDC1) (Bonilla et al., 2008; Majka, J. & Burgers, P. M. J., 2003), and Mec1p 
activation and DNA damage site localization (DDC2) (Bandhu et al., 2014; Rouse & Jackson, 
2000), however resulting expression levels were below the detection thresholds for the GFP 
reporter assay (data not shown).   
We then sought to identify extrinsic pathways with putative involvement in MEC1 repair 
pathway repression.  At high doses of the cellular stress agents, hydrogen peroxide and acetic 
acid, reactive oxygen species (ROS) signal an apoptotic response that triggers a global response 
that modulates response protein expression levels and abundance (Carmona-Gutierrez et al., 
2010).  We theorized that a similar apoptotic-dependent pathway may execute in response to 
high titers of alkylating agents; therefore, ROS accumulation and pro-apoptotic proteins offer 
prospective factors involved in the suppression of the MEC1 repair response.  Interestingly 
though, ROS accumulation (as measured by dihydrorhodamine 123 staining and flow cytometry) 
showed nominal increases at all except the highest MMS dosage, despite MEC1 pathway gene 
expression reduction at the lower levels of MMS (Figure 4.2).  Knockouts of two apoptotic 
genes, AIF1 and MCA1, also did not affect MEC1 gene repression at high dosages, though these 
knockouts did show a considerable shift in GFP peak intensity and attenuation of signal intensity 
(Figure 4.3).  Previous reports have demonstrated reduced sensitivity of mca1 deletions to 
hydrogen peroxide; therefore, it is likely that the mca1 and aif1 deletions exert reduced 
sensitivity effects for other DNA damaging through a similar mechanism.  Moreover, apoptotic 
signals in yeast have been shown to be MEC1-dependent (Qi et al., 2003).  Our findings further 
extend this observation, as the attenuated GFP signaling in the aif1 and mca1 deletion mutants 
implicate AIF1 and MCA1 in the feedback of MEC1-mediated signal propagation. 
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Intra-S phase arrest is a hallmark of the MMS-induced DNA damage response, as cellular 
machinery restrict cell cycle progression to prevent duplication of damaged DNA.  The 
concerted, adaptor-mediated MEC1 activation of Rad53p ensures late origin firing and slowed S-
phase progression.(Ciccia & Elledge, 2010; Harper & Elledge, 2007; Huang et al., 1998; Zhou & 
Elledge, 2000)  Checkpoint activation has been shown to require threshold levels of damage to 
adequately phosphorylate Rad53p to initiate the DNA damage response.(Shimada et al., 2002)  
Likewise, global transcriptional analysis of S. cerevisiae exposed to high concentrations (0.1%) 
of MMS show reduced signatures of genes in the DNA damage response and an increase in 
genes characteristically expressed during stationary phase,(Benton et al., 2007; Benton et al., 
2006; Jelinsky et al., 2000) which further emphasizes the importance of cell phase on gene 
expression.  Our cell cycle analysis corroborates previous data showing slowed and arrested S-
phase arrest (Figure 4.4.E, F).  High alkylation damage, however, did not show characteristic 
intra-S-phase arrest.  Instead, cultures showed no indications of cell cycle progression and 
remained in the quiescent state for the entirety of the 8h experiment.  This result was unexpected, 
but aligns with previous reports expressing similarities between stationary phase and 0.1% 
MMS-treated log-phase cells gene expression.(Jelinsky et al., 2000)  Likewise, unusual cell 
phase arrest occurs under the exact conditions as the right-handed portion of the MEC1 reporter 
biphasic peak, suggesting a link between the extreme alkylation, immediate arrest, and 
repression of MEC1 repair pathway genes.  Our ROS and apoptotic gene response data indicate 
the mechanisms responsible for these profiles are independent of apoptosis commitment 
subroutines.  Interestingly, quiescent state commitment is immediate and acute in the highest two 
alkylating dosages, suggesting the DNA damage response and, by extension, the MEC1 
checkpoint response fails to activate.  As MMS alkylates proteins as well as DNA and RNA 
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(Boffa & Bolognesi, 1985), it is possible that critical MMS levels alkylate proteins upstream of 
the MEC1 response and targets them to the proteasome.  Previous studies have shown that genes 
required for protein degradation are upregulated while protein synthesis are reduced in response 
to MMS (Jelinsky et al., 2000; Jelinsky & Samson, 1999); likewise, a significant increase in 
global protein degradation was reported in response to high MMS dosages (0.3%).(Burgis & 
Samson, 2007)  However, the reason behind the increase in stationary gene transcript expression 
and our corroborating evidence showing immediate quiescent cell arrest at critical MMS dosages 
remains uncharacterized and warrants further investigation. 
4.6. Conclusion  
In this study, we have characterized the differential and temporal response of five yeast 
checkpoint pathway genes (MEC1, RAD53, DUN1, HUG1, and RNR3) to a survey of DNA 
damaging, physical and replicative stress agents.  The biphasic response of MEC1 and genes in 
its phosphorylation cascade was shown to be specific to the alkylating agents, MMS and EMS.  
MEC1 pathway gene repression at high alkylating dosages was shown to occur outside of the 
MEC1-RAD53-DUN1 pathway and is independent of reactive oxygen species accumulation and 
apoptotic genes, AIF1 and MCA1, though the knockouts of the latter genes did show effects on 
MEC1 signal amplification.  Cell cycle analysis on wild-type strains exposed to mildly toxic 
MMS dosages corroborates previous reports of S-phase arrest, however, at high MMS dosages, 
cells experienced an immediate and enduring arrest in a quiescent state.  This suggests high 
levels of alkylating damage provoke an alternate quiescent arrest pathway marked by stationary 







4.7. Supplementary tables and figures 
4.7.1. List of strains used in the study  
Table 4.2. List of strains used in the study 
STRAIN NAME GENOTYPE DESCRIPTION SOURCE 
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4.7.2. List of primers used in this study  





SEQUENCE (5' --> 3') 

































Colony PCR Verification Primers 
MEC1 MEC1-Ver_F AATTCCTTTTCAAGGCTCCA 
RAD53 RAD53-Ver_F TTTTCATTTCGAGGGTGAGG 
DUN1 DUN1-Ver_F TGTTGGTGATCGTGTGGACT 
RNR3 RNR3-Ver_F TCTGCCTACGGTTGTCACAG 
HUG1 HUG1-Ver_F TCGGACTTACTCAAAGGGTTG 
GFP(S65T) GFP(S65T)_R AAAGGGCAGATTGTGTGGAC 
AIF1 AIF1-Ver_F GTCTTGAAGAAGACTTCAATGGTGT 
MCA1 MCA1_Ver_F AATAGTGGACGAAATCCATCTTGTA 
KANMX4 KanB-Ver_R CTGCAGCGAGGAGCCGTAAT 




4.7.3. mec1Δ∷GFP promoter-reporter system data  
 
Figure 4.5. mec1Δ∷GFP promoter-reporter temporal and dose dependent response to (A) MMS, (B) EMS, (C) SDMH, 





4.7.4. rad53Δ∷GFP promoter-reporter system data   
 
Figure 4.6. rad53Δ∷GFP promoter-reporter temporal and dose dependent response to (A) MMS, (B) EMS, (C) 
SDMH, (D) hydroxyurea, (E) phleomycin, (F) 4-NQO, (G) camptothecin, (H) hydrogen peroxide (H2O2), and (I) 
formaldehyde.  Exposure times are denoted as follows: 2 hr ( ), 4hr ( ), 6hr ( ), and 8hr ( ) 
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4.7.5. dun1Δ∷GFP promoter-reporter system data 
  
 
Figure 4.7. dun1Δ∷GFP promoter-reporter temporal and dose dependent response to (A) MMS, (B) EMS, (C) SDMH, 
(D) hydroxyurea, (E) phleomycin, (F) 4-NQO, (G) camptothecin, (H) hydrogen peroxide (H2O2), and (I) 
formaldehyde.  Exposure times are denoted as follows: 2 hr ( ), 4hr ( ), 6hr ( ), and 8hr ( ) 
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4.7.6. hug1Δ∷GFP promoter-reporter system data 
  
 
Figure 4.8. hug1Δ∷GFP promoter-reporter temporal and dose dependent response to (A) MMS, (B) EMS, (C) SDMH, 
(D) hydroxyurea, (E) phleomycin, (F) 4-NQO, (G) camptothecin, (H) hydrogen peroxide (H2O2), and (I) 
formaldehyde.  Exposure times are denoted as follows: 2 hr ( ), 4hr ( ), 6hr ( ), and 8hr ( ) 
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4.7.7. rnr3Δ∷GFP promoter-reporter system data   
 
Figure 4.9. rnr3Δ∷GFP promoter-reporter temporal and dose dependent response to (A) MMS, (B) EMS, (C) SDMH, 
(D) hydroxyurea, (E) phleomycin, (F) 4-NQO, (G) camptothecin, (H) hydrogen peroxide (H2O2), and (I) 
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This chapter is a continuation of major discoveries made Chapter 4, which established 
HUG1 as a negative regulator of the MEC1 checkpoint pathway.  In Chapter 4, we proposed 
HUG1’s inhibitory activity was the result of its co-localization with the small subunit of 
ribonucleotide reductase, RNR2.  In this chapter, we will further examine the putative interaction 
with between HUG1 and RNR2 using an array of yeast-specific protein interaction techniques, 
including co-immunoprecipitation assays and traditional and fluorescent yeast two-hybrid 
systems.  Further, we will explore the effects of HUG1 mutations on the ability of HUG1 to 
perform its inhibitory function.  Finally, we will discuss the discovery of new HUG1 interaction 
partners, the human RNR2 homologues p53R2 and hRRM2.  
5.2. Introduction 
Eukaryotic organisms employ sophisticated surveillance machinery to identify and 
respond to endogenous and exogenous sources of DNA damage.(Ciccia & Elledge, 2010)  To 
preserve DNA fidelity, cells coordinate a complex network of signal sensing and transduction 
mechanisms to mend DNA lesions.(Harper & Elledge, 2007)  Prevention of unstable genome 
inheritance is paramount to the DNA damage response, and, as such, effective repair requires the 
initiation of arrest stages (termed “checkpoints”) to halt cell cycle progression.(Zhou, B. B. & 
Elledge, 2000) Alongside initiating cell cycle arrest, checkpoint pathways induce a host of 
cellular activities, including transcriptional activation of genes required for repair (Huang et al., 
1998), regulation of  replication origin firing (reviewed in (Yekezare et al., 2013)), and, in the 
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case of insurmountable DNA damage, initiation of apoptotic subroutines.(Norbury & 
Zhivotovsky, 2004).   
In the budding yeast, Saccharomyces cerevisiae, the DNA damage response is mainly 
controlled by a highly conserved transduction pathway, known as the MEC1 checkpoint 
response. Upon its activation, MEC1 (homolog to the human Ataxia telangiectasia and Rad3 
related – ATR) phosphorylates a cascade of effector kinases, such as Rad53p and Dun1p, which 
are required for transcript induction and repair target activation.(Ainsworth et al., 2013; Chabes 
et al., 1999; Chabes et al., 2003; Chen et al., 2007; Ciccia & Elledge, 2010; Harper & Elledge, 
2007; Huang et al., 1998; Lee et al., 2008; Zhou, B. B. & Elledge, 2000)  An essential element 
of the DNA repair response is the ability to supply adequate levels of DNA monomers, dNTPs, 
for DNA lesion repair.  Ribonucleotide reductase (RNR) genes, the enzyme that performs the 
rate-limiting dNTP synthesis step, is a downstream target of the MEC1 pathway and is 
fundamental to maintaining cellular dNTP pools during normal and genotoxic stress 
conditions.(Chabes et al., 2000; Sanvisens et al., 2013; Sommerhalter et al., 2004)  The active 
RNR complex is composed of a homodimer large subunit (Rnr1p), which houses the catalytic 
and two allosteric sites,(Xu, Faber, Uchiki, Fairman, et al., 2006) and a heterodimer small 
subunit (Rnr2p-Rnr4p), which contains the diferric-tyrosyl radical cofactor necessary for NTP 
reduction chemistry.(Chabes et al., 2000; Sommerhalter et al., 2004)  However, tight regulation 
of RNR activity is required as suboptimal or excessive dNTP concentrations have been linked to 
increased mutagenesis rates.(Chabes & Stillman, 2007; Kumar, D. et al., 2010) 
S. cerevisiae implement a unique, MEC1-mediated regulation regime to control RNR 
activity at both the transcriptional and post-translational levels.  During the normal cell cycle, 
RNR subunit genes, RNR2, RNR3, and RNR4, are repressed by the DNA binding protein, Ctr1p, 
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which recruits the Ssn6p and Tup1p repressor complex to RNR gene promoter sites.(Huang et 
al., 1998).  After DNA damage is sensed, however, MEC1-RAD53 mediated hyper 
phosphorylation of Crt1p detaches the repression complex from the RNR promoters and allows 
transcription to be initiated.(Huang et al., 1998)  RNR1 transcription is also regulated by a DNA 
binding protein, Ixr1p, which has been shown to be required for normal RNR1 
expression.(Tsaponina et al., 2011) 
The RNR complex is also repressed during normal cell growth by two MEC1 negative 
regulator proteins unique to S. cerevisiae.  The large RNR homodimer subunit (Rnr1p) is 
inhibited by the protein, Sml1p, which interacts through a conserved Rnr1 interaction domain 
domain.(Chabes et al., 1999; Zhao et al., 2000)  The small RNR heterodimer subunit, Rnr2p-
Rnr4p, is inhibited through Dif1p-mediated nuclear localization whereby it is anchored by 
Wtm1p.  This effectively sequesters the small subunit and prevents formation of the active RNR 
complex in the cytoplasm.(Lee et al., 2008; Wu & Huang, 2008)  In response to DNA damage, 
Sml1p and Dif1p are phosphorylated at a conserved phosphodegron site and degraded.  Active 
RNR complex then readily assembles in the cytoplasm as Sml1p no longer inhibits the Rnr1p 
homodimer and the Rnr2p-Rnr4p heterodimer is relieved from Dif1p-Wtm1p mediated nuclear 
sequestration. (Chabes et al., 1999; Lee et al., 2008; Wu & Huang, 2008; Zhao et al., 2000) 
Our lab has recently determined that the MEC1 target, HUG1, also negatively regulates 
the MEC1 response.(Ainsworth et al., 2013)  Sequence alignments between the Saccharomyces 
cerevisiae negative regulators HUG1, DIF1 and SML1 and the functionally analogous 
Schizosaccharomyces pombe SPD1 and Ashbya gossypi Aer122c genes revealed a series of 
conserved domains that is likely the result of ancestral gene duplication of the Aer122c gene.  
DIF1 and SML1 shared the phosphodegron site required for protein degradation upon genotoxic 
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stress induction.  SPD1, which serves dual function to inhibit large RNR subunit and sequester 
the small RNR subunit, had a conserved “Sml” domain also present in SML1 which is required 
for large subunit inhibition.   Most interestingly, DIF1, HUG1, and SPD1 all contained 
homology in the “Hug” domain, a region originally identified in DIF1 as the region necessary for 
small subunit nuclear localization.(Lee et al., 2008) 
Corroborating this data, our lab examined the subcellular compartmentalization of Hug1p 
in response to replication stress agent, hydroxyurea, and found that its localization profile 
correlated to that the small subunit heterodimer, Rnr2p-Rnr4p.(Ainsworth et al., 2013)  Taken 
together with data demonstrating Hug1p’s delayed response to hydroxyurea relative to the 
positive MEC1 effector, Rnr3p, we proposed Hug1p to be a negative regulator of the MEC1 
pathway that functions in cellular recovery through its co-localization with Rnr2p-
Rnr4p.(Ainsworth et al., 2013)   
Despite this, the mechanism by which Hug1p regulates the MEC1 pathway remains 
undetermined.****  Utilizing a fluorescent yeast-two hybrid system and co-immunoprecipitation 
assays, we determined that Hug1p indeed interacts with the RNR small subunit, Rnr2p-Rnr4p.  
dNTP pools were also measured with and without Hug1p overexpression to assess the Hug1p’s 
putative RNR inhibitory role.  Several biochemical techniques were then utilized to determine 
the amino acid regions required for this interaction, including error-prone PCR and EMS 
mutagenesis and site-directed scanning alanine mutagenesis of the HUG1 ORF.  Overexpression 
plating and liquid growth analysis were performed on the resulting mutants to determine the 
                                                 
**** Hug1’s interaction with Rnr2p-Rnr4p has since been confirmed and interaction domains identified in the 
publication, Meurisse, J., Bacquin, A., Richet, N., Charbonnier, J.-B., Ochsenbein, F., & Peyroche, A. (2014). Hug1 
is an intrinsically disordered protein that inhibits ribonucleotide reductase activity by directly binding Rnr2 subunit. 
Nucleic Acids Res. (Meurisse et al., 2014).  These findings and their relation to this study will be discussed in the 
Conclusions section.   
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overall effects of the mutations on Hug1p’s inhibitory activity.  Western blot analysis and co-
immunoprecipitation assays were also carried out to assess mutant expression levels and identify 
mutation-related loss-of-interaction.  Finally, the positive interaction between intact Hug1p and 
two human RNR2 homologs, p53R2 and hRRM2, was identified using the fluorescent yeast-two 
hybrid system.  These discoveries further clarified Hug1p’s role in the MEC1 recovery process 
and identified new domains required for its interaction with the RNR small heterodimeric 
subunit, Rnr2p-Rnr4p.   
5.3. Materials and methods 
5.3.1. Strains and plasmids construction 
Plasmid and primer sequences used throughout this study are available upon request.  
pMB379 was created as described in previous studies.(Basrai et al., 1999)  Plasmids pGAD-C1 
and pGBD-C1 were used to create the traditional yeast two hybrid expression vectors to test 
HUG1 and RNR2 interaction.(James et al., 1996).  HUG1 was inserted by restriction enzyme 
digestion and ligation into the pGAD-C1 vector by amplifying its ORF from the BY4741 
genomic DNA extractions using high-fidelity PCR ad mutagenic primers containing a BamHI 
and SalI sites on the forward and reverse primers respectively.  RNR2 was inserted into the 
pGBD-C1 vector using a similar method, with the exception PstI restriction enzyme site was 
used in the reverse primer.   
The fluorescent yeast two-hybrid system was designed in accordance with previous split 
GFP constructs.(Barnard et al., 2008) yEGFP1 (pKT218; EUROSCRAF) was used as the 
template for split GFP fragment construction.  Overlap extension PCR was used to construct a 
poly-GGGS linker sequence at the N- and C-terminus, depending on split GFP fragment fusion 
location desired.  Primers were designed to truncate yEGFP1 from amino acids 1-157 (N-
terminal yEGFP1 fragment, or NyEGFP1) and amino acids 158-238 (C-terminal yEGFP1 
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fragment, or CyEGFP1).  Two vector sets were developed to allow PCR mediated gene deletion 
and fusion with the NyEGFP1 and CyEGFP1 fragments (pFA6a-NyEGFP1-KANMX6 and 
pFA6a-CyEGFP1-HIS)(Longtine et al., 1998)  The pRS-plasmid vector set was used to fuse 
CyEGFP1 and NyEGFP1 fragments N- and C-terminally to HUG1, RNR2, p53R2 (synthesized 
using idtDNA’s gBlock technology from GenBank accession number AB036063), hRRM2 
(amplified from pET-hRRM2.T2; a kind gift of Dr. Andres Chabes)(Guittet et al., 2001), and 
DNA2 (amplified from the yeast BY4741 genome) and placed under GAL, HUG1, or RNR2 
promoter control where indicated.(Mumberg et al., 1995) 
Strains utilized in HUG1 overexpression phenotyping analysis and dNTP determinations 
were constructed in accordance with previous investigations (Ainsworth et al., 2013; Basrai et 
al., 1999).  PJ69-4A and PJ69-4α (kind gifts of Dr. Munira Basrai and Dr. James P. Halladay) 
were used for the traditional yeast two-hybrid assays as described previously (James et al., 
1996).  Fluorescent yeast two-hybrid strains were constructed from BY4741 (MATa his3Δ1 
leu2Δ0 met15Δ0 ura3Δ0).  hug1Δ knockouts and C-terminal fusions of the split GFP fragments 
and HA-epitope tag (from plasmid pFA6a-3xHA-KANMX6) were performed using PCR 
mediated gene deletion and gene fusion protocols as described.(Longtine et al., 1998)  Strains 
Y300 (MATa can1-100 ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1) and MHY343 (Y300 
rnr2∷PRNR2-FLAG-RNR2-kan) were provide by Dr. Mingxia Huang and constructed as 
previously described.(An et al., 2006)  All yeast transformations were performed using the high 
efficiency lithium acetate / single-stranded carrier DNA / PEG transformation method. (Gietz & 




5.3.2. Quantitation of dNTP pools†††† 
dNTP extraction, HPLC measurements, and calculation of dNTP pools were performed 
as described previously.(Chabes et al., 2003; Chabes & Stillman, 2007) 
5.3.3. Western blot and co-immunoprecipitation assays‡‡‡‡ 
Protein extraction, western blotting, and co-immunoprecipitation assays were carried out 
as described with slight modifications.(Basrai et al., 1999; Mishra et al., 2015; Ohkuni et al., 
2015)  Briefly, strains expressing the HUG1-HA construct under native promoter control were 
induced with hydroxyurea for 1.5 and 3.5 hours and whole cell extracts (WCE) collected.  WCE 
were then added to anti-HA beads to pulldown the HUG1-HA.  Western blots were then run 
using both WCE and anti-HA pulldown elutions.  Anti-HA antibodies were used to identify 
Hug1p and anti-RNR2 (a kind gift of Dr. Joanne Stubbe) were used to stain Rnr2p pulled down 
by the anti-HA beads.   
5.3.4. Overexpression phenotype plating and liquid growth assays 
Overexpression phenotype plating assays were performed according to previous methods 
(Ainsworth et al., 2013; Basrai et al., 1999). Serial dilutions of log-phase cultures were spotted at 
a dilution factor of five and allowed to grow for three to seven days, as indicated.  
Overexpression liquid growth assays were carried out as described (Toussaint & Conconi, 2006) 
with slight modifications.  Triplicate cultures were grown overnight in selective media 
containing 2% raffinose and reseeded the following day in fresh media to an absorbance of 
OD600 of 0.1.  Cultures were then incubated additional 5 hours to ensure log-phase growth, 
                                                 
†††† dNTP experiments were performed in collaboration with Dr. Sushma Sharma and Dr. Andrei Chabes at Umeå 
University in Umeå, Sweden. 
 
‡‡‡‡Whole cell protein extractions, Western blots, and co-immunoprecipitation assays were performed in 
collaboration with Dr. Munira Basrai and Dr. Wei Au at the Center for Cancer Research, National Cancer Institute 
in Bethesda, MD. 
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whereupon 95µL of each sample was transferred to a low-evaporation 96-well plate.  5µL of 
galactose media with or without hydroxyurea was added to each well to give a final galactose 
concentration of 2% and a final hydroxyurea concentration of 150mM.  The plate was wrapped 
in parafilm and immediately placed in the SpectraMax M5 microplate reader.  The plate reader 
was set to take kinetic measurements of the absorbance at 660nm every 10 minutes for 48 hours 
with shaking occurring 2 minutes immediately before reading.  Data was exported to and 
analyzed in Microsoft Excel. For data analysis, background was subtracted from all sample 
measurements using blank wells containing selective media only.  Growth rates were determined 
as the slope of five consecutive OD points in time.  Maximal growth rates were averaged from at 
least three replicates and used to determine the effect of intact and mutant HUG1 overexpression 
and hydroxyurea induction.   
5.3.5. Random and site-directed mutagenesis 
Error-prone PCR was performed on the HUG1 ORF in accordance with previous 
protocols (McCullum et al., 2010) whereby the mutated HUG1* was placed under HUG1 and 
GPD promoter controls in the respective pRS-vector sets by co-transformation and plasmid 
reconstruction by homologous recombination. (Ma et al., 1987; Mumberg et al., 1995)   Intact 
HUG1 PCR fragments were also mutagenized by EMS mutagenesis to reduce base mutation 
bias.(Winston, 2008)  All mutants were transformed into yPP8 with a hug1 deletion (MATα ade2 
ade3 leu2 ura3 trp1 mec1Δ::TRP1 his3 hug1Δ∷HIS3 [pEF208=URA3 ADE3 MEC1 
CEN).(Basrai et al., 1999)  Transformants were plated on selective media with low adenine 
concentrations to allow for red-white colony selection, in accordance with previous 
protocols.(Ma et al., 1987; Zhao et al., 2000)  All white and red-white segregated colonies were 
replica plated onto selective media with low adenine prior to plasmid extraction and sequencing.  
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Site-directed mutagenesis was performed using the Phusion site-directed mutagenesis kit 
(Thermo Scentific) in accordance with manufacturer’s instructions.  22 primer sets were 
designed to mutate three to four amino acids to alanines and to add a PstI digestion site for 
preliminary selection.  The pUC18-HUG1 used as the mutagenesis template contained homology 
to the pRS- GAL promoter and CYC1 terminator up-and downstream of the HUG1 ORF. After 
verification of the mutants by sequencing, MHY343 hug1Δ2∷HIS3 knockouts were transformed 
with the HUG1 mutants and linearized vector set, whereby the HUG1* mutants were inserted 
under GAL promoter control by plasmid reconstruction by homologous recombination.(Ma et 
al., 1987).  Overexpression assays were then carried out as described. 
5.3.6. Fluorescent yeast two hybrid (split GFP) assay 
Strains expressing fusions of the NyEGFP1 and CyEGFP1 fragments were grown 
overnight in selective media containing 2% raffinose.  The following day, strains were reseeded 
to an OD600 of 0.1 and allowed to grow for an additional 3.5 hours to ensure log-phase growth.  
At that time, 2% galactose was added to induce expression from the galactose promoter and 
incubated at 30°C for 3.5 hours.  For strains under HUG1 promoter control, hydroxyurea was 
then added to a final concentration of 150mM and allowed to incubate for 3.5 hours.  Samples 
were washed in PBS and prepared for microscopy as previously described.(Ainsworth et al., 
2013) 
5.4. Results and discussion 
5.4.1. Effects of HUG1 overexpression on cellular dNTP levels 
We have previously shown that Hug1p is a negative regulator of the MEC1 DNA damage 
checkpoint pathway and proposed that the interaction serves aids in cellular recovery after DNA 
damage (Ainsworth et al., 2013; Basrai et al., 1999).  We also observed similar subcellular co-
compartmentalization of Hug1p and Rnr2p when exposed to the replication stress agent, 
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hydroxyurea, which suggests Hug1p’s activity putatively arises from its interaction with Rnr2p 
(Ainsworth et al., 2013).  As Rnr2p contains a diferric tyrosyl radical cofactor required for de 
novo radical reduction of ribonucleotides (NTPs) to deoxyribonucleotides (dNTPs) (Chabes et 
al., 2000; Sommerhalter et al., 2004), we proposed that the Hug1p’s negative regulation activity 
may arise from its inhibition of dNTP production by RNR.     
To examine the effects of Hug1p expression on dNTP levels, we overexpressed Hug1p in 
wild-type (BY4741) strains transformed with an episomal plasmid containing intact HUG1 under 
a galactose-inducible promoter (PGAL1), as described in previous overexpression phenotype 
plating assays (Ainsworth et al., 2013; Basrai et al., 1999).  Galactose-induced strains were also 
simultaneously exposed to hydroxyurea to produce conditions of growth inhibition synergism 
between Hug1p overexpression and dNTP depletion as seen in our previous overexpression 
plating analysis (Ainsworth et al., 2013).  After 3.5 hours under these conditions, dNTPs were 
purified and analyzed as previously described (Chabes et al., 2003)††††.  Normalized dNTP 
levels determined with or without galactose overexpression of HUG1 at various induction times 
and with or without the replication stress agent, hydroxyurea, are given in Figure 5.1.  Temporal 
overexpression of HUG1 with galactose shows a qualitative drop in dNTPs pools (Figure 5.1.A), 
however a one-way ANOVA reveals that there is no significant difference between dNTPs 
(dCTP, dTTP, dATP, and dGTP) of the wild-type and that of the 1, 2, and 3hr galactose-induced 
HUG1 (p=0.552, 0.437, 0.470, and 0.213 for dCTP, dTTP, dATP, and dGTP, respectively).   
dNTP measurements were also collected for strains overexpressing HUG1 in the absence 
or presence of hydroxyurea (Figure 5.1.B).  One-way ANOVA revealed significant differences 
between wild-type and HUG1 overexpression strains with and without hydroxyurea for all  
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dTNPs (F(3,4)=2.360; p=0.231).  A significant reduction was seen in all dNTPs when HU was 
included in the media for both no (Figure 5.1.B; WT+HU) and overexpression of HUG1 strains 
(Figure 5.1.B; GAL1-HUG1+HU) as determined by a one-way ANOVA with Bonferroni post-
hoc analysis (p<0.005 for all dNTPs). Bonferroni post-hoc was used as a small number of mean 
comparisons was performed (Field, 2005).  No significant different was seen between wild-type 
strains and strains overexpressing HUG1 for dCTP and dTTP (p>0.160); however, significant 
differences were noted for dATP and dGTP (p<0.005).  Despite a qualitative reduction in dCTP 
values between wild-type and HUG1 overexpressed strains induced with hydroxyurea (Figure 
5.1.B; WT+HU and GAL1-HUG1+HU, respectively), the Bonferroni post-hoc test revealed no 
significant differences between the two (p=0.567).   
 
Figure 5.1.†††† Effects of HUG1 overexpression on wild-type (WT; BY4741) stain dNTP levels with and without 
hydroxyurea for 1, 2, and 3hrs.  (A)  WT strains with and without galactose-inducible HUG1 (WT HUG1 and GAL1-
HUG1, respectively) were grown in galactose for 1, 2, and 3hrs and dNTP levels (dCTP, dTTP, dATP, and dGTP) 
measured by HPLC.  (B) WT strains with and without the galactose-inducible HUG1 (WT HUG1 and GAL1-HUG1, 
respectively) were grown in the presence of galactose with and without 200mM hydroxyurea (HU) for 3.5 hours 
whereby the dNTP levels (dCTP, dTTP, dATP, and dGTP) were analyzed by HPLC.  Duplicate biological 
measurements were run for each sample.  Bars represent the mean of the dNTP measurements and error bars indicate 
the standard deviation of the mean. 
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Similarly, dTTP, dATP, and dGTP values also showed no significant differences between 
wild-type and HUG1 overexpressed strains induced with hydroxyurea (Figure 5.1.B; p>0.168).  
Due to the rigor of performing the experiment, the sample size (n=2) is very small, and thus 
these statistical results may not be reflective of HUG1’s true effect on dNTP concentrations.  
Likewise, hydroxyurea reduces dNTP levels to concentrations that approach the dNTP 
extraction’s lower detection threshold (Andrei Chabes, personal correspondence).  A new DNA 
damaging agent that does not dramatically and directly affect cellular dNTP levels should be 
used for future experiments. 
5.4.2. Traditional yeast two-hybrid fails to verify the Hug1p-Rnr2p interaction 
One of the ways to verify the Hug1p-Rnr2p interaction is to use the traditional yeast two-
hybrid assay (Y2H).  The traditional Y2H system requires the fusion of two putatively 
interacting proteins to the GAL4 activating domain (GAL4-AD) and the GAL4 binding domain 
(GAL4-BD).  The GAL4-BD binds to the upstream activating sequence of GAL1 (UAS-GAL1) 
and, upon activation by the activating domain, begins transcribing genes under GAL1 promoter 
control.  Protein fusions to the GAL4 binding and activating domains can determine protein 
interaction propensity, as the proximity of interacting proteins allows for the GAL4 activator 
domain to trigger binding domain mediated GAL1 promoter gene transcription. Designer stains, 
such as PJ69-4a, have been engineered to include HIS3 selection under the GAL1 promoter to 
enable facile selection of strains with interacting proteins; however, the leakiness of the HIS3 
selection marker requires media to contain a HIS3 competitive inhibitor, 3-amino-1,2,4-triazole 
to reduce false positives or an additional, stringent selection marker (for instance, PJ69-4a/α uses 
ADE2 as the extra selection marker under the GAL2 promoter, which activates downstream of 
GAL1 and requires GAL1 promoter activation for its expression).  (James et al., 1996) 
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Thus, to test the Hug1p-Rnr2p interaction using the traditional Y2H, we fused the GAL4 
activation domain to the N-terminus of Rnr2p (GAL4-AD-RNR2) and the GAL4 binding domain 
to the Hug1p N-terminus (GAL4-BD-HUG1).  BigDye® Terminator sequencing was used to 
verify correct reading frame of all plasmid constructs.  We then co-transformed GAL4-AD-
RNR2 and GAL4-BD-HUG1 into the traditional Y2H-compatible designer strain, PJ69-4a (kind 
gifts of Dr. Munira Basrai and Dr. James P. Halladay), whereby positive uptake of the plasmids 
was verified by colony PCR.  Strains were then grown to log phase and plated in serial dilutions 
on selective media lacking either histidine (SD-HIS) or histidine and adenine (SD-HIS-ADE).  
Likewise, strains were also plated on selective media lacking histidine and containing titrations 
5, 10, 25, and 100mM 3-AT (SD-HIS+3AT).  Strains were allowed to grow for several days to 
allow colony growth on the selective media.  However, after seven days of growth, the plates 
demonstrated no strain new growth on even on the lowest selection stringency, SD-HIS, despite 
normal growth on media selective for the GAL4-AD and BD plasmids alone (SD-URA-LEU). 
Attempts at switching the fusions (AD-HUG1 and BD-RNR2) also proved unsuccessful as 
similar results were obtained for both constructs.   
There are many potential reasons as to why this assay did not initially function.  First, in 
order to express appropriate levels of HUG1 in the pRS-vector sets, at least 35 bases of the 
upstream HUG1 promoter sequence and 66 bases of the HUG1 terminator sequence are 
required.(Basrai et al., 1999) Likewise, an even higher induction can be achieved in GAL-HUG1 
vectors if replication stress agent hydroxyurea or DNA damaging agent, MMS, are included with 
the galactose induction.  Interestingly, full derepression of the HUG1 and other DNA damage 
response genes requires the transcriptional derepressor, Asf1p.(Minard et al., 2011)  Thus, when 
placing the HUG1 under different promoter controls, the Asf1p depression sequence is lost.  
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HUG1 expression is therefore severely reduced as it no longer contains the depressor binding site 
to relieve transcriptional repression machinery. 
5.4.3. Fluorescent yeast two-hybrid reveals the Hug1p-Rnr2p in vivo 
Failure of the traditional Y2H system in the above section may be the result of poor 
expression of the HUG1 and RNR2 constructs from their respective plasmids.  In fact, proper 
expression of HUG1 in plasmid constructs requires the inclusion of at least 35 bases of the 
HUG1 upstream promoter region for proper expression (Dr. Munira Basrai; personal 
communication).  To mitigate these expression effects, we required a system that allowed use of 
intact fusion proteins under native promotion.    
The fluorescent yeast two hybrid system (also known as the split GFP system) was 
chosen as the ideal candidate for protein interaction as it allowed both genomic fusion construct 
creation and it offered redundant verification of our previous Hug1p-GFP subcellular 
localization results.  Likewise, signal-to-noise ratios for the split GFP assay are high which, as a 
result, reduces the likely of false positive identification.   
The split GFP system works similarly to the traditional Y2H system described in the 
previous section and is diagrammed in Figure 5.2.A.  Briefly, the yeast enhanced green 
fluorescent protein (yEGFP1) is split into two fragments: the N-terminal fragment, NyEGFP1, 
contains the M1 through Q157 amino acids while the C-terminal fragment, CyEGFP1, contains 
amino acids K158 to K238.   
These fragments are then fused to the respective potential proteins of interest and 
expression induced in wild-type strains.  If the proteins interact, the yEGFP1 fragments will 
come in close proximity of each other and refold into the fluorescent yEGFP1.  Otherwise, no 
fluorescence will be seen.(Barnard et al., 2008; Park et al., 2007)  Due to steric hindrances 
introduced by the fragment fusion and/or proximity requirements of the fragments, yEGFP1 
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fragment fusions to the N- and C-terminus of both putative interacting proteins must be designed 
and empirically confirmed verify a non-functioning split GFP assay (Figure 5.2.B). 
We first constructed a galactose-inducible, C-terminal fusion of the yEGFP1 fragments, 
NyEGFP1 and CyEGFP1, to Rnr2p and Dif1p respectively to verify correct construction and 
function of the split GFP assay.  However, upon inducing with galactose, the resulting PCR 
verified strains did not exhibit fluorescence when examined by epifluorescent microscopy (data 
not shown).  Since Rnr2p’s C-terminus contains a binding region required for its proper 
interaction and folding with the Rnr1 homodimer (Chabes et al., 1999; Xu, Faber, Uchiki, Racca, 
 
 
Figure 5.2. Diagram of the split GFP system and conformation variants using yeast enhanced green fluorescent protein 
(yEGFP1).  (A)  yEGFP1 is split a t amino acids 1-157 (NyEGFP1) and 158-238 (CyEGFP1) and fused to potential 
interacting partners.  If proteins interact, the split yEGFP1 fragments refold to form active yEGFP1.  If they do not 
interact, no fluorescence is seen.  (B) Due to steric hindrances and the required proximity of the yEGFP1 fragments, 
various positional fusion constructs are necessary to confirm interaction via yEGFP1 refolding.  These positions 
include: C-terminal fusion of both yEGFP1 fragments (C-C fusion), N-terminal fusion of NyEGFP1 and C-terminal 
fusion of CyEGFP1 (N-C fusion), C-terminal fusion of NyEGFP1 and N-terminal fusion of CyEGFP1 (C-N fusion), 
and N-terminal fusion of both yEGFP1 fragments to putative interacting proteins. 
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et al., 2006), we theorized that the Rnr2p-NyEGFP1 construct was likely nonfunctional and 
therefore unlikely to correctly fold and bind to Dif1p-CyEGFP1.  Further, when we genomically 
integrated NyEGFP1 at the C-terminus of RNR2 in haploid strains, resulting PCR verified 
constructs grew significantly slower than wild type strains (3 hours vs 1.5 hours, respectively), 
indicating a partial disruption in the Rnr2p activity.  
We thus reconstructed the Rnr2p construct with an N-terminal fusion of NyEGFP1 and 
placed this under galactose promoter control.  The resulting plasmid was co-transformed with the 
galactose inducible Dif1p-CyEGFP1 and positive constructs containing both plasmids were 
verified by colony PCR.  A negative construct was also designed to include only the two split 
GFP fragments under galactose promoter control.  Both strains were then induced with galactose 
for 6 hours, after which strains were washed, resuspended in PBS, and prepared for microscopy 
as described previously (Ainsworth et al., 2013).  Epifluorescent microscopy was used to verify 
the expression levels of the split GFP system; representative images of the resulting GFP 
fluorescence for NyEGFP1/CyEGFP1 only and Dif1p-CyEGFP1/NyEGFP1-Rnr2p are given in 
Figure 5.3.  The negative control (Figure 5.3, top row) shows little to no fluorescence in the GFP 
channel.  Similarly, all strains grown in glucose for 6 hours also had little to no fluorescence in 
the GFP, indicating successful repression of the galactose promoter in these constructs (data not 
shown).  Meanwhile, clear fluorescence is seen in the GFP channel for the Dif1p-
CyEGFP1/NyEGFP1-Rnr2p constructs, indicating that the split GFP system is functional.  
Interestingly, the Dif1p/Rnr2p GFP signal is localized to the nucleus, which corroborates 
previous results demonstrating Dif1p’s role in sequestering Rnr2p-Rnr4p to the nucleus (Lee et 
al., 2008).   
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As the split GFP was proven to successfully capture the Dif1p/Rnr2p interaction, we then 
created a galactose inducible Hug1p-CyEGFP1 plasmid for use in testing the Hug1p-Rnr2p 
interaction.  This construct was then co-transformed with galactose inducible NyEGFP1-Rnr2p 
and colony PCR was used to verify the uptake of both constructs.  The new Hug1p-
CyEGFP1/NyEGFP1-Rnr2p strain was then induced with galactose for 6 hours and prepared and 
analyzed by microscopy as described above.  A noticeable, but slight increase in GFP signal was 
noted in GFP channel for the galactose induced Hug1p-CyEGFP1/NyEGFP1-Rnr2p strains when 
 
Figure 5.3. Representative images of split GFP assay measured by fluorescent microscopy showing resulting 
fluorescence of various bait and prey constructs under galactose inducible promoter control.  Strains were induced 
with galactose for 6hr and imaged using a Zeiss AxioCam MRm microscope using GFP and DAPI filter sets (left and 
center column, respectively).  (Top row) Negative control strain containing NyEGFP1 and CyEGFP1 fragments only 
under galactose promotion.  (Middle row) Positive control containing bait Dif1p-CyEGFP1 and prey NyEGFP1-Rnr2p 
under galactose promotion.  (Bottom row) Galactose-induced co-expression of bait Hug1p-CyEGFP1 and prey 
NyEGFP1-Rnr2p induces GFP fluorescence. Scale bars represent 20µm. 
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compared with negative controls (Figure 5.3, bottom row), demonstrating that Hug1p does in 
fact interact with Rnr2p.   
As the GFP signal was low in the Hug1p-CyEGFP1/NyEGFP1-Rnr2p strains described 
above, we attempted to improve the signal quality by fusing the CyEGFP1 fragment at the C-
terminus of the HUG1 in the genome (i.e., under native HUG1 promoter control).  This was 
performed using the PCR gene fusion method as described with the CyEGFP1 fragment created 
in the pFA6a series plasmids (Longtine et al., 1998).  The genomic Hug1p-CyEGFP1 construct 
was co-transformed with PGAL1-NyEGFP1-RNR2 used in the previous experiments to allow 
galactose induction of the NyEGFP1-Rnr2p construct.  Successful transformations were 
confirmed by colony PCR.   
Strains containing the genomic HUG1-CyEGFP1 and PGAL1-NyEGFP1-RNR2 constructs 
were first grown in galactose for 6 hours to induce NyEGFP1-Rnr2p expression, followed by 
transfer to glucose media with or without 150mM hydroxyurea for 3.5 hours to induce Hug1p-
CyEGFP1 expression.  Samples were then washed and prepared for microscopy as described 
above.  In strains not induced with hydroxyurea, no fluorescence is noted in the GFP channel 
(Figure 5.4, top row), consistent with the lack of Hug1p-CyEGFP1 expression.  However, upon 
induction with hydroxyurea, bright fluorescence is noted in the GFP channel in several cells in 
the representative and total image (Figure 5.4, bottom row).  This further serves as confirmation 
of the Hug1p-Rnr2p interaction, with physiological conditions inducing enough Hug1p 
expression to be detected by the split GFP assay. 
For each construct described above, at least 300 cells were counted to determine the 
efficiency of the split GFP construct in for the combinations of bait/prey and expression systems.  
Cells containing appreciable fluorescent signal (2-fold or greater relative to control) as  
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determined by GFP signal densiometric analysis were deemed “GFP positive”.  Any cells failing 
to meet this criteria were considered to be GFP negative.  The galactose inducible constructs 
containing NyEGFP1 and CyEGFP1 only had the lowest percent positive cells at 1%.  Similarly, 
constructs with genomic HUG1-CyEGFP1 and PGAL-NyEGFP1-RNR2 induced with only 
galactose also exhibited 1% GFP positive cells.  The positive split GFP control strain containing 
PGAL-DIF1-CyEGFP1 and PGAL-NyEGFP1-RNR2 plasmid constructs had 25% GFP positive, 
while the unknown test strain containing PGAL-HUG1-CyEGFP1 and PGAL-NyEGFP1-RNR2 
plasmid constructs exhibited only 17% GFP positive.  A two-fold increase in percent positive 
(34%) was seen when the genomic HUG1-CyEGFP1 and PGAL-NyEGFP1-RNR2 were induced 
with both galactose and hydroxyurea when compared to the same split GFP constructs placed 
under galactose promoter control.  
 
 
Figure 5.4.  Representative images of split GFP assay measured by fluorescent microscopy showing resulting 
fluorescence from galactose and hydroxyurea (HU) induction.  Fluorescence in the GFP channel indicates successful 
detection of GFP refolding using the split GFP bait Hug1p-CyEGFP1 under native promoter control and prey 
NyEGFP1-Rnr2p under galactose promoter control without (top row) and with (bottom row) 150mM HU induction.  
Strains were induced with galactose for 6hr, transferred to glucose media with or without 150mM HU, and incubated 
for an additional 3.5 hours.  Images were taken using a Zeiss AxioCam MRm microscope with GFP and DAPI filter 
sets (left and center column, respectively).  Scale bars represent 20µm. 
  
133 
5.4.4. Co-immunoprecipitation of HUG1-HA and Rnr2p corroborates fluorescent Y2H results 
Though the split GFP system successfully verified the Hug1p-Rnr2p interaction, further 
proof is required to corroborate the fluorescence results.  As such, a co-immunoprecipitation 
assay was run on strains containing a C-terminal fusion of the epitope tag, hemagglutinin A 
(HA), to genomic HUG1 and intact (unmodified) RNR2.  The procedure was run as described in 
(Mishra et al., 2015; Ohkuni et al., 2015)  WCE probed with anti-RNR2 and anti-HA antibodies 
demonstrate significant staining of the Rnr2p and Hug1p-HA proteins after 1.5 hours and 
continuing to 3.5 hours post-HU induction, respectively, and show successful extraction of the 
desired proteins.  WCE do not contain Hug1p-HA at the initial 0 hour induction time point, 
which is consistent with DNA damage or replication arrest induction of Hug1p (Basrai et al., 
1999).   
anti-HA pulldown elutions also showed enrichment of Hug1p-HA as given by positive 
anti-HA staining at 1.5 and 3.5 hours post-HU (Figure 5.5, right column).  Again, no Hug1p-HA 
was noted at the 0 hour induction point as Hug1p is only expressed in response to replication 
arrest or DNA damage (Basrai et al., 1999).  Finally, positive enrichment of Rnr2p was seen 
when probed with anti-RNR2.  This evidence corroborates the split GFP results which originally 
identified the Hug1p-Rnr2p interaction and indicates a successful pulldown of Rnr2p via its 
interaction with Hug1p-HA.    














NyEGFP1 CyEGFP1 GAL / GAL GAL / 6hr 2205 23 1% 
RNR2 DIF1 GAL / GAL GAL / 6hr 440 101 25% 
RNR2 HUG1 GAL / GAL GAL / 6hr 514 88 17% 
RNR2 HUG1 GAL / HUG1 GAL / 3.5hr 374 4 1% 
RNR2 HUG1 GAL / HUG1 GAL+HU / 6hr+3.5hr 212 72 34% 
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5.4.5. Determination and effects of large-domain HUG1 knockout targets on HUG1 inhibitory 
activity 
Confirmation of the Hug1p-Rnr2p interaction is a major initial finding that elucidates 
Hug1p’s inhibitory mechanism; however, this discovery does not provide insight into whether 
the Hug1p-Rnr2p binding event alone is required for its inhibition or if Hug1p has distinct 
domains separately involved in Rnr2p binding and inhibition.  Indeed, our previous studies have 
shown that galactose-induced expression of Hug1p-GFP retains the propensity to co-localize 
with Rnr2p, despite overexpression plating analysis demonstrating a loss of Hug1p inhibitory 
activity (Ainsworth et al., 2013).  These results support the model whereby Hug1p utilizes 
independent domains to bind and inhibit, however more work to identify these regions is 
required.   
A typical method to classify necessary domains is to perform scanning alanine 
mutagenesis, whereby amino acid regions believed to be involved in protein activity are mutated 
to alanine and protein function tested by enzyme specific assays (Lefèvre et al., 1997).  
 
 
Figure 5.5.‡‡‡‡ Western blot analysis demonstrating antibody staining of whole cell 
extracts (WCE) and anti-HA pulldown, co-immunoprecipitation (Co-IP) of HUG1-HA 
bearing strains after hydroxyurea induction.  Log phase strains containing HUG1-HA 
under native promotion were incubated with 150mM hydroxyurea for 0, 1.5, and 3.5 
hours whereby WCE were collected.  WCE were then bound to anti-HA beads and eluted.  
WCE and anti-HA resin elutions were run on SDS-PAGE gel and stained against anti-
RNR2 and anti-HA to confirm Hug1p-Rnr2p interaction. 
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However, determining these regions for HUG1 is not trivial, as global protein alignment 
software (e.g., Protein BLAST) and conserved domain databases (e.g., NCBI Conserved Domain 
Search) fail to find sequences with adequate homology to the HUG1 primary sequence.   
Interestingly, a recent study has found that the S. cerevisiae protein, Dif1p, contains a 
domain that is required for Rnr2p-Rnr4p nuclear localization; this domain has been termed the 
“Hug domain” due to its local sequence similarity to HUG1.  Likewise, it was found that HUG1 
arose from DIF1 gene duplication and, thus, likely retains characteristic features of DIF1, 
including the ability to bind (and inhibit) Rnr2p (Lee et al., 2008).  The comparable Dif1-hug1 
mutant region in Hug1p offers an ideal candidate as a necessary HUG1 domain (Figure 5.6.B) 
and was thus selected for scanning alanine mutagenesis (Figure 5.6.G).   
Despite the absence of Hug1p structural data and the failure of local conserved domain 
databases to identify domain similarity within Hug1p primary sequence, secondary sequence 
protein prediction software offers a valuable alternative to finding unverified but probable 
secondary structures within proteins lacking requisite homology and/or structural information.   
The primary sequence of HUG1 (Figure 5.6.A) was used to poll a panel of secondary 
structure prediction software to identify potential secondary structures within HUG1.  Slight 
differences between the individual software’s prediction capabilities results in variable secondary 
structure outputs that, when aligned with other prediction software outputs, results in a consensus 
of probable secondary structures.  Our survey of prediction software included: I-TASSER 
(Iterative Threading ASSEmbly Refinement) (Roy et al., 2010; Yang et al., 2015; Zhang, Y., 
2008) (Figure 5.6.C), RaptorX (Peng & Xu, 2011) (Figure 5.6.D), Phyre2 (Figure 5.6.E) (Kelley 
et al., 2015), and PSIPRED (Buchan et al., 2013) (Figure 5.6.F).  An α-helix spanning 
Hug1.Pro9 to Hug1.Lys35 was identified by all secondary structure prediction programs (Figure 
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5.6.C-F).  Using overlapping regions from all α-helix predictions, the optimal region within 
HUG1 chosen for alanine mutagenesis was the region spanning Hug1.Val17 to Hug1.Cys24 
(Figure 5.6.G; HUG1.D1).  A β-sheet was also predicted by RaptorX (Figure 5.6.D) at 
Hug1.Tyr38 to Hug1.Asp43; therefore, comparable alanine mutagenesis was performed at 
Hug1.Lys35 to Hug1.Phe40 (Figure 5.6.I; HUG1.D3) to probe potential β-sheet involvement in 
HUG1 activity.  The β-sheet predicted by both RaptorX (Figure 5.6.D) and PSIPRED (Figure 
5.6.F) between Hug1.Ile50 and Hug1.Gly57 (Figure 5.6.J; HUG1.D4) provided the last domain 
to be targeted for scanning alanine. 
Scanning alanine mutagenesis was performed on each domain as described in (Lefèvre et 
al., 1997; Zhao et al., 2000) and resulting galactose-inducible plasmids expressing HUG1.D1-
HUG1.D4 were transformed into hug1Δ∷KANMX6 deletion strains.  Overexpression plating 
analysis was then carried out as previously described (Ainsworth et al., 2013).  All strains 
demonstrated constant and unimpeded growth on dextrose-containing media (Figure 5.7; left 
panel) and galactose media (Figure 5.7; center panel), which is consistent with glucose 
repression of the GAL promoter (and, by extension, repression of HUG1 expression) and 
(A) HUG1 MTMDQGLNPKQFFLDDVVLQDTLCSMSNRVNKSVKTGYLFPKDHVPSANIIAVERRGGLSDIGKNTSN 
(B) DIF1 -------------------------*******------------------------------------ 
 
(C) I-TASSER -----------------HHHHHHHHHHHHH-----------------------------HHHHHHHH- 
(D) RaptorX ----------EEE-HHHHHHHHHHH------------EEEEEE------EEEEEEEE----------- 
(E) Phyre2 ---------------HHHHHHHHHHHHHHHHHHHH---------HHHH-------------------- 
(F) PSIPRED --------HHHHHHHHHHHHHHHHHHHHHH-------------------EEEEEE-----HH------ 
 
(G) HUG1.D1 ----------------DDDDDDDD-------------------------------------------- 
(H) HUG1.D2 -------------------------DDDDDDD------------------------------------ 
(I) HUG1.D3 ----------------------------------DDDDDD---------------------------- 
(J) HUG1.D4 -----------------------------------------------DDDDDDDDD------------ 
 
Figure 5.6. Hug1p sequence, secondary structure prediction, and rational design of HUG1 knockouts.  (A) Primary 
sequence of Hug1p, (B) location of the Dif1-hug mutation region (*) (Lee et al., 2008), (C-F) protein secondary 
structure prediction by (C) I-TASSER (Roy et al., 2010; Yang et al., 2015; Zhang, Y., 2008), (D) RaptorX (Peng & 
Xu, 2011), (E) Phyre2 (Kelley et al., 2015), and (F) PSIPRED (Buchan et al., 2013) where H and E indicate predicted 
helices and beta-sheets, respectively,  (G-J) rational design of HUG1 knockouts (D) encompassing a predicted α-helix 
region (G), the Dif1-hug mutation region (H), and predicted beta-strands (I and J). 
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previous results showing galactose-induced HUG1 overexpression is not sufficient in causing 
growth inhibition phenotypes, respectively (Ainsworth et al., 2013; Basrai et al., 1999).  
Whenever hydroxyurea is included in the media (Figure 5.7; right panel), significant growth 
differences are noted between GAL1-HUG1 and the mutant variants.   
Consistent with previous reports, hug1Δ strains with GAL vector only (Figure 5.7.A) 
shows the least growth inhibition while hug1Δ strains expressing intact HUG1 under galactose 
promotion (Figure 5.7.B) shows the strongest inhibition (Ainsworth et al., 2013; Basrai et al., 
1999).  All four HUG1 mutants, HUG1.D1-D4 (Figure 5.7.C-F, respectively), demonstrate no 
growth effects and grow at similar rates to the GAL vector only control (Figure 5.7.A).  These 
results clearly indicate that all scanning alanine mutations in HUG1 had significant effects on 
Hug1p functionality.  However, since these mutations altered at least 10% of the total amino 
acids within HUG1, true domain features and distinct amino acids functionality in Hug1p 
activity cannot be resolved.  Thus, a more focused approach is required to identify key functional 
elements within Hug1p. 
 
 
Figure 5.7. Overexpression phenotype plating assay of galactose-inducible HUG1 (GAL1-HUG1) and four mutant 
HUG1 variants (GAL1-HUG1.D1-D4) in hug1Δ deletion strains.  Log phase cultures were serially diluted on plates 
supplemented with dextrose (DEX; left panel), galactose (GAL; center panel), and galactose with 150mM 
hydroxyurea (GAL+150mM HU; right panel).  Plates were incubated at 30°C for 4 days and imaged.  
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5.4.6. Error-prone PCR and EMS-induced random mutagenesis of HUG1 fails to identify 
required HUG1 interaction regions 
As the previous scanning alanine mutagenesis process lacked robustness in identifying 
independent interaction or binding domains, we explored alternative options to introduce and 
screen for mutations affecting HUG1 activity.  To verify regions required for Sml1p’s inhibition 
of its binding partner, Rnr1p, Zhao et al utilized error-prone PCR mutagenesis and plasmid 
reconstruction by homologous recombination to uncover amino acids required for Sml1p’s 
inhibitory action (Zhao et al., 2000).   
Transformation and plasmid recombination into strains carrying mec1Δ sml1Δ deletions 
and complementation plasmid ADE3-PMEC1-MEC1 allowed for colorimetric selection of colonies 
bearing the mutagenized Sml1p, as dysfunctional Sml1p mutants exhibit a mec1Δ sml1Δ 
phenotype and the complementary ADE3-PMEC1-MEC1 plasmid is lost in division as it is no 
longer required for cell progression.  The colorimetric assay leverages ade3Δ ade2Δ designer 
strains and the ADE3 gene (which is epistatic to ADE2 in the metabolic pathway) whose 
expression in ade3Δ ade2Δ strains results in red colonies and absence results in the formation of 
white colonies (Forsburg, 2001).  Thus, when the complementary ADE3-PMEC1-MEC1 plasmid is 
lost in division, white-red segmented colonies form that can easily be identified by inspection 
(Forsburg, 2001; Zhao et al., 2000).  Segmented colonies can then be picked, plasmid extracted, 
and sequence verified to determine the mutated amino acids that affected expression (Forsburg, 
2001).  This exact approach was applied towards determining important regions in the HUG1.  
The specifics of strain creation is outlined in detail in the Materials and methods.   
A diagram of the mutagenesis in given in Figure 5.8 and discussed briefly here.  Using a 
parent plasmid containing intact HUG1, primers binding up- and down-stream of HUG1 are 




Figure 5.8.  Diagram of HUG1 mutagenesis by error-prone PCR or 
EMS mutagenesis with outcomes for HUG1 mutations with and 
without effect on inhibitory activity. 
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homologous regions given as orange and blue rectangles, respectively).  Error-prone PCR is then 
run to mutagenize the HUG1 insert (McCullum et al., 2010).  Alternatively, EMS was added 
after low-fidelity PCR amplification to induce mutagenesis in the fragment and provide alternate 
base conversions for broader potential base exchanges (Lai et al., 2004).  Mutagenized PCR 
fragments (HUG1*) were then purified and co-transformed into mec1Δ hug1Δ strains bearing an 
ADE3-PMEC1-MEC1 plasmid using a linearized vector to place the HUG1* mutants under 
HUG1 promoter control via the 45bp of homology flanking the HUG1* fragments.   
Previous reports have indicated that hug1Δ deletions recover the synthetic lethality of 
mec1Δ (Basrai et al., 1999).  Using similar logic applied to Sml1p functional inhibition 
determinations, we reasoned that HUG1* mutations which affect HUG1 functionality will 
present with the mec1Δ hug1Δ phenotype, and thereby discard the ADE3-PMEC1-MEC1 plasmid, 
while functional HUG1* will require the ADE3-PMEC1-MEC1 plasmid to avoid synthetic lethality 
of the mec1Δ. We thus anticipated white colonies to contain mutagenized HUG1* with 
significant effects on HUG1’s inhibitory function, while red colonies retained functional HUG1.  
After plating on selective media with low adenine concentrations, an assortment of red and white 
colonies were seen after 5 days of growth at 30°C.  White and white-red segmented colonies 
were replica plated onto selective media with low adenine to ensure white colony formation 
(Figure 5.9).   
After growing for an additional 3 days, white colonies were reseeded into selective 
media, grown overnight, and plasmids extracted.  Extracted plasmids were then transformed into 
E. coli competent cells whereby plasmid was re-extracted for DNA sequencing.  Of the eight 
strains verified by BigDye® terminator sequencing, one strain was positively mutated within the 
HUG1* open-reading frame.  The remaining seven strains all contained intact HUG1.  Thus the 
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assay as designed was considered to be insufficient at finding ineffective HUG1* mutants.  We 
also attempted to exchange the HUG1 promoter with that of the high expression and constitutive 
GPD/TDH3 promoter to improve the expression of HUG1* mutants and increase the likelihood 
of intact HUG1-mediated synthetic lethality, however all five new white colonies tested by 
sequencing containing intact HUG1.  The assay was thereby abandoned as it yielded HUG1* 
mutants only 8% of the time and was not stringent enough to detect mutational effects on 
HUG1* inhibitory activity. 
5.4.7. Site-directed mutagenesis of HUG1 
Failure of the error-prone PCR mutagenesis prompted a new approach to solving HUG1’s 
domain dependencies.  Similar to error-prone PCR, site-directed mutagenesis (SDM) utilizes 
PCR to create desired mutational constructs in gene ORFs.  The major difference, however, is 
 
Figure 5.9. Replica plates of PHUG1-HUG1* bearing 
mec1Δ hug11Δ strains with potentially affected 
HUG1* mutants.  White colonies chosen for 
sequencing indicated with white arrows. 
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that SDM allows for selective, rationally-designed (i.e., non-random) mutations in gene products.  
Likewise, mutations can be engineered to incorporate desired amino acid modifications to 
change global protein features such as solubility as well as local effects to amino acid such as 
size, charge, and polarity.    
In section 5.4.5, scanning alanine mutagenesis (a type of SDM) was employed to mutate 
large domains within HUG1 to identify regions of secondary structure with functional 
importance.  However, mutations were too large to discriminately identify specific effects on 
HUG1’s inhibitory activity.  To mitigate these shortfalls, we redesigned the scanning alanine 
mutagenesis protocol to only modify three to four amino acids to alanine, and iterated this 
process across the entire HUG1 protein to create a total of 22 HUG1* mutants (HUG1 contains a 
total of 67 amino acids excluding start and stop codons).   
Figure 5.10 outlines the design of the 22 HUG1* mutant plasmids using plasmid 
reconstruction by homologous recombination.  Briefly, intact HUG1 (flanked by 35bp of the 
HUG1 promoter on the 5’ end and 66bp of the HUG1 terminator on the 3’ end) was inserted into 
a small shuttle plasmid to serve as template for the scanning alanine mutagenesis.  Mutagenic 
primers were designed to flank the site of the desired mutation and contain sequences coding for 
three alanines at the 5’ ends.   
Primers were then phosphorylated and high-fidelity PCR used to amplify the entire 
plasmid, thereby creating a large, linear strand of DNA with phosphorylated ends (Figure 
5.10.A).  T4 ligase was then used to re-circularize the linear strand into a functional plasmid 
which was subsequently transformed into E. coli competent cells (Figure 5.10.B).  This 
effectively forms a mutated HUG1* where the mutation is directed by the binding site of the 
original mutagenic primers.   
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To create a galactose inducible form of the HUG1*, HUG1* was amplified from the 
newly-created plasmid by high-fidelity PCR and co-transformed into hug1Δ PRNR2∷FLAG∷RNR2 
strains with a linearized target vector containing the GAL promoter and homologous ends used 
for plasmid reconstruction by homologous recombination (Figure 5.10.C; orange and green 
rectangles).  Strains containing an N-terminally FLAG epitope tagged RNR2 
(PRNR2∷FLAG∷RNR2) and the hug1Δ deletion were chosen to facilitate downstream expression 
and co-immunoprecipitation assays (sections 5.4.9 and 5.4.10, respectively).  Strains positive for 
 
 
Figure 5.10. Diagram of the HUG1 short-range scanning alanine mutagenesis to create 22 HUG1 mutants.  Plasmid 
reconstruction by homologous recombination incorporates HUG1* mutants under GAL promoter control with 35bp 
of the HUG1 promoter sequence upstream and 66bp of the HUG1 terminator sequence downstream of the HUG1* 
mutant insertion site.   
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PGAL-HUG1* uptake were verified by selection and colony PCR.  Notably, mutagenesis to three 
alanines also results in the introduction of a PstI restriction enzyme site which was used for more 
extensive verification prior to plasmid sequencing.  To sequence the new constructs, plasmids 
were extracted from yeast, transformed into E. coli competent cells, purified, then sequenced by 
BigDye® terminator sequencing.  Successful transformants were used in overexpression plating 
analysis, western blot expression experiments, and co-immunoprecipitation assays described in 
Sections 5.4.8, 5.4.9, and 5.4.10.   
5.4.8. Overexpression phenotyping assay reveal region-specific growth variability across 
HUG1* mutations 
HUG1 overexpression growth phenotyping assays have previously been used to 
demonstrate HUG1’s negative role in the MEC1 pathway (Ainsworth et al., 2013; Basrai et al., 
1999) as well as determine the effects of large-domain HUG1 knockouts on growth inhibition 
(Section 5.4.5).  The new HUG1* SDM mutants were placed under identical promoter control 
and are compatible with the overexpression plating assays described previously.  As such, strains 
containing all 22 HUG1* SDM mutants§§§§ were grown, treated, and serial dilutions plated as 
described previously (Ainsworth et al., 2013; Basrai et al., 1999).  After seven days of growth, a 
large variation in growth effects were observed across the mutants (Figure 5.11.A).  Strains 
expressing HUG1*.1-7 exhibited similar growth patterns to the intact HUG1 control (GAL-
HUG1) whereby density of cells at higher dilutions was considerably lower than the vector 
control.  Interestingly, a clear loss of growth inhibition was seen in HUG1* mutants, HUG1*.6, 
8, 10, 12-17, and 19.  This region is clustered with the Dif1-hug mutation and exhibited a high 
                                                 
§§§§ Note that HUG1* mutants are annotated with the mutant notation followed by the respective mutant number 
(Hug1*.1p).  The mutant number is indicative of the amino acids altered in sets of three starting with Hug1p’s 
second amino acid, Thr2.  For example, Hug1*.14p refers to the amino acid change from P41K42D43  to A41A42A43.  
The only exception is Hug1*.22p, which mutates the final four amino acids in the Hug1p to alanines. 
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density of hydrophobic amino acids (common to protein interaction motifs).  More importantly, 
suggests an independent and identifiable domain that is vital to HUG1 functionality.  The 
remaining mutants showed little growth variation with respect to the intact HUG1 control.   
To corroborate these results, we also performed a complementary overexpression growth 
assay in liquid media as described previously (Toussaint & Conconi, 2006) with some 
modifications.  Briefly, log-phase culture dilutions of the same strains used in the overexpression 
 
Figure 5.11. Overexpression phenotype assay of HUG1 and HUG1* mutants as measured by plating or 
spectrophotometry. (A) HUG1, vector control, and HUG1* mutant strains under GAL1 promoter control (GAL-HUG1, 
GAL only, and GAL1-HUG1*.1-22, respectively) were serially diluted from log phase cultures onto selective media 
plates containing galactose and 150mM hydroxyurea and allowed to grow for 7 days.  Growth phenotype is measured 
qualitatively as poor growth (-) to good growth (+++) and is dependent on the density of the cell patch with increasing 
dilution.  (B) HUG1, vector control, and HUG1* mutant strains under GAL promoter control (H, G, and 1-22, 
respectively) were diluted in triplicated from log phase culture growth into a 96-well plate containing liquid selective 
media supplemented with galactose and 150mM hydroxyurea.  Growth was then monitored by spectrophotometric 
absorbance readings at 660nm every 10 minutes.  Maximum growth rate (μmax) was determined for each replicate 
and the results averaged.  Bars represent the mean of the μmax average and error bars indicate the standard deviation 
from the mean. 
  
146 
plating phenotype assay were aliquoted into 96 wells in triplicate and HUG1* mutant expression 
induced with galactose and 150mM hydroxyurea.  A spectrophotometric plate reader was used to 
monitor the 660nm absorbance wavelength (OD660; giving an approximation of cell 
concentration) for all cultures every ten minutes for 48 hours.  The growth rate of each sample 
was determined by measuring the differential OD660 versus time at five consecutive points.  The 
maximal growth rates (µmax) for each strain replicate was found and averaged.  Maximal growth 
ate means clearly vary according to strain type (Figure 5.11.B), however considerable variability 
exists for the maximal growth rate between replicates.  A one-way ANOVA comparing the all 
means of strain maximal growth rates shows no significant difference (F(23,48)=0.624; 
p=0.889).  Thus, the overexpression liquid phenotype assay was not sensitive enough to capture 
the growth related variations of overexpressed HUG1* mutant strains when exposed to 
hydroxyurea.  
5.4.9. Western blotting assays uncovers expression problems in the HUG1 mutant constructs 
Verification of the unique HUG1* growth inhibition profile identified in Figure 5.11.A 
required corroboration with proteomic data to rule out false reads due to variable protein 
expression levels.  As such, strains with and without HUG1* mutations were run via Western 
blot‡‡‡‡ to provide protein quantities upon induction of galactose and hydroxyurea.  Log-phase 
strains containing GAL1 only, GAL1-HUG1 and GAL1-HUG1* mutants 1-4, 7, were transferred  
to selective media supplemented with galactose and 100mM hydroxyurea and expression 
induced for 3 hours prior to collecting whole cell extracts.  Whole cell extracts were then loaded 
on an SDS-PAGE gel and run.  Western blot analysis‡‡‡‡ was then run on the resulting gel using 
antibodies to Hug1p (anti-HUG1).  Clear deviations in Hug1p and Hug1*p cellular expression 
levels was seen across the mutants tested.  While the wild-type Hug1p exhibited normal levels of 
expression (Figure 5.12.A.1), the Hug1p mutants, Hug1*.1p and Hug1*.3p, both showed no 
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measurable expression under similar conditions (Figure 5.12.A.3 and Figure 5.12.A.5).  
Hug1*.2p and Hug1*.4p, on the other hand, both exhibited appreciable levels of expression 
(Figure 5.12.A.4 and Figure 5.12.A.6), with Hug1*.4p demonstrating a higher level of 
expression than the intact Hug1p control.   
 
Similar expression variability was seen in other Hug1p mutant strains, including low 
expression in the Hug1*.7p and Hug1*.12p (Figure 5.12.B.3 and Figure 5.12.B.5, respectively) 
relative to their respective control (Figure 5.12.B.1) and normal expression in the Hug1*.10p and 
Hug1*.21p strains (Figure 5.12.B.4 and Figure 5.12.B.6).  Clearly, these expression differences 
can cause significant problems in interpreting the overexpression plating analysis results, 
whereby low mutant expression prevents inhibition effects regardless of truly modified inhibition 
activity of the Hug1p mutants.   
Interestingly, low expression was seen in the Hug1*.7p mutant strain, but the comparable 
strain in the overexpression plating analysis demonstrates significant reduction in growth and 
appears to be acting as wild-type Hug1p.  This conflicting result suggests a more nuanced and 
Figure 5.12.‡‡‡‡  Western blot expression analysis of GAL1-HUG1 and the GAL1-HUG1* mutant strains.  (A) Whole 
cell extracts were collected from strains expressing intact HUG1 (GAL1- HUG1), HUG1* mutants (GAL1-HUG1*.1-
4), or a vector control (GAL only) after induction with galactose and 100mM hydroxyurea for 3 hours and a Western 
blot performed with antibodies binding to Hug1p (anti-HUG1) and Tub1p (anti-TUB1; loading control).  (B)  Whole 
cell extracts were collected from strains expressing intact HUG1 (GAL1- HUG1), HUG1* mutants (GAL1-HUG1*.7, 
10, 12, and 21), or a vector control (GAL only) after induction with galactose and 100mM hydroxyurea for 3 hours 
and a Western blot performed with antibodies binding to Hug1p (anti-HUG1) and the FLAG epitope (anti-FLAG) to 
analyze FLAG-Rnr2p expression. 
  
148 
complex relationship between Hug1p expression levels and its inhibition activity, though it also 
indicates that protein expression levels may not be the major contributing factor to Hug1p-
mediated growth inhibition seen in the plating assays. 
5.4.10. Co-immunoprecipitation assays demonstrate weak interaction between select Hug1p 
mutants and Rnr2p 
Despite the poor expression seen in the Western blotting assays from the previous 
section, co-immunoprecipitation assays were carried out on the galactose and hydroxyurea-
induced HUG1 mutant strains to examine the effects of mutations on Hug1p’s interaction with 
Rnr2p.  Unlike the previous co-immunoprecipitation assay (Section 5.4.4), these assays were 
designed to pulldown Rnr2p via the FLAG epitope tag fused to its N-terminus.  Intact HUG1 and 
HUG1* mutant strains were prepared as described in the previous section and whole cell extracts 
collected.  Whole cell extracts‡‡‡‡ were then run through an anti-FLAG column to bind FLAG-
RNR2.  Elutions were subjected to Western blotting analysis‡‡‡‡ whereby anti-FLAG and anti-
HUG1 antibodies were used for staining.   
To account for variable Hug1p concentrations, Western blots‡‡‡‡ were loaded with 
respective to total protein concentrations as well as Hug1p and Hug1*p normalized 
Figure 5.13.‡‡‡‡ Co-immunoprecipitation analysis of FLAG-Rnr2p and intact Hug1p or select Hug1p mutants.  
Western blots of FLAG pulldown assay elutions were stained with antibodies to Hug1p (anti-HUG1) and to the FLAG 
epitope (anti-FLAG) with protein loading normalized to (A) total protein concentration and (B) relative Hug1p and 
Hug1*p mutant protein concentrations.  
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concentrations.  Westerns run with total protein concentration loaded (Figure 5.13.A) stained 
with large amounts of FLAG-Rnr2p (Figure 5.13.A; bottom row), however no staining was 
evident for the wild-type Hug1p control (GAL1-HUG1; Figure 5.13.A.1).  No Hug1p was pulled 
down for mutant strains Hug1*.10p and Hug1*.12p (Figure 5.13.A.4 and Figure 5.13.A.6, 
respectively) while only very faint staining of Hug1*.7p and Hug1*.21p (Figure 5.13.A.3 and 
Figure 5.13.A.5, respectively) were noted.  When protein loading was normalized to the relative 
Hug1p or mutant concentrations, slightly different results were obtained.  All strains containing a 
form of Hug1p (intact or mutant) stained positive for Hug1p (Figure 5.13.B), but were all very 
faint with the exception of Hug1*.7p Figure 5.13.B.3.   
These results further confound our understanding of the Hug1p-Rnr2p interaction 
mechanism.  As Rnr2p is known to interact with other proteins, it is likely that pulling down 
Rnr2p instead of Hug1p results in significantly lower instances of Rnr2p-Hug1p complexes.  
Indeed, when Hug1p was used as the pulldown target, considerably higher concentrations of both 
Hug1p and Rnr2p were observed.  Taken together, these results suggest improvements to the co-
elution can be achieved by co-expressing FLAG-Rnr2p and Hug1p-HA and running co-
immunoprecipitations using anti-HA beads to pulldown Hug1p-HA.     
5.4.11. Fluorescent yeast two-hybrid assay uncovers interactions between HUG1 and two human 
RNR2 homologues 
Eukaryotes utilize an evolutionarily conserved mechanism to respond to DNA damage.  
Proteins expressed in the ATR damage pathway share both functional and sequence similarity to 
those in the yeast MEC1 pathway, including effector kinases ATR (Mec1p in S. cerevisiae), 
ATRIP (Ddc2p in yeast) and the ribonucleotide reductase small subunits, R1 (Rnr1p in yeast) 
and R2/hRRM2 (Rnr2p in yeast).(Ciccia & Elledge, 2010; Harper & Elledge, 2007; Zhou, B. B. 
& Elledge, 2000)  Humans express two isoforms of the ribonucleotide reductase small subunit: 
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hRRM2, whose expression is restricted to S-phase where it produces dNTPs for DNA synthesis, 
and p53R2, whose expression can be found in G0/G1 phase and early S-phase, but is more 
importantly significantly induced in response to DNA damage by a p53 (a human tumor 
suppressor gene).(Engstrom et al., 1985; Nakano et al., 2000; Tanaka et al., 2000; Xue et al., 
2003; Yamaguchi et al., 2001)  Overexpression of hRRM2 has been correlated to increased 
pancreatic adenocarcinoma invasiveness (Duxbury & Whang, 2007) and implicated in tumor 
angiogenesis (Zhang, K. et al., 2009).  Both p53R2 and hRRM2 serve as prognostic biomarkers 
for colon cancer metastasis (Liu et al., 2007) and Stage I and II Non-small cell lung cancers (Hsu 
et al., 2011) 
Interestingly, sequence alignment of hRRM2 and p53R2 to the yeast RNR2 using 
EMBOSS Needle global alignment (Supplementary Figure 5.15 and Figure 5.17, respectively) 
showed the yeast RNR2 shared  approximately 70% sequence similarity between the human 
homologs.  This is especially remarkable considering p53R2 and hRRM2 share 76% sequence 
similarity between each other using the same metric (Supplementary Figure 5.16).   As Hug1p 
has been discovered to interact and inhibit the yeast Rnr2p, we reasoned that it may also serve 
similar function when expressed alongside the human Rnr2p homologs since the sequence 
homology is similar. 
Thus, the p53R2 and hRRM2 cDNA sequences were both fused to the NyEGFP1 split 
GFP fragment and transformed into strains containing HUG1-CyEGFP1 under its native 
promotion.  Cultures were then grown and induced with galactose and hydroxyurea as described 
for the original Hug1p-Rnr2p split GFP experiment and imaged by fluorescent microscopy.  In 
both p53R2 and hRRM2, faint but detectable signal was observed (Figure 5.14).  Interesting, 
p53R2 (Figure 5.14, bottom row) demonstrated roughly 2 fold brighter fluorescent intensity 
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when compared to hRRM2 (Figure 5.14, top row) split GFP constructs as determined by 
densiometric analysis.  This is likely due to slight sequence variations between p53R2 and 
hRRM2 that results in more favorable binding conditions for Hug1p into p53R2.  A recent 
structural analysis of the two proteins has shown that a key tyrosine (Tyr221) in hRRM2 
involved in coordinating the hydrogen bond network for the dityrosyl radical transfer is replaced 
by phenylalanine (Phe183) in p53R2 which results in significant effects to the respective RNR’s 
activity.(Zhou, B. et al., 2010)   
Sequence alignments of the yeast RNR2 to p53R22 reveals that the yeast also express a 
phenylalanine at the comparable site (Phe228; Figure 5.17, yellow highlight).  This similarity 
provides a tenuous link between the brighter fluorescence seen in p53R2 and the yeast RNR2 
split GFP assays.  Interestingly, when we mutated Rnr2p.Phe228 to Tyr228, we saw no growth 
effects in the mutant strains.  However, overexpression phenotype assays revealed no significant 
disruption in Hug1’s ability to inhibit cell growth in the mutant Rnr2p.Tyr228 stain (data not 
 
 
Figure 5.14. Fluorescent yeast two hybrid analysis of Hug1-CyEGFP1 and human ribonucleotide reductase small 
subunit (hRRM2; top row) and human p53-inducible ribonucleotide reductase small subunit (p53R2; bottom row) 
with and without 2% galactose and/or 150mM hydroxyurea.  Arrows indicate positive fluorescence as detected by 
densiometric analysis.   
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shown).  As such, further studies are required to identify the Hug1 interaction regions within 
yeast Rnr2p and the human RNR homologs. 
5.5. Conclusions 
In our previous work, we stablished HUG1 as a negative regulator of the MEC1 DNA 
damage response pathway.  We proposed that Hug1p’s inhibitory action was the result of its co-
localization with the RNR small subunit heterodimer, Rnr2p-Rnr4p based on sequence homology 
and fluorescent microscopy data.(Ainsworth et al., 2013)  In this study, we extended the findings 
of our previous work to examine if Hug1p interacts with Rnr2p and, if so, which domains within 
Hug1p are important to the interaction.  
Overexpression of Hug1p did appear to significantly affect dNTP levels in the presence 
of hydroxyurea.  However, as hydroxyurea already drastically reduces dNTP concentrations, it is 
likely that, though Hug1p may be affecting dNTP pools, dNTP levels were at the lower limit of 
HPLC detection thereby making it difficult to quantitate actual Hug1p effects.   
The traditional yeast two-hybrid system - commonly used to quickly detect protein-
protein interactions - failed to detect an interaction between HUG1 and RNR2.  However, these 
results may be explained by the disruption of the ASF1 depressor sequence when the HUG1 ORF 
is transferred into the new vector constructs, resulting in significantly reduced HUG1 expression. 
An alternate method of protein interaction was therefore pursued.  Using the fluorescent 
yeast two-hybrid system (split GFP), C- and N-terminal yEGFP1 fragments were fused to HUG1 
and RNR2 and placed under native and GAL promoter control, respectively.  Hydroxyurea and 
galactose induced expression of the constructs revealed bright fluorescence indicative of a 
positive Hug1p-Rnr2p interaction.  These results were further verified by a co-
immunoprecipitation assay demonstrating that Rnr2p co-elutes with Hug1p.   
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We next sought to identify the regions in the Hug1p sequence required for its interaction 
with Rnr2p.  First, error-prone PCR and EMS mutagenesis was first attempted to randomly 
mutate HUG1, however the selection system for HUG1* mutants failed to identify true positives 
as determined by sequencing. Instead, 22 HUG1* mutants spanning the HUG1 gene were 
generated by site-directed mutagenesis and growth inhibition effects confirmed by 
overexpression plating analysis.  A novel region spanning amino acids Hug1p.Lys23 to 
Hug1p.Gly58 was found to affect Hug1p’s inhibitory, however overexpression liquid growth 
analysis cold not corroborate the profiles due to large variances in the maximal growth rate 
means.  Likewise, western blot analysis revealed variable protein expression levels that may be 
influencing the overexpression results.  Co-immunoprecipitation of FLAG-Rnr2p also 
demonstrated inconsistent co-elution of Hug1p, Hug1*p, and Rnr2p.  Currently, the HUG1* 
mutants are being redesigned to incorporate a C-terminal fusion of the HA-epitope tag to allow 
for direct pulldown of Hug1*p mutants and counterstaining to the FLAG-Rnr2p.  We anticipate 
these new constructs will more accurately detect the Hug1p-Rnr2p as Hug1p likely binds Rnr2p 
stoichiometrically (resulting in equal protein staining when Hug1p-HA is pulled down) while 
Rnr2p interacts with other partners (resulting in fewer bound Hug1p and, by extension, less 
detected in the FLAG-Rnr2p pulldown assay).  
Finally, the HUG1 split GFP was used to test the interaction between two human RNR2 
homologs, p53R2 and hRRM2.  Surprisingly, fluorescence was observed for both human 
homologs, indicating a positive interaction between Hug1p and p53R2, and Hug1p and hRRM2.  
The interaction signal, however, was weaker than that of the Rnr2p-Hug1p split GFP experiment 
which suggests that though may be a common interaction motif in between the RNR homologs, 
slight sequence variations and amino acid composition result in weaker interactions.   
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A recently released study has confirmed the Hug1p-Rnr2p interaction through co-elution 
assays similar to the co-immunoprecipitation assays performed in this study.  Also, circular 
dichroism, size exclusion chromatography, and NMR structural analysis revealed that Hug1p is 
an intrinsically disordered protein that is natively “pre-molten globule like” with weak helical 
propensity between amino acids Hug1p.V17-S27.  NMR was also used to determine regions 
within Hug1p that were perturbed by titrating Rnr2p-Rnr4p with 15N labeled Hug1p and 
monitoring intensity shifts.  They found that the region spanning amino acids Hug1p.Asn28 to 
Hug1p.Gly57 were slightly-to-highly perturbed by the titrations, and proposed that this domain 
was likely involved in Rnr2p binding.  Excitingly, our overexpression phenotype analysis 
corroborates these results; we show that the amino acids covered by Hug1*.10-16 are indeed 
necessary for Hug1p’s inhibitory activity. Not perturbed during the NMR titration experiments 
was the weak helical structural region.  Meurisse et al did not perform mutations within the 
helical structure to verify the NMR perturbation results.  Interestingly, our overexpression 
analysis detected a small region in the helical structure that is important in Hug1p inhibition 
(Figure 5.7; Hug1*p.8).  Meurisse et al further performed mutagenesis on HUG1 and defined 
four distinct mutations that affected Hug1p’s ability to bind Rnr2p: Hug1p.R29A, 
Hug1p.G37AY38A, Hug1p.Y38L39E, and I50EI51E.  Again, our overexpression plating assay 
correctly identified these mutations as important to Hug1p’s inhibitory activity (Hug1*p.10, 
Hug1*p.10, Hug1*p.12 and 13, and Hug1*p.17).  Finally, Meurisse et al utilized a traditional 
yeast two-hybrid system to identify a separate Hug1p binding partner, Dna2.  Though no further 
analysis was performed with respect to HUG1 mutational analysis, the result is intriguing in that 
Dna2p has been shown to activate the MEC1 response in S-phase.(Kumar, S. & Burgers, 2013)  
This finding may offer new insights into an independent Hug1p function whereby inhibition of 
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Dna2p works to deactivate the MEC1 response after DNA damage has been repaired or upon 
completion of S-phase.  
5.6. Supplementary material 
5.6.1. EMBOSS Needle global protein alignment between yeast RNR2 and the human homolog, 
hRRM2  
# 1: RNR2 
# 2: hRRM2 (human RNR2) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Length: 408 
# Identity:     236/408 (57.8%) 
# Similarity:   285/408 (69.9%) 
# Gaps:          27/408 ( 6.6%) 
# Score: 1187.5 
#======================================= 
RNR2              1 --------MPKETPSKAAADALSDLEIKDSKSNLNKELETLREENRVKSD     42 
                            .|...|.:.....|..|.:.| |.|....|    ...||.:. 
hRRM2             1 MLSLRVPLAPITDPQQLQLSPLKGLSLVD-KENTPPAL----SGTRVLAS     45 
 
RNR2             43 MLKEKLSKDAENHKAYLKSHQVHRHKLKEMEKEEPLLNEDKERTVLFPIK     92 
                    ....::.::....|....:..|         ::||||.|:..|.|:|||: 
hRRM2            46 KTARRIFQEPTEPKTKAAAPGV---------EDEPLLRENPRRFVIFPIE     86 
 
RNR2             93 YHEIWQAYKRAEASFWTAEEIDLSKDIHDWNNRMNENERFFISRVLAFFA    142 
                    ||:|||.||:||||||||||:||||||..|.: :...||:|||.|||||| 
hRRM2            87 YHDIWQMYKKAEASFWTAEEVDLSKDIQHWES-LKPEERYFISHVLAFFA    135 
 
RNR2            143 ASDGIVNENLVENFSTEVQIPEAKSFYGFQIMIENIHSETYSLLIDTYIK    192 
                    ||||||||||||.||.||||.||:.||||||.:||||||.|||||||||| 
hRRM2           136 ASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTYIK    185 
 
RNR2            193 DPKESEFLFNAIHTIPEIGEKAEWALRWIQDADALFGERLVAFASIEGVF    242 
                    ||||.|||||||.|:|.:.:||:||||||.|.:|.:|||:||||::||:| 
hRRM2           186 DPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEGIF    235 
 
RNR2            243 FSGSFASIFWLKKRGMMPGLTFSNELICRDEGLHTDFACLLFAHLKNKPD    292 
                    |||||||||||||||:|||||||||||.||||||.|||||:|.||.:||. 
hRRM2           236 FSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHKPS    285 
 
RNR2            293 PAIVEKIVTEAVEIEQRYFLDALPVALLGMNADLMNQYVEFVADRLLVAF    342 
                    ...|.:|:..||.|||.:..:||||.|:|||..||.||:|||||||::.. 
hRRM2           286 EERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLMLEL    335 
 
RNR2            343 GNKKYYKVENPFDFMENISLAGKTNFFEKRVSDYQKAGVMSKSTKQEAGA    392 
                    |..|.::|||||||||||||.||||||||||.:||:.||||..|:   .: 
hRRM2           336 GFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTE---NS    382 
 
RNR2            393 FTFNEDF*    400 
                    ||.:.||  
hRRM2           383 FTLDADF-    389  
 
Figure 5.15. EMBOSS Needle global protein alignment between yeast RNR2 and the human homolog, hRRM2. 
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5.6.2. EMBOSS Needle global protein alignment between human homologs p53R2 and hRRM2 
 
 
# 1: BAA92434.1 
# 2: hRRM2 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Identity:     273/406 (67.2%) 
# Similarity:   310/406 (76.4%) 
# Gaps:          72/406 (17.7%) 
# Score: 1450.5 
# ======================================= 
 
p53R2         1 --------------------------------------------------      0 
                                                                        
hRRM2         1 MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARR     50 
 
p53R2         1 -MGDPERPE----AAGLDQDERSSSDTNESEIKSNEEPLLRKSSRRFVIF     45 
                 ..:|..|:    |.|::                 :|||||::.|||||| 
hRRM2        51 IFQEPTEPKTKAAAPGVE-----------------DEPLLRENPRRFVIF     83 
 
p53R2        46 PIQYPDIWKMYKQAQASFWTAEEVDLSKDLPHWNKLKADEKYFISHILAF     95 
                ||:|.|||:|||:|:||||||||||||||:.||..||.:|:|||||:||| 
hRRM2        84 PIEYHDIWQMYKKAEASFWTAEEVDLSKDIQHWESLKPEERYFISHVLAF    133 
 
p53R2        96 FAASDGIVNENLVERFSQEVQVPEARCFYGFQILIENVHSEMYSLLIDTY    145 
                |||||||||||||||||||||:.||||||||||.:||:|||||||||||| 
hRRM2       134 FAASDGIVNENLVERFSQEVQITEARCFYGFQIAMENIHSEMYSLLIDTY    183 
 
p53R2       146 IRDPKKREFLFNAIETMPYVKKKADWALRWIADRKSTFGERVVAFAAVEG    195 
                |:|||:||||||||||||.||||||||||||.|:::|:|||||||||||| 
hRRM2       184 IKDPKEREFLFNAIETMPCVKKKADWALRWIGDKEATYGERVVAFAAVEG    233 
 
p53R2       196 VFFSGSFAAIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFQYLVNK    245 
                :|||||||:|||||||||||||||||||||||||||||||||||::||:| 
hRRM2       234 IFFSGSFASIFWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFKHLVHK    283 
 
p53R2       246 PSEERVREIIVDAVKIEQEFLTEALPVGLIGMNCILMKQYIEFVADRLLV    295 
                ||||||||||::||:||||||||||||.||||||.|||||||||||||:: 
hRRM2       284 PSEERVREIIINAVRIEQEFLTEALPVKLIGMNCTLMKQYIEFVADRLML    333 
 
p53R2       296 ELGFSKVFQAENPFDFMENISLEGKTNFFEKRVSEYQRFAVMAETTDNVF    345 
                ||||||||:.|||||||||||||||||||||||.||||..||:..|:|.| 
hRRM2       334 ELGFSKVFRVENPFDFMENISLEGKTNFFEKRVGEYQRMGVMSSPTENSF    383 
 
p53R2       346 TLDADF    351 
                |||||| 
hRRM2       384 TLDADF    389 
 
Figure 5.16. EMBOSS Needle global protein alignment between p53R2 and hRRM2. 
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5.6.3. EMBOSS Needle global protein alignment between yeast RNR2 and the human homolog, 
p53R2 
  
# 1: p53R2 
# 2: RNR2 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Identity:     221/400 (55.2%) 
# Similarity:   282/400 (70.5%) 
# Gaps:          49/400 (12.2%) 
# Score: 1169.5 
#======================================= 
 
p53R2         1 --------------------------------MGDPERPEAAGLDQDERS     18 
                                                :.:..|.::..|.:.... 
RNR2          1 MPKETPSKAAADALSDLEIKDSKSNLNKELETLREENRVKSDMLKEKLSK     50 
 
p53R2        19 SSDTNESEIKSN------------EEPLLRKSSRRFVIFPIQYPDIWKMY     56 
                .::.:::.:||:            |||||.:...|.|:|||:|.:||:.| 
RNR2         51 DAENHKAYLKSHQVHRHKLKEMEKEEPLLNEDKERTVLFPIKYHEIWQAY    100 
 
p53R2        57 KQAQASFWTAEEVDLSKDLPHW-NKLKADEKYFISHILAFFAASDGIVNE    105 
                |:|:||||||||:|||||:..| |::..:|::|||.:||||||||||||| 
RNR2        101 KRAEASFWTAEEIDLSKDIHDWNNRMNENERFFISRVLAFFAASDGIVNE    150 
 
p53R2       106 NLVERFSQEVQVPEARCFYGFQILIENVHSEMYSLLIDTYIRDPKKREFL    155 
                ||||.||.|||:|||:.||||||:|||:|||.|||||||||:|||:.||| 
RNR2        151 NLVENFSTEVQIPEAKSFYGFQIMIENIHSETYSLLIDTYIKDPKESEFL    200 
 
p53R2       156 FNAIETMPYVKKKADWALRWIADRKSTFGERVVAFAAVEGVFFSGSFAAI    205 
                ||||.|:|.:.:||:||||||.|..:.||||:||||::||||||||||:| 
RNR2        201 FNAIHTIPEIGEKAEWALRWIQDADALFGERLVAFASIEGVFFSGSFASI    250 
 
p53R2       206 FWLKKRGLMPGLTFSNELISRDEGLHCDFACLMFQYLVNKPSEERVREII    255 
                |||||||:|||||||||||.||||||.|||||:|.:|.|||....|.:|: 
RNR2        251 FWLKKRGMMPGLTFSNELICRDEGLHTDFACLLFAHLKNKPDPAIVEKIV    300 
 
p53R2       256 VDAVKIEQEFLTEALPVGLIGMNCILMKQYIEFVADRLLVELGFSKVFQA    305 
                .:||:|||.:..:||||.|:|||..||.||:|||||||||..|..|.::. 
RNR2        301 TEAVEIEQRYFLDALPVALLGMNADLMNQYVEFVADRLLVAFGNKKYYKV    350 
 
p53R2       306 ENPFDFMENISLEGKTNFFEKRVSEYQRFAVMAETTD---NVFTLDADF-    351 
                ||||||||||||.|||||||||||:||:..||:::|.   ..||.:.||  
RNR2        351 ENPFDFMENISLAGKTNFFEKRVSDYQKAGVMSKSTKQEAGAFTFNEDF*    400 
 




Ainsworth, W. B., Hughes, B. T., Au, W. C., Sakelaris, S., Kerscher, O., Benton, M. G., & 
Basrai, M. A. (2013). Cytoplasmic localization of Hug1p, a negative regulator of the 
MEC1 pathway, coincides with the compartmentalization of Rnr2p-Rnr4p. Biochem 
Biophys Res Commun, 439(4), 443-448. 
An, X., Zhang, Z., Yang, K., & Huang, M. (2006). Cotransport of the heterodimeric small 
subunit of the Saccharomyces cerevisiae ribonucleotide reductase between the nucleus 
and the cytoplasm. Genetics, 173(1), 63-73. 
Barnard, E., McFerran, N. V., Trudgett, A., Nelson, J., & Timson, D. J. (2008). Development 
and implementation of split-GFP-based bimolecular fluorescence complementation 
(BiFC) assays in yeast. Biochem Soc Trans, 36(Pt 3), 479-482. 
Basrai, M. A., Velculescu, V. E., Kinzler, K. W., & Hieter, P. (1999). NORF5/HUG1 is a 
component of the MEC1-mediated checkpoint response to DNA damage and replication 
arrest in Saccharomyces cerevisiae. Mol Cell Biol, 19(10), 7041-7049. 
Buchan, D. W., Minneci, F., Nugent, T. C., Bryson, K., & Jones, D. T. (2013). Scalable web 
services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res, 41(Web 
Server issue), W349-357. 
Chabes, A., Domkin, V., Larsson, G., Liu, A., Graslund, A., Wijmenga, S., & Thelander, L. 
(2000). Yeast ribonucleotide reductase has a heterodimeric iron-radical-containing 
subunit. Proc Natl Acad Sci U S A, 97(6), 2474-2479. 
Chabes, A., Domkin, V., & Thelander, L. (1999). Yeast Sml1, a protein inhibitor of 
ribonucleotide reductase. J Biol Chem, 274(51), 36679-36683. 
Chabes, A., Georgieva, B., Domkin, V., Zhao, X., Rothstein, R., & Thelander, L. (2003). 
Survival of DNA Damage in Yeast Directly Depends on Increased dNTP Levels Allowed 
by Relaxed Feedback Inhibition of Ribonucleotide Reductase. Cell, 112(3), 391-401. 
Chabes, A., & Stillman, B. (2007). Constitutively high dNTP concentration inhibits cell cycle 
progression and the DNA damage checkpoint in yeast Saccharomyces cerevisiae. 
Proceedings of the National Academy of Sciences, 104(4), 1183-1188. 
Chen, S.-h., Smolka, M. B., & Zhou, H. (2007). Mechanism of Dun1 Activation by Rad53 
Phosphorylation in Saccharomyces cerevisiae. Journal of Biological Chemistry, 282(2), 
986-995. 
Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: making it safe to play with 
knives. Mol Cell, 40(2), 179-204. 
Duxbury, M. S., & Whang, E. E. (2007). RRM2 induces NF-κB-dependent MMP-9 activation 
and enhances cellular invasiveness. Biochem Biophys Res Commun, 354(1), 190-196. 
  
159 
Engstrom, Y., Eriksson, S., Jildevik, I., Skog, S., Thelander, L., & Tribukait, B. (1985). Cell 
cycle-dependent expression of mammalian ribonucleotide reductase. Differential 
regulation of the two subunits. J Biol Chem, 260(16), 9114-9116. 
Field, A. (2005). Discovering statistics using SPSS (2nd ed.). Thousand Oaks, CA, US: Sage 
Publications, Inc. 
Forsburg, S. L. (2001). The art and design of genetic screens: yeast. Nat Rev Genet, 2(9), 659-
668. 
Gietz, R. D., & Schiestl, R. H. (2007a). Frozen competent yeast cells that can be transformed 
with high efficiency using the LiAc/SS carrier DNA/PEG method. Nat Protoc, 2(1), 1-4. 
Gietz, R. D., & Schiestl, R. H. (2007b). High-efficiency yeast transformation using the LiAc/SS 
carrier DNA/PEG method. Nat Protoc, 2(1), 31-34. 
Guittet, O., Hakansson, P., Voevodskaya, N., Fridd, S., Graslund, A., Arakawa, H., Nakamura, 
Y., & Thelander, L. (2001). Mammalian p53R2 protein forms an active ribonucleotide 
reductase in vitro with the R1 protein, which is expressed both in resting cells in response 
to DNA damage and in proliferating cells. J Biol Chem, 276(44), 40647-40651. 
Harper, J. W., & Elledge, S. J. (2007). The DNA damage response: ten years after. Mol Cell, 
28(5), 739-745. 
Hsu, N. Y., Wu, J. Y., Liu, X., Yen, Y., Chen, C. Y., Chou, M. C., Lin, C. H., Lee, H., & Cheng, 
Y. W. (2011). Expression status of ribonucleotide reductase small subunits 
hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. 
Anticancer Res, 31(10), 3475-3481. 
Huang, M., Zhou, Z., & Elledge, S. J. (1998). The DNA replication and damage checkpoint 
pathways induce transcription by inhibition of the Crt1 repressor. Cell, 94(5), 595-605. 
James, P., Halladay, J., & Craig, E. A. (1996). Genomic libraries and a host strain designed for 
highly efficient two-hybrid selection in yeast. Genetics, 144(4), 1425-1436. 
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015). The Phyre2 
web portal for protein modeling, prediction and analysis. Nat. Protocols, 10(6), 845-858. 
Kumar, D., Viberg, J., Nilsson, A. K., & Chabes, A. (2010). Highly mutagenic and severely 
imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids 
Res, 38(12), 3975-3983. 
Kumar, S., & Burgers, P. M. (2013). Lagging strand maturation factor Dna2 is a component of 
the replication checkpoint initiation machinery. Genes & Development, 27(3), 313-321. 
Lai, Y.-P., Huang, J., Wang, L.-F., Li, J., & Wu, Z.-R. (2004). A new approach to random 
mutagenesis in vitro. Biotechnology and Bioengineering, 86(6), 622-627. 
  
160 
Lee, Y. D., Wang, J., Stubbe, J., & Elledge, S. J. (2008). Dif1 is a DNA-damage-regulated 
facilitator of nuclear import for ribonucleotide reductase. Mol Cell, 32(1), 70-80. 
Lefèvre, F., Rémy, M.-H., & Masson, J.-M. (1997). Alanine-stretch scanning mutagenesis: a 
simple and efficient method to probe protein structure and function. Nucleic Acids 
Research, 25(2), 447-448. 
Liu, X., Zhou, B., Xue, L., Yen, F., Chu, P., Un, F., & Yen, Y. (2007). Ribonucleotide reductase 
subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin 
Colorectal Cancer, 6(5), 374-381. 
Longtine, M. S., McKenzie, A., 3rd, Demarini, D. J., Shah, N. G., Wach, A., Brachat, A., 
Philippsen, P., & Pringle, J. R. (1998). Additional modules for versatile and economical 
PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast, 14(10), 
953-961. 
Ma, H., Kunes, S., Schatz, P. J., & Botstein, D. (1987). Plasmid construction by homologous 
recombination in yeast. Gene, 58(2-3), 201-216. 
McCullum, E. O., Williams, B. A., Zhang, J., & Chaput, J. C. (2010). Random mutagenesis by 
error-prone PCR. Methods Mol Biol, 634, 103-109. 
Meurisse, J., Bacquin, A., Richet, N., Charbonnier, J.-B., Ochsenbein, F., & Peyroche, A. (2014). 
Hug1 is an intrinsically disordered protein that inhibits ribonucleotide reductase activity 
by directly binding Rnr2 subunit. Nucleic Acids Res. 
Minard, L. V., Williams, J. S., Walker, A. C., & Schultz, M. C. (2011). Transcriptional 
Regulation by Asf1: NEW MECHANISTIC INSIGHTS FROM STUDIES OF THE 
DNA DAMAGE RESPONSE TO REPLICATION STRESS. J Biol Chem, 286(9), 7082-
7092. 
Mishra, P. K., Guo, J., Dittman, L. E., Haase, J., Yeh, E., Bloom, K., & Basrai, M. A. (2015). 
Pat1 protects centromere-specific histone H3 variant Cse4 from Psh1-mediated 
ubiquitination. Molecular Biology of the Cell, 26(11), 2067-2079. 
Mumberg, D., Muller, R., & Funk, M. (1995). Yeast vectors for the controlled expression of 
heterologous proteins in different genetic backgrounds. Gene, 156(1), 119-122. 
Nakano, K., Balint, E., Ashcroft, M., & Vousden, K. H. (2000). A ribonucleotide reductase gene 
is a transcriptional target of p53 and p73. Oncogene, 19(37), 4283-4289. 
Norbury, C. J., & Zhivotovsky, B. (2004). DNA damage-induced apoptosis. Oncogene, 23(16), 
2797-2808. 
Ohkuni, K., Takahashi, Y., & Basrai, M. A. (2015). Protein purification technique that allows 
detection of sumoylation and ubiquitination of budding yeast kinetochore proteins Ndc10 
and Ndc80. J Vis Exp(99), e52482. 
  
161 
Park, K., Yi, S. Y., Lee, C. S., Kim, K. E., Pai, H. S., Seol, D. W., Chung, B. H., & Kim, M. 
(2007). A split enhanced green fluorescent protein-based reporter in yeast two-hybrid 
system. Protein J, 26(2), 107-116. 
Peng, J., & Xu, J. (2011). RaptorX: exploiting structure information for protein alignment by 
statistical inference. Proteins, 79(Suppl 10), 161-171. 
Roy, A., Kucukural, A., & Zhang, Y. (2010). I-TASSER: a unified platform for automated 
protein structure and function prediction. Nat. Protocols, 5(4), 725-738. 
Sanvisens, N., de Llanos, R., & Puig, S. (2013). Function and regulation of yeast ribonucleotide 
reductase: cell cycle, genotoxic stress, and iron bioavailability. Biomed J, 36(2), 51-58. 
Sommerhalter, M., Voegtli, W. C., Perlstein, D. L., Ge, J., Stubbe, J., & Rosenzweig, A. C. 
(2004). Structures of the Yeast Ribonucleotide Reductase Rnr2 and Rnr4 
Homodimers†,‡. Biochemistry, 43(24), 7736-7742. 
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & 
Nakamura, Y. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-
cycle checkpoint for DNA damage. Nature, 404(6773), 42-49. 
Toussaint, M., & Conconi, A. (2006). High-throughput and sensitive assay to measure yeast cell 
growth: a bench protocol for testing genotoxic agents. Nat Protoc, 1(4), 1922-1928. 
Tsaponina, O., Barsoum, E., Åström, S. U., & Chabes, A. (2011). Ixr1 Is Required for the 
Expression of the Ribonucleotide Reductase Rnr1 and Maintenance of dNTP Pools. PLoS 
Genet, 7(5), e1002061. 
Winston, F. (2008). EMS and UV mutagenesis in yeast. Curr Protoc Mol Biol, Chapter 13, Unit 
13.13B. 
Wu, X., & Huang, M. (2008). Dif1 controls subcellular localization of ribonucleotide reductase 
by mediating nuclear import of the R2 subunit. Mol Cell Biol, 28(23), 7156-7167. 
Xu, H., Faber, C., Uchiki, T., Fairman, J. W., Racca, J., & Dealwis, C. (2006). Structures of 
eukaryotic ribonucleotide reductase I provide insights into dNTP regulation. Proc Natl 
Acad Sci U S A, 103(11), 4022-4027. 
Xu, H., Faber, C., Uchiki, T., Racca, J., & Dealwis, C. (2006). Structures of eukaryotic 
ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. 
Proc Natl Acad Sci U S A, 103(11), 4028-4033. 
Xue, L., Zhou, B., Liu, X., Qiu, W., Jin, Z., & Yen, Y. (2003). Wild-type p53 regulates human 
ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 
subunits. Cancer Res, 63(5), 980-986. 
  
162 
Yamaguchi, T., Matsuda, K., Sagiya, Y., Iwadate, M., Fujino, M. A., Nakamura, Y., & Arakawa, 
H. (2001). p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle 
checkpoint. Cancer Res, 61(22), 8256-8262. 
Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., & Zhang, Y. (2015). The I-TASSER Suite: 
protein structure and function prediction. Nat Meth, 12(1), 7-8. 
Yekezare, M., Gómez-González, B., & Diffley, J. F. X. (2013). Controlling DNA replication 
origins in response to DNA damage – inhibit globally, activate locally. Journal of Cell 
Science, 126(6), 1297-1306. 
Zhang, K., Hu, S., Wu, J., Chen, L., Lu, J., Wang, X., Liu, X., Zhou, B., & Yen, Y. (2009). 
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in 
human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol 
Cancer, 8, 11. 
Zhang, Y. (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9, 
40. 
Zhao, X., Georgieva, B., Chabes, A., Domkin, V., Ippel, J. H., Schleucher, J., Wijmenga, S., 
Thelander, L., & Rothstein, R. (2000). Mutational and structural analyses of the 
ribonucleotide reductase inhibitor Sml1 define its Rnr1 interaction domain whose 
inactivation allows suppression of mec1 and rad53 lethality. Mol Cell Biol, 20(23), 9076-
9083. 
Zhou, B., Su, L., Yuan, Y.-C., Un, F., Wang, N., Patel, M., Xi, B., Hu, S., & Yen, Y. (2010). 
Structure Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of 
Human Ribonucleotide Reductase Small Subunits hp53R2 and hRRM2. Molecular 
cancer therapeutics, 9(6), 1669-1679. 
Zhou, B. B., & Elledge, S. J. (2000). The DNA damage response: putting checkpoints in 





6.1. Closing Remarks 
Themes of transcriptional and post-translational control of the MEC1 DNA damage 
response were explored throughout this study.  Utilizing our understanding of the MEC1 DNA 
damage transcriptional response, a survey of MEC1 checkpoint pathway gene candidates were 
examined for their potential as transcript reporters in a carcinogen-sensing yeast whole cell 
biosensor.  The MEC1 DNA damage response, HUG1, as the most differentially expressed gene 
in response to DNA damage and replication stress (Basrai et al., 1999), prevailed as the ideal 
candidate for use in biosensor development.  We thus inserted a yeast optimized luciferase 
reporter under HUG1 promoter control and analyzed its response to the DNA alkylating agent, 
methyl methanesulfonate (MMS).  Compared to established fluorescent biosensors, the new 
luciferase whole cell biosensor exhibited improved sensitivity and dynamic range in detecting 
low titers of carcinogen.  Likewise, we designed the system to reduce sample preparation time by 
establishing a simple one-step, in vivo protocol.  Finally, a new vector system was generated to 
allow simple transfer of the improved luciferase reporter gene to new promoters systems. 
Global transcription studies had previously revealed a unique transcriptional profile of 
MEC1 DNA repair genes to increasing concentrations of alkylating agents.  We first sought to 
further characterize this response using a GFP promoter-reporter system coincidentally with 
MEC1 pathway genes.  We then exposed the MEC1/GFP promoter reporters to an assortment of 
alkylating agents, and cellular and replicative stress inducers and monitored the activity of the 
GFP response by flow cytometry.  We found that the biphasic gene response was reproduced 
only upon exposure to alkylating agents.  All other DNA damaging and replicative stress agents 
either did not induce a response or demonstrated a monotonically increasing GFP reporter 
response without a characteristic decline in gene expression.  Furthermore, the biphasic response 
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was found to persist through the MEC1 cascade, indicating that external epigenetic regulation 
was the cause of the unique profile.   
To identify the origin of this response, we then examined accumulation of reactive 
oxygen species (ROS) as a potential cause as ROS accumulation has been linked to inhibition of 
stress response genes.  Dihydrorhodamine 123 staining of ROS revealed that insignificant 
accumulation of ROS at low to mid-high ranges of MMS, and a large accumulation of ROS at 
the highest dosages.  As MEC1 gene loss-of-induction occurs prior severe ROS accumulation, 
we determined that ROS were not the causative factor behind MEC1 gene repression.  Apoptotic 
gene knockdowns were also performed to examine the role of apoptosis in MEC1 gene 
regulation.  Despite a significant attenuation in MEC1 gene signaling, repression of MEC1 genes 
still occurred at the highest alkylating dosages, and we therefore concluded that apoptotic genes 
did not contribute to the MEC1 biphasic response.   
Cell cycle analysis revealed that cells experiencing low to low-mid range alkylating 
agents proceed normally through the cell cycle, while those experiencing mid-high levels of 
alkylating agent arrest in the characteristic intra-S phase.  At the highest MMS dosage, cells did 
not exit the cellular stage upon alkylating induction and instead entered a senescent state.  This 
finding corroborates previous results which show that high MMS dosages induce gene 
transcription seen in the yeast stationary phase.  We thus suggested that the MEC1 biphasic 
response was the result of an uncharacterized repression mechanism induced upon cellular entry 
into senescence.  
Though demonstrating characteristics of a MEC1 negative regulator, the role of Hug1p in 
the MEC1 DNA damage response remained unclear.  Using overexpression plating analysis, we 
discovered that HUG1 overexpression sensitized yeast strains to replication arrest by 
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hydroxyurea and DNA damage by MMS and bleomycin.  Comparison of time-dependence of the 
positive MEC1 regulator, Rnr3p, to Hug1p revealed that Hug1p shows a delayed response to 
replication stress and its temporal expression profile was reflective of MEC1 negative regulators.  
Subcellular localization studies using GFP fused to the HUG1 C-terminus demonstrated that 
Hug1p-GFP localizes to the nucleus in the absence of DNA damage, but shuttles to the 
cytoplasm in the presence of replication stress.  This unique subcellular redistribution was found 
to be dependent on genes in the MEC1 pathway and correlated with the localization of the MEC1 
positive effector, Rnr2p.  These results suggested that Hug1p’s negative regulation was likely the 
result of its co-localization with Rnr2p. 
As Hug1p shares sequence homology with Dif1p, a known Rnr2p inhibitor, we further 
investigated the putative interaction between Hug1p and Rnr2p.  Traditional yeast two-hybrid 
assays were found to be ineffective at detecting the interaction, likely due to the disruption of the 
HUG1 depression mechanism when engineering the plasmid constructs.  An alternative yeast 
two-hybrid system - the split GFP assay – was developed to allow for the fusion of the split GFP 
fragment to HUG1 while retaining HUG1’s promoter sequence.  Using the fluorescent yeast two-
hybrid system, we discovered that Hug1p does interact with Rnr2p as corroborated by Hug1p 
pulldown assays.  We next set out to define regions within Hug1p that were necessary for its 
inhibition activity.  Random mutagenesis of the HUG1 ORF by error-prone PCR and EMS 
mutagenesis failed to identify new regimes within HUG1.  Site-directed mutagenesis was then 
utilized to generate a total of 22 mutants which spanned the HUG1 ORF.  Overexpression plating 
analysis of strains expressing the HUG1 mutants demonstrated uncovered a series of amino acids 
required for Hug1p inhibitory activity.  However, attempts to corroborate these findings through 
co-immunoprecipitation assays have been unsuccessful, as Hug1p expression is too variable to 
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reliably assess hug1p-Rnr2p co-elution efficiency.  Finally, the split GFP system was used to test 
Hug1p’s interaction capacity with human RNR2 homologs, p53R2 and hRRM2, and found to 
successfully (but weakly) interact with both homologs.  These results indicate that Hug1p 
inhibits the ribonucleotide small subunit through a conserved interaction mechanism.  
6.2. Future Work 
Discoveries made throughout this dissertation brought about new and exciting questions 
to be addressed.  Below is a brief outline of potential extensions to this project. 
6.2.1. Next-generation biosensors based on the secretable Gaussia luciferase 
Our study utilized a single firefly luciferase in the DNA damage experiments whereby 
signal was normalized to cell concentration.  Though effective, a dual luciferase provides a 
considerably better alternative to signal normalization.  In a dual luciferase system, a Renilla 
luciferase (Rluc) is typically fused under a constitutive promoter, such as PGK1 or ADH1, which 
stably expresses Rluc while firefly luciferase (Fluc) is fused to the promoter of the gene-of-
interest.  As the Rluc and Fluc utilize different substrates (coelenterazine and D-luciferin, 
respectively), luminescence from either enzyme can be easily differentiated with little cross-
signal contamination.(McNabb et al., 2005)   
A new luciferase has recently been discovered that has several exciting new properties.  
The Gaussia luciferase (Gluc) is naturally secreted, relatively small (19kDa), incredibly stable, 
utilizes the staple coelenterazine substrate, and is tremendously bright (nearly 1000-times 
brighter than Rluc and Fluc).(Wu et al., 2015)  All of these properties make it an ideal reporter 
for use in yeast whole cell carcinogen biosensing.  The next stage of the enhanced luciferase 
detection system lies in the combination of Gluc with the Fluc system described in this 
dissertation.  Instead of using the Fluc as a reporter, however, Fluc can be incorporated under a 
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constitutive promoter and serve a normalization control while Gluc is placed under the desired 
promoter and acts as the reporter.   
6.2.2. Connecting MMS-induced senescence and stationary phase genes  
We have found that the MEC1 biphasic induction in response to alkylating agents is the 
result of cells entering a senescent state, however the genes required for that repression and the 
mechanisms by which the cells shut down the DNA damage response are still unknown.  
However, potential genes involved in that process may be able to be determined by a thorough 
revisiting of the global transcription analysis performed under high alkylating agent 
conditions.(Benton et al., 2006; Jelinsky et al., 2000; Jelinsky & Samson, 1999)  Candidate 
genes can then be tested for effects on the MEC1 biphasic response by using the hug1Δ∷GFP 
reporter system we implemented in this work. 
6.2.3. Extending the split GFP system to the yeast HUG1* mutants and human RNR2 homologs 
We have demonstrated the utility of the split GFP system in determining Hug1p 
interactions with Rnr2p, p53R2, and hRRM2.  The next logical step for this project is to utilize 
the split GFP system in conjunction with the HUG1* mutant constructs to determine whether the 
Hug1p inhibition activity is lost due to disruption in its Rnr2p binding ability or disruption of an 
as-yet characterized inhibition role.  These data can be further corroborated with co-
immunoprecipitation assays that pulldown the Hug1*p mutants and assess Rnr2p co-elution.  
Likewise, the HUG1* mutant split GFP system can also be used to probe mutant interactions 
with p53R2 and hRRM2 through a similar experiment.   The results from these studies can be 
used to clarify whether a conserved region within Hug1p is being used to bind across the RNR2 
homologs.  It is important to note that the split GFP system is amenable to high-throughput 
systems, such as flow cytometry, which can be used to quickly and quantitatively assess the 
strength of the split GFP interactions. 
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6.2.4. The novel interaction between HUG1 and DNA2  
A recent study has shown that Hug1p also binds to Dna2p, a helicase/nuclease involved 
in S-phase activation of MEC1, and that the binding region is independent of the one used in the 
Rnr2p interaction.(Meurisse et al., 2014)  However, little remains known about the mechanism 
or function of the Dna2p-Hug1p interaction.  Utilizing the split-GFP system, we can confirm that 
Hug1p indeed interacts with Dna2p.  Likewise, we can use the mutant HUG1* in combination 
with the split GFP system to define the specific regions within Hug1p necessary for its 
interaction.  More importantly, Hug1p-mediated inhibition needs to be determined.  This is 
considerably more complex than determining the Hug1p’s inhibition of Rnr2p (i.e., dNTP 
measurements and overexpression plating analysis).  However, an assay can be designed that 
leverages Dna2p stimulation of Mec1p activity in vitro to assess Hug1p’s potential inhibition of 
this mechanism.(Kumar & Burgers, 2013)  Briefly, the Mec1p-Dna2p phosphorylation assay is 
performed as previously described, with the exception that increasing titers of purified Hug1p are 
added to the assay.  Hug1p’s inhibitory action against Dna2p can then be determined by the 
relative reduction in Mec1p stimulation.(Kumar & Burgers, 2013)  Hug1p inhibition of Dna2p 
has potential to be a significant discovery, as it would further explain Hug1p’s recovery role in 
the DNA damage response and would provide new evidence for Hug1p’s involvement in the 
downregulation of the MEC1 response.     
6.3. References 
Basrai, M. A., Velculescu, V. E., Kinzler, K. W., & Hieter, P. (1999). NORF5/HUG1 is a 
component of the MEC1-mediated checkpoint response to DNA damage and replication 
arrest in Saccharomyces cerevisiae. Mol Cell Biol, 19(10), 7041-7049. 
Benton, M. G., Somasundaram, S., Glasner, J. D., & Palecek, S. P. (2006). Analyzing the dose-
dependence of the Saccharomyces cerevisiae global transcriptional response to methyl 
methanesulfonate and ionizing radiation. BMC Genomics, 7, 305. 
  
169 
Jelinsky, S. A., Estep, P., Church, G. M., & Samson, L. D. (2000). Regulatory networks revealed 
by transcriptional profiling of damaged Saccharomyces cerevisiae cells: Rpn4 links base 
excision repair with proteasomes. Mol Cell Biol, 20(21), 8157-8167. 
Jelinsky, S. A., & Samson, L. D. (1999). Global response of Saccharomyces cerevisiae to an 
alkylating agent. Proc Natl Acad Sci U S A, 96(4), 1486-1491. 
Kumar, S., & Burgers, P. M. (2013). Lagging strand maturation factor Dna2 is a component of 
the replication checkpoint initiation machinery. Genes Dev, 27(3), 313-321. 
McNabb, D. S., Reed, R., & Marciniak, R. A. (2005). Dual luciferase assay system for rapid 
assessment of gene expression in Saccharomyces cerevisiae. Eukaryot Cell, 4(9), 1539-
1549. 
Meurisse, J., Bacquin, A., Richet, N., Charbonnier, J. B., Ochsenbein, F., & Peyroche, A. (2014). 
Hug1 is an intrinsically disordered protein that inhibits ribonucleotide reductase activity 
by directly binding Rnr2 subunit. Nucleic Acids Res, 42(21), 13174-13185. 
Wu, N., Rathnayaka, T., & Kuroda, Y. (2015). Bacterial expression and re-engineering of 
Gaussia princeps luciferase and its use as a reporter protein. Biochimica et Biophysica 




JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Sep 24, 2015 
 
 
This Agreement between William Ainsworth ("You") and John Wiley and Sons ("John 
Wiley and Sons") consists of your license details and the terms and conditions provided by 
John Wiley and Sons and Copyright Clearance Center. 
 
License Number 3715440063133 
License date  Sep 24, 2015 
Licensed Content Publisher  John Wiley and Sons 
Licensed Content Publication  Yeast 
Licensed Content Title  
 
Construction of a cytosolic firefly luciferase reporter 
cassette for use in PCR mediated gene deletion and fusion 
in Saccharomyces cerevisiae 
Licensed Content Author  W. B. Ainsworth, C. M. Rome,M. A. Hjortsø, M. G. 
Benton 
Licensed Content Date  Nov 21, 2012 
Pages  13 
Type of use  Dissertation/Thesis 
Requestor type  Author of this Wiley article 
Format  Print and electronic 
Portion  Full article 
Will you be translating?  No 
Title of your thesis / dissertation Analyses of the MEC1 DNA damage pathway in 
Saccharomyces cerevisiae 
Expected completion date  Nov 2015  






TERMS AND CONDITIONS 
Sep 24, 2015 
 
 
This is a License Agreement between William Ainsworth ("You") and Elsevier ("Elsevier") provided by Copyright Clearance 
Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment 
terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form. 
 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name William Ainsworth 
License Number 3715440208229 
License date  Sep 24, 2015 
Licensed Content Publisher  Elsevier 
Licensed Content Publication  Biochemical and Biophysical Research Communications 
Licensed Content Title  
 
Cytoplasmic localization of Hug1p, a negative regulator of the MEC1 
pathway, coincides with the compartmentalization of Rnr2p–Rnr4p 
Licensed Content Author  William B. Ainsworth, Bridget Todd Hughes, Wei Chun Au, Sally Sakelaris, 
Oliver Kerscher, Michael G. Benton, Munira A. Basrai 
Licensed Content Date  4 October 2013 
Licensed content volume number 439 
Licensed content issue number 4 
Pages  6 
Start Page 443 
End Page 448 
Type of use  Reuse in a thesis/dissertation 
Intended publisher of new work Other 
Portion Full article 
Format  Both print and electronic 
Are you the author of this Elsevier article? Yes 
Will you be translating?  No 
Title of your thesis / dissertation Analyses of the MEC1 DNA damage pathway in Saccharomyces cerevisiae 
Expected completion date  Nov 2015  
Expected size (number of pages) 150 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 







THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE LICENSE 
TERMS AND CONDITIONS 




This is a License Agreement between William Ainsworth ("You") and The American Association for the Advancement of Science 
("The American Association for the Advancement of Science") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by The American Association for the Advancement of Science, 
and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form. 
License Number 3733700417245 
License date Oct 21, 2015 
Licensed content publisher The American Association for the Advancement of Science 
Licensed content publication Science 
Licensed content title Integrating Genetic Approaches into the Discovery of Anticancer Drugs 
Licensed content author Leland H. Hartwell, Philippe Szankasi, Christopher J. Roberts, Andrew W. Murray, Stephen H. 
Friend 
Licensed content date Nov 7, 1997 
Volume number 278 
Issue number 5340 
Type of Use Thesis / Dissertation  
Requestor type Scientist/individual at a research institution 
Format Print and electronic 
Portion Figure 
Number of figures/tables 1 
Order reference number None 
Title of your thesis / dissertation Analyses of the MEC1 DNA damage pathway in Saccharomyces cerevisiae 
Expected completion date Nov 2015 
Estimated size(pages) 150 
Total 0.00 USD  







TERMS AND CONDITIONS 




This is a License Agreement between William Ainsworth ("You") and Elsevier ("Elsevier") provided by Copyright 
Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and 
the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this 
form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
License number 3733801331856 
License date Oct 21, 2015 
Licensed content publisher Elsevier 
Licensed content publication Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 
Licensed content title Structure, function, and mechanism of ribonucleotide reductases 
Licensed content author Matthias Kolberg,Kari R Strand,Pål Graff,K Kristoffer Andersson 
Licensed content date 1 June 2004 
Licensed content volume number 1699 
Licensed content issue number 1-2 
Number of pages 34 
Start Page 1 
End Page 34 
Type of Use reuse in a thesis/dissertation  
Intended publisher of new work other  





Format both print and electronic  




Will you be translating? No  
Original figure numbers Figure 3  
Title of your thesis/dissertation Analyses of the MEC1 DNA damage pathway in Saccharomyces cerevisiae  
Expected completion date Nov 2015  
Estimated size (number of pages) 150  
Elsevier VAT number GB 494 6272 12 
  
174 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 




This is a License Agreement between William Ainsworth ("You") and Nature Publishing Group ("Nature Publishing 
Group") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Nature Publishing Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of 
this form. 
License Number 3733761478962 
License date Oct 21, 2015 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature 
Licensed content title The DNA damage response: putting checkpoints in perspective 
Licensed content author Bin-Bing S. Zhou and Stephen J. Elledge 
Licensed content date Nov 23, 2000 
Volume number 408 
Issue number 6811 
Type of Use reuse in a dissertation / thesis  
Requestor type academic/educational 





Figures Figure 1: A contemporary view of the general outline of the DNA damage 
response signal-transduction pathway. 
Author of this NPG article no 
Your reference number None 
Title of your thesis / dissertation Analyses of the MEC1 DNA damage pathway in Saccharomyces cerevisiae 
Expected completion date Nov 2015 
Estimated size (number of pages) 150 
Total 0.00 USD  





William Barrett Ainsworth was born in Lafayette, Louisiana in 1985. He attended high 
school at Fontainebleau High School in Mandeville, Louisiana and graduated in 2004. He then 
matriculated at Louisiana State University where he completed his Bachelor of Science degree in 
Biochemistry with a minor in Chemistry in 2008. After transitioning into the Department of 
Chemical Engineering undergraduate program in August 2008 to obtain his second B.S. degree, 
Barrett was exposed to the department’s diversity in research, including the yeast DNA damage 
response work of his future mentor, Dr. Michael Benton.  Upon enrolling into graduate school at 
Louisiana State University in January 2010, he focused his doctoral studies on uncovering novel 
features of the yeast MEC1 checkpoint pathway.  This work resulted in the development of 
improved MEC1-specific whole-cell biosensors, revealed new cell cycle regulatory mechanisms 
of MEC1 pathway genes, and uncovered the function and mechanism of a previously 
uncharacterized protein in the MEC1 pathway. He will fulfill the requirements for the Doctor of 
Philosophy degree in Chemical Engineering in December 2015. He hopes to secure a research 
scientist position within the pharmaceutical industry where he can apply his knowledge of the 
DNA damage response towards the advancement of next generation cancer treatments. 
